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Myelin injury plays a role in many devastating conditions, including multiple sclerosis, and 
neuromyelitis optica. Previous work in understanding myelin injury has utilised a combination 
of high-resolution static imaging modalities, such as electron microscopy, and ensemble-
averaged imaging, such as immunohistochemistry. Within the work presented in this thesis 
the behaviour of myelin basic protein was addressed, during various stages of differentiation 
and injury.  
In order to explore this several reporters for myelin basic protein were designed and encoded 
within Semliki forest constructs in order to induce protein transduction in oligodendroglial 
cells. Reporters utilised several fluorescent tags including Dendra2, mCherry, and GFP. These 
viral vectors were characterised to determine the expression kinetics and toxicity within cells. 
Following the production of the MBP reporters, a complement injury modality was optimised 
to induce myelin/oligodendrocyte specific injury with little injury within axons/neurones. This 
myelin injury was utilised for live imaging of myelin using the MBP reporters produced 
previously. 
The reporters produced were utilised to explore the change in particle dynamics following 
myelin injury, using single molecule TIRF imaging. Responses to injury were compared over 
various stages of oligodendrocyte differentiation, where it was found that MBP dynamics 
following injury varied most when mature oligodendrocytes were injured. 
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"Magic is just science that we don't understand yet"  
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1.1  Overview of the Central nervous system 
 
The nervous system encodes and regulates all the body’s functions, and consists of two 
elements, the central nervous system (CNS), and the peripheral nervous system (PNS)1,2. The 
key processing centre within the nervous system is the CNS, which itself consists of two key 
elements, the brain and the spinal cord. This is the part of the nervous system which is 
responsible for cognition, emotions, reflexes, and sensory processing1. This contrasts with the 
PNS which possesses most of the sensory receptors, to provide information on both the 
internal and external environment1. The key function of the PNS is to relay information to the 
CNS for processing, and to initiate a response in effectors such as glands and skeletal muscle 
in regards to this information1,2. Due to the differences in functions within the CNS and PNS, 
these environments have different physiologies and use different transmitters to convey 
information. In order to maintain the environmental differences which characterise the CNS, 
as well as protect the CNS from inhomogeneity and pathogens, the central and peripheral 
systems are separated by a layer of tight-junctioning epithelial cells, known as ependymal 
cells3,4. 
1.1.1  The Brain 
The brain is one of the most complicated and important organs within the human body. 
Forming the higher centres of the CNS, it is responsible for higher processing and coordinating 
all the functions of an individual1,5. A brain exists within the nervous system of all vertebrates 
and most invertebrates, and rests within the cranial cavity in the skull. It consists of many 
different regions, all of which are specialised in their functions. The main categories within the 
brain consists of the cerebrum, brain stem, and the cerebellum1,2,5. 
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The cerebrum is the largest part of the brain consisting of two hemispheres, here is where 
“higher functions” are processed, including personality, emotion, and memory5,6. The outer 
part of the cerebrum is known as the cerebral cortex, mainly consisting of grey matter. The 
morphology of the cortex varies with smaller mammals having a smoother cortex, whereas 
large mammals have sulci and gyri which form a more folded morphology, allowing a greater 
volume of tissues and hence greater capacity of functions7. The cortex consists of 5 main lobes, 
all of which have specialised structure and function. These lobes are the frontal, occipital, 
parietal, temporal and insular lobes5,8. Each lobe specialises in the information it processes, 
with the frontal working on higher cognitive functions, such as risk taking behaviour, 
reasoning, problem solving, the parietal lobe processing sensory information such as auditory 
information, taste, and touch, the occipital lobe involved processing of optic information, as 
well as recognition of faces, temporal lobe dealing with language, and the insula involved in 
motivation, interoception and subjectivity1,9,10. Deeper within the cerebrum many structures 
exist consisting of structures such as the thalamus, amygdala, hippocampus, and basal 
ganglia1. These have roles in many functions such as memory, motor planning, pleasure, 
satiety, disgust, and attention1,11. 
Below the cerebrum is the brain stem which is heavily involved in the regulation of cardiac 
and respiratory function2,5. This area consists of the medulla oblongata, Pons, and 
mesencephalon. The medulla oblongata, commonly referred to as the medulla, is the lowest 
part of the brain connecting with the spinal cord12. The medulla plays a role within many 
reflexes, such as swallowing and the gag reflex, as well as thermal homeostasis, heart rate, 
and digestion2,5. Laying rostrally from the medulla is the pons1,2,5. The pons is the point of 
origin of four of the cranial nerves, and connects the medulla to the cerebellum. The pons 
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contains the pontine nuclei which relays information from the cerebral cortex to the 
cerebellum. Rostrally from the pons is the mesencephalon, also referred to as the midbrain, 
which play a role within the oculomotor system, and motor planning13. The midbrain contains 
many important structures, such as the red nucleus, which receives most of the output of the 
cerebellum, the substantia nigra, which is heavily involved in motor regulation and implicated 
in Parkinson’s disease, and the superior & inferior colliculi which are heavily involved in gaze 
regulation and attention shifting14–16. 
The cerebellum exists posteriorly to the cerebrum, and forms a key part of the hind brain, 
consisting of the cerebellum and the brain stem17,18. The cerebellum, like the cerebrum, is 
divided into 2 hemispheres, divided by a structure referred to as the vermis, and has sulci and 
gyri, referred to as fissures and fossa17,18. The cerebellum has a more regular pattern of 
fissures and fossa than the cerebrum17,18. The cerebellum plays a role in motor coordination, 
precision and timing of movements. With damage causing impaired gait, equilibrium, and 
motor learning17. The cerebellum consists of 3 lobes, the anterior, posterior and 
flocculonodular lobes, which contain 4 deep nuclei which connect with other regions within 
the brain, the dentate, globose, emboliform and fastigial nuclei5,17. 
1.1.2  The Spinal cord 
The spinal cord in addition to the lower part of the brain, known as the brain stem, make up 
the lower processing centres within the CNS5,11. These centres are responsible for most of the 
reflexive activities, in addition to the homeostatic actions, of the body. The spinal cord itself 
carries all impulses from the brain to the PNS, in addition to signals to the brain from the PNS, 
other than those conveyed by cranial nerves1,11. These impulses from the brain are carried by 
nerves that descend through the spinal cord till it reaches the spinal nerve at the appropriate 
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level, where the impulse is transmitted out of the spinal cord and is eventually conveyed to its 
effector by elements of the PNS.  The spine has approximately 31 pairs of spinal nerves that 
either enter or exit the spinal cord at each vertebral level, these are 8 cervical nerves, 12 
thoracic nerves, 5 lumbar nerves, 5 sacral nerves, and 1 coccygeal nerve1,5,11,12. A high 
concentration of spinal nerves are in the narrowing at the end of the spinal cord, conus 
medullaris, which produces the structure referred to as the cauda equina11,12.  
The spinal cord is a long tubular structure encased in a membrane known as the thecal sac 
within the vertebral canal12,19. It consists of 2 enlargements to this shape, known as the 
cervical and lumbar enlargements11,12. The cervical enlargement extends from the fourth 
cervical vertebra to the first thoracic vertebra, and is responsible for the nerves extending to 
and from the upper limbs. Inferior to the cervical enlargement is the lumbar enlargement, 
which extends from the ninth to the twelfth thoracic vertebra11,12. This enlargement is 
responsible for housing the nerves to and from the lower limbs. Inferior to this enlargement 
is the conus medullaris where the spinal cord terminates, which within adults arises between 
the first and second lumbar vertebra11,12. The spinal cord itself consists of grey matter, which 
exists within the centre within a butterfly shape, and white matter which surrounds it1,5,11,12. 
The grey matter receives and transmits information from the body, and is split into 2, the 
dorsal grey horn which receives sensory information and ventral grey horn which transmits 
motor information to the skeletal muscles5,11,12. The white matter within the spinal cord 
contains the spinal tracks, which transmits information up and down the spinal cord, examples 
of which are the ascending spinothalamic tracks for thermal and nociceptive information, and 
the descending corticospinal tracks conveying voluntary motor information1,5,11,12.   
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1.1.3  The Blood Brain Barrier 
The blood brain barrier (BBB) is a group of physiological occurrences which occur within the 
CNS in order to tightly regulate the movement of molecules, ions, and cells between blood 
and the CNS20. The microvasculature which effects the CNS is non-fenestrated, in order to 
maintain CNS homeostasis and allow efficient neural function21,22. This function mainly lies 
within the endothelial cells of the vasculature, but also is influenced by the pericytes 
surrounding them, the glial cells within the CNS, the neurones, and the immune system 
itself23–25. The composition of this structure also varies slightly between the brain and the 
spinal cord19. 
CNS endothelial cells are exceptionally thin compared to their analogues within the 
periphery26. These cells are held together by tight junctions to restrict large molecular 
movements27–29, with a number of transporters for lipophilic, and nutrient molecules30–33. 
Endothelial cells within the BBB contain many more mitochondria than seen in other 
endothelial cells in the body, as maintenance of conditions within the CNS requires movement 
of molecules against their diffusion gradients34. 
Above endothelial cells lay the pericytes, which rarely contact the endothelial cells35. These 
cells are embedded within the basement membrane surrounding them20,35. Pericytes are 
essential for control of the diameter of the vasculature, as well as being involved within wound 
healing, and immunoregulation20,36,37. The interaction of pericytes with the endothelial cells 
prevent the expression of leukocyte adhesion molecules within the cells, as well as inhibiting 
molecule movement through transcytosis38,39. Pericytes also contact with astrocytes in order 
to receive information on neuronal actions to regulate blood flow40. Astrocytes themselves 
have also been shown to be important in the formation of the blood brain barrier40,41. 
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The pericytes are embedded in an extracellular matrix referred to as the basement 
membrane, secreted by the pericytes, endothelial cells, and astrocytes within the system42,43. 
The basement membrane is composed of many secreted molecules such as laminins, 
glycoproteins, and collagen20. This provides processes which are signalling the vasculature an 
anchor as well as providing an extra filter for molecules being transported20. 
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1.2  Cerebellum 
The cerebellum is a key part of the hind brain1,11. Its name is derived from latin meaning little 
brain, due to its appearance as a smaller version of the brain44. The cerebellum plays a role in 
motor control and the control of cognitive functions, like attention, however, it should be 
noted that it does not initiate motor activity but plays a role in the coordination, precision and 
timing of movements17,44,45. Damage to the Cerebellum results in a variety of impairments 
including the inability to perform fine movements, impaired gait and posture, poor 
equilibrium, and impaired motor learning18,46,47. Unlike the cerebrum, where damage would 
cause impairments contralaterally, when cerebellar damage causes motor impairments they 
tend to occur ipsilaterally48. As well as motor and balance impairments, cerebellar injury can 
also induce cerebellar affective syndrome, where the symptoms are more emotional and 
behavioural49. The spectrum of cerebellar affective syndrome symptoms include 
distractibility, impulsiveness, anxiety, inability to understand social boundaries, aggression, 
dysphoria, and ritualistic behaviours49. 
1.2.1  Anatomy of the cerebellum 
The cerebellum is located in the posterior cranial fossa, behind the pons and medulla, with all 
connections to and from the cerebellum travelling through the pons11,17,18. Like the Cerebrum 
the cerebellum consists of 2 hemispheres, with gyri, referred to as folia, and a midline, 
referred to as the vermis11,18,45. Unlike the cerebrum which has an irregular pattern to its sulci 
and gyri, the folia in the cerebellum are arranged in parallel11,17,18. The cerebellum is covered 
in the Tentorium Cerebelli, which is the layer of dura mater which separates the cerebellum 
from the cerebrum50. The surface of the cerebellum is exclusively grey matter, with the white 
matter within the cerebellum forming the structure referred to as the arbor vitea, due to the 
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similarity of its structure with a branching tree51. The arbor vitae conceals 4 cerebellar nuclei, 
the dentate, globose, emboliform, and fastigial (Figure 1.2 A)17. The globose and emboliform 
nuclei are referred together as the interposed nuclei, and with the fastigial nuclei are a 
component of the spinocerebellum11,17. Connecting the cerebellum to the rest of the nervous 
system are the 3 cerebellar peduncles11,17. The superior peduncle is mainly used to output 
information to the cerebral cortex, the middle peduncle receive inputs from the pontine nuclei 
which relay information from the cortex, the inferior peduncle receives inputs from the 
vestibular nuclei, spine and tegmentum, and output to the vestibular nuclei and reticular 
formation11,17. The cerebellum has 3 main arteries which supply it, the superior cerebellar, 
anterior inferior cerebellar, and posterior inferior cerebellar11,52. The superior cerebellar 
artery supplies the upper region of the cerebellum, the anterior inferior supplies the front of 
the under surface of the cerebellum, and the posterior inferior serves the cerebellar notch 
and the rest of the under surface. All the arteries anastomose within the pia matter52. 
The cerebellum is subdivided into 3 lobes the anterior lobe, the posterior lobe, and the 
flocculonodular lobe (Figure 1.1)17,18. The flocculonodular lobe, also known as the 
vestibulocerebellum or archicerebellum, is the oldest part of the cerebellum17. Its main 
connection is the vestibular nuclei, as well as sensory inputs. It is involved in balance and 
spatial orientation, as seen when damage occurs, as it leads to gait and equilibrium issues17. 
The medial areas of the anterior and posterior lobes form the paleocerebellum, also known 
as the spinocerebellum, this region fine tunes limb and body movememnts17,44,51. The 
spinocerebellum receives mainly proprioceptive and cranial trigeminal inputs, as well as visual 
and auditory17,44,51. Fibres from this region project mainly to cerebellar nuclei to modulate 
descending motor signals in the cerebrum and brain stem. The lateral zone consists of the 
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lateral regions of the anterior and posterior lobes, and is the largest part of the cerebellum, 
also known as the cerebrocerebellum or neocerebellum17,44. This region receives inputs from 
the cerebral cortex, mainly the parietal lobe, through the pontine nuclei, and out puts are 
mainly to the red nucleus and thalamus. It is suggested that this region plays a role in 
movement and cognitive planning. Damage to this region leads to dysarthria, dysmetria, 
intention tremors, as wells as errors in speed force and direction of movements11,53. 
 
Figure 1.1: Cerebellar anatomy, showing its lobular structures, where they are, and how they are bounded. The anterior 
lobe ends at the primary fissure where the posterior lobe starts, the posterior fissure separates this from the 
flocculonodular lobe. This figure was extracted from O’Brien and Hill 2016. 18 
 
1.2.2  Cell types and circuitry of the cerebellum 
The cerebellum has more neurones than the rest of the brain, with the total being more than 
3 times that of the neocortex54. These neurones produce 3 types of axonal projections mossy 
fibres, climbing fibres, and parallel fibres11,17. Mossy fibre projections originate from the 
pontine nuclei and project excitatory synapses onto the granule cells in the granule layer of 
the cerebellum, which project to Purkinji cells through parallel fibres, which ultimately signal 
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the deep nuclei, some mossy fibres may also project directly to the deep nuclei as well11,17. 
Within the granule layer the ends of mossy fibres form enlargements known as rosettes, which 
can contact up to 20 granule cells at a time55,56. The contacts between granule cells and mossy 
fibres are referred to as glomeruli56. Climbing fibres project to Purkinji cells, and form 
collaterals to deep nuclei55,56. Climbing fibres transfer signals from inferior olivary nuclei to 
Purkinji cells, each climbing fibre inputs into 1 Purkinji cell, but makes many synapses with 
it11,17,55,56. Climbing fibres have a low fire rate, however, they induce multiple action potentials 
due to the multiple synapses11,17,55,56. The third type of projection is the parallel fibre 
connections, which originate from bifurcations of granule cell projection and project onto 
Purkinji cells, Golgi cells, basket cells and stellate cells11,17,55,56. The signal of each parallel fibre 
is weak, and projects onto multiple Purkinji cells17. In order to excite the Purkinji cells multiple 
parallel fibres must be active. Many of the larger projections within the cerebellum tend to 
project to the deep cerebellar nuclei and use glutamate as a neurotransmitter, producing 
excitatory synapses11,17,55,56. On the other hand, smaller cells tend to be GABAergic, and tend 
to project to the inferior olivary nucleus17,55.  
The Cerebellum consists of 3 cellular layers, the granular layer, Purkinji layer, and the 
molecular layer (Figure 1.2 C)11,17,55,56. Deepest layer is the granule layer which is densely 
packed with granule cells and interneurons. Granule cells are some of the smallest neurones 
within the brain, but amount to about ¾ of the neurones in the brain11,17,55,56. Granule cells 
project between 4 and 5 dendrites, ending with a dendritic enlargement, known as a dendritic 
claw11,17,55. These dendritic claws receive excitatory inputs from mossy fibres, and inhibitory 
inputs from Golgi cells11,17,55. Granule cell projections tend to be thin and unmyelinated, and 
project to Purkinji cells. Granule fibres project up to the molecular layer, where they bifurcate 
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and form parallel fibres, making the characteristic T shape11,17,55. The next layer along is the 
Purkinji layer where the cell bodies of the Purkinji cells lie11,17,55,56. Purkinji cells are 
distinguished by their flattened profusely branching dendritic trees. All the dendrites form in 
the plane perpendicular to the cerebellar folds17,55. Purkinji cells have many dendritic spines 
to receive inputs from multiple parallel fibres, as their signals are weak and many are needed 
to induce an action potential17,55. Purkinji cells have spherical cell bodies, which express the 
marker calbindin, and use GABA as their neurotransmitter11,17,55,56. The outer most layer 
within the cerebellum is the molecular layer where the dendritic trees of the Purkinji cells 
project. The parallel fibres cross this layer and synapse with the Purkinji cells and interneurons 








Figure 1.2: Structure of the Cerebellum. A) Depiction of a singular hemisphere of the cerebellum, showing location of 
cerebellar nuclei. B) Cross sectional image of the cerebellum showing the structure, with the arbor vitae in the centre. C) 
Depiction of the cellular structure of the cerebellum, showing the location of the various layers and the organisation 
within the layer. These images have been extracted from Moulton et al 2010.57 
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1.3  Neurones 
The nervous system is divided into the CNS, which consists of the brain and spinal cord, and 
the PNS, which consists of the rest of the nervous system elements1,58. There are two key cell 
types within the nervous system, the neurones and the glial cells11.  
Neurones are seen as the main cells of the nervous system, as they are essential to produce 
the observed activity of the brain11,59,60. The human brain has approximately 86 million 
neurones, most of which are within the cerebellum61,62. The general structure of a neurone 
consists of dendrites to receive incoming information, this information is transmitted to the 
cell body which contains the nucleus and intracellular organelles, and an axon, which relays 
the information away from the cell body, and transfers signals to other cells1,11,51. Although 
many cells contain all these structures they are not present in all neurones, such as retinal 
amacrine cells which do not have axons or photoreceptors which have no dendrites1,11,63. 
Clusters of neurones working on similar functions are known as ganglia outside of the brain, 
and within the brain as nuclei11.  
The role of neurones is to transfer and integrate information to produce a response to a 
stimuli. These signals are normally conducted through changes in the electrochemical gradient 
of the cell, known as action potentials64 (Figure 1.3).  At rest neurones have a net negative 
membrane potential of about -70mV, which is maintained by the ion channels within the cells 
and the presence of large anions which are too large to cross the membrane1,11. This is the 
state of the neurone until it receives an input. These inputs are normally received by the 
dendrites, through a variety of ways. One example is the dendrites of skin stretch receptors, 
where stretch in the ruffini corpuscle causes the dendrites of the sensory neurone to become 
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discharged1,11.   This can also be achieved by inputs from other dendrites, in this case there 
can be a number of dendrites, or a number of synapses involved1,11. These signals are then 
conducted to the cell body, where the signals from all the dendrites are processed, and 
summated, if the resulting signals are large enough an action potential is initiated within the 
axon1,11. Action potential generation occurs when a large enough depolarising signal is 
received that pushes the membrane potential past the threshold, causing voltage-gated 
sodium ion channels to open, as the sodium concentration intracellularly is low, and the 
electrochemical gradients favour influx, it diffuses in, causing further depolarisation1,11,64. 
Activated sodium channels enter an inactive state within 1-2 ms of activation terminating the 
depolarising influx. The membrane potential is then restored to the resting potential by the 
delayed opening of voltage gated potassium channels, which allow potassium ion efflux along 
the electrochemical gradients created by the action potential and pre-existing high levels of 
potassium ions inside the neuron, hyperpolarising the cell below resting potential. The 
potassium channels then close, and the sodium potassium pumps within the neuronal plasma 
membrane re-establish the resting potential by importing potassium and exporting sodium at 
a 3:2 ratio1,11,64. The depolarisation is unidirectional as the parts of the preceding region of the 
axon will remain unresponsive to further depolarisation as the voltage gated sodium channels 
will be in their refractory periods and the region will be in a hyperpolarised state1,11,64. An 
important feature of the action potential as a signalling mechanism is that the process is time 
exhaustive as it requires channel opening, and the restoration of ion gradients by slow active 
transporter pumps, so for the nervous system to work efficiently some of its neurones acquire 
an insulating material, known as myelin65, to allow the signal to travel further distances 
without need for signal boosts from action potential generation, this process is known as 
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saltatory conduction1,11,64,66–68. Gaps occur between segments of myelination known as nodes 
of Ranvier, these exist to modulate the signal allowing interactions with ligands, other 
processes and allows the signal to be amplified1,11,64.  
 
Figure 1.3: Depiction of an action potential, showing the ion movements during each phase of the action potential. 1 
shows the membrane at rest where the sodium potassium pump maintains the membrane potential at approximately -
70mV. 2 shows depolarisation of the membrane following stimulation beyond threshold. Here the membrane potential 
is reduced to approximately 30mV as sodium diffuses in as the voltage-gated sodium channels open. 3 voltage-gated 
sodium channels close due to refractory, and voltage-gated potassium channels open. This repolarises the membrane 
beyond resting potential. 4 the membrane potential returns to rest, achieved by the sodium potassium pump. 
 
Based on their functions neurones are split into 3 groups, sensory neurones, motor neurones, 
and interneurons58,69. Sensory neurones receive information from sensory receptors on the 
state of either the environment (exteroceptive), the state of the body (interoceptive) or body 
position (proprioceptive)58.  These cells tend to be pseudounipolar, as they have axons which 
branch into 2, one of which take on the function of a dendrite whilst the other is used for 
transmission, in the case of primary sensory neurones this allows their cell bodies to be in the 
dorsal root ganglia or the cranial sensory ganglia5,58,69,70. The next group of neurones are the 
motor neurones, these carry information to effectors such as muscles, organs, and glands5. 
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Motor neurones are much larger than sensory neurones and tend to be multiple polar 
cells58,70. There are 3 classifications of motor neurones, somatic motor neurones, special 
visceral, and general visceral58,71. Somatic neurones innervate skeletal muscles and tend to be 
involved in locomotion, special visceral which innervates muscles involved with facial 
expression, phonation, chewing and swallowing1,11,58,71. The third classification is the general 
visceral neurones, which innervates smooth muscle, glands, and indirectly signals cardiac 
muscle1,11,58,71. Interneurones may receive information and send information from other 
neurones1,11,58,71. These neurones play a role in signal integration, and learning. These cells 
can make many contacts, like in the hippocampus where interneurones make about 1000 
synapses with other cells58. 
The structure of neurones are divided into about 4 groups, depending on their numbers of 
projections from the cell body, and the position of their cell bodies (Figure 1.4). Unipolar 
neurones are not normally seen in vertebrates, as cells which present as unipolar, such as 
photoreceptor cells, start of life as bipolar cells and therefore are termed pseudounipolar72. 
Bipolar cells have 2 projections from the cell body, an example of which within the body would 
be retinal bipolar cells which receive inputs from photoreceptors and transmits them to the 
retinal ganglion cells5,58,69,70. Intermediately between the unipolar and bipolar cells is the 
pseudounipolar cells, these cells have one projection from the cell body, however, this 
branches into 2 fibres5,58,69,70. These cells are commonly utilised as sensory fibres. Beyond 
bipolar cells are multipolar cells, which have numerous projections from the cell body, this is 
the structure more commonly associated with neurones, as many motor and interneurones 
use this structure, an example of which are the purkinji cells within the cerebellum5,58,69,70.  




Figure 1.4: Classifications of neurones. i) Depiction of the different types of neurones, showing their variations in sizes, 
and number, of projections, and location of the cell body. ii) The different categorisations of neurone morphologies, 
based on the number of projections from the soma existent, unipolar cells are not exceptionally common within the 
human body, but can exist with cells like amacrine cells58. Figures were extracted from Concepts of Biology—1st 
Canadian Edition73. 
 
1.3.1  Markers of neurones 
Different neurones within the body express a number of unique molecules which can be used 
to identify them as neurones. Within this work only two of these were addressed for use with 
CNS neurones. 
Neurofilament (NF) is the name given to the intermediate filaments found the cytoplasm of 
neurones. These form the cytoskeleton of the neurones with the microtubules and 
microfilaments. There are up to 5 proteins which neurofilament is composed of, which can co-
assemble in different formations for different neuronal subtypes. Of key interest in 
myelinating cells is neurofilament H, which exists as a 200kDa band in SDS page, also referred 
to neurofilament-200 (NF200)46. Expression of this neurofilament is low in developing 
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neurones, but increases postnatally during myelination74,75. Another interesting 
Neurofilament is vimentin, which is up regulated for neurite outgrowth in the CNS74,76.  
Calbindin is a marker for projecting neurones, such as purkinji cells and neocortical 
interneurones. Calbindin is a calcium binding protein, with some cross reactivity with 
magnesium, however, it has a greater affinity to calcium77. For this reason calbindin is 
suggested to be a calcium sensor rather than a buffer78–80. This is also supported as calbindin 
undergoes a conformational change upon calcium binding but not upon magnesium binding, 
which could aid in its role within calcium transport81. In addition to this calbindin is known to 
play a role in the prevention of apoptosis within osteoblast cells, through the inhibition 
caspase-377.  
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1.4  Glial Cells 
The second main component of the CNS, working alongside the neurones, are the glial cells. 
Glial cells first were described by Virchow who referred to them as nervenkitt, which was 
German for nerve glue82. The name was later translated to Greek leading to the name 
neuroglia. These cells are smaller than neurones, and exist within both the CNS and PNS, 
however, as these cells were referred to as nerve glue the role of these cells were neglected 
for a number of years60,82. Glia constitute to between 33% to 66% of the brain mass depending 
on the organism, therefore there must be more to their roles than to fill the space neurones 
don’t occupy54,59,83. Glial cells do not participate directly within the nervous signally within the 
human brain, however glia are believed to outnumber the neurones 3 to 1. Although the exact 
numbers of glia in relation to neurones is a source of contention61,84,85. The discovery of this 
phenomenon has led to a resurgence of research into glial cells in the recent years, showing 
that these cells have numerous important roles within the nervous system. Their known roles 
include maintaining the cellular environment and ionic  milieu within the CNS, providing tropic 
support to neurones, guiding neural development both through signalling and as scaffolds in 
early development,  controlling the  uptake  of  neurotransmitters, and protecting the brain 
from pathogenic attack60,86–92.  Glial cells have been characterised into 3 categories, the 
macroglia, consisting of the astrocytes and oligodendrocytes, and microglia. These different 
type of glia each display unique morphological and functional properties11 (Figure 1.5). 




Figure 1.5: Types of Neuroglia, not to scale.  Figure depicts an Oligodendrocyte myelinating an axon, Astrocyte, and a 
microglial cell. Image is modified from Blausen Medical 201493. 
1.4.1  Microglia 
Microglia are seen as important for producing an immune response within the CNS. They are 
commonly referred to as the macrophages of the nervous system, as they have share many 
properties with peripheral macrophages60. Microglia are small highly ramified cells, which 
patrol the CNS at rest, and when a pathogen is detected or the blood brain barrier is 
compromised, are known to change into an active state to perform a phagocytic role91. They 
exist in similar numbers in the CNS to neurones, and have highly dynamic, active processes at 
rest. Microglia don’t originate from the ectoderm like other glia, and the majority of microglial 
cells are made postnatally94,95. This could be related to the role of microglia in synaptic 
pruning, which would be in higher demand postnatally96,97. 
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1.4.2  Astrocytes 
Astrocytes are seen as mainly support cells within the CNS60. This is mainly due to its role in 
maintaining the extracellular environment59. However, astrocytes have been observed to 
have a number of different functions within the CNS. The first role is its role in producing 
elements of the extracellular matrix (ECM) to support neurones, as well as controlling the 
volume of ECM 98,99. In addition to controlling the ECM composition the astrocytes play a role 
in controlling the environment within the synapse, astrocytes are known to wrap around the 
pre- and post- synaptic termini to form a tripartite synapse100–102 . This allows the astrocyte to 
control the signalling within the synapse, through the control of the movement of ions, the 
uptake of neurotransmitters, or the release of gliotransmitters103,104. These functions can be 
facilitated as astrocytes possess receptors for various neurotransmitters59.   In addition to this 
signalling it is suggested that astrocytes may also signal other neurones59,105, this may be 
achieved through gliotransmitters, but also through the control of metabolites as astrocytes 
contact both neurones and capillaries to shuttle nutrients and metabolites between 
them106,107.  
Astrocytes also play a role in the protection of the CNS from pathogenic material, it has  been 
shown astrocytes play a role in the formation and control of the blood brain barrier, which 
prevents pathogenic material from the periphery from entering the CNS25,59. In addition to 
this, it has also been observed that astrocytes play a role in the immune response to 
pathogens, and are known to be the main source of reactive oxygen species scavengers, and 
to be involved in the formation of neural scars59,86,108–115. 
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1.4.3  Oligodendrocytes   
Oligodendrocytes (OLs) are the myelinating glial cells of the CNS (Figure 1.6). This insulation 
provides the neurones with a lipid rich coating, known as the myelin sheath, which has a low 
water content making it well suited to provide the cells with electrical insulation, and is not 
universal, with OLs only selecting axons with diameters greater than 0.2 μm to myelinate90. In 
order to ensure correct myelination, OLs have receptors which detect neuronal activation, 
which plays a role in OL differentiation, and myelination116,117. Part of this signalling between 
myelin and neurones also plays a role in channel positioning, with myelination causing sodium 
channels to cluster at nodes of ranvier118–120. Myelin is known to also play a role in trophic 
support for axons, and is needed to maintain long axons68,121,122. Conditions where 
myelination is impaired, such as leukodystrophies and multiple sclerosis, lead to reduced 
cognitive and neurological function, and loss of various abilities. 
    
 
Figure 1.6: Myelination from an oligodendrocyte. Figure shows the organisation of myelin with nodes of Ranvier 
between myelin segments to allow signal propagation. The figure also shows that an axon may have many myelin 
sheaths from a singular oligodendrocyte, and may also have sheaths from a number of oligodendrocytes. 
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1.4.4  Myelin 
One of the key functions of OLs is the production of myelin. Myelin was first described by 
Antoni Van Leeuwenhoek in 1717 who identified nerves consisting of vessels (myelin) and 
canals (neurones)67. Unfortunately as the secrets of Leeuwenhoek’s lenses died with him, this 
was not corroborated until Ehrenberg who showed that nerves consist of a marrow sheath 
(myelin) and brain tube (neurones)123. Following this re-discovery numerous researchers 
looked into the marrow sheath, and many different names were produced. This led to Virchow 
coining the word myelin to identify these sheaths as well as some other entities with the same 
colour, based on the word myelos which refers to the bone marrow like colour124. The function 
of this sheath and how it was produced was not understood, with the dominating theory of 
the time being that the myelin sheath was produced by the axon itself. It was not till the 
discovery of the osmium stain, which allowed myelin to further be understood, that myelin 
was able to be defined as fibres rather than globules67,125. These fibres of myelin were 
discovered to form concentric layers of 170-186Å thickness in the PNS and approximately 160 
Å thickness in the CNS. The Bunge lab found that within the CNS these layers are produced by 
OLs, whose processes can extend as far as 12µm, and that individual OLs can produce multiple 
regions of myelination (internodes) on multiple axons67,126–129. Myelin was discovered to be 
70-85% lipid, and 15-30% protein with differences in these ratios arising between the CNS and 
PNS130.  
Virchow rightfully identified that the role of the myelin sheath was to insulate the axon 
(Virchow 1858), which was later supported by Ranvier125. This insulation was later understood 
to be key for salutatory conduction 66,131–133. Saltatory conduction refers to the ability to 
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propagate an action potential along myelinated fibres, providing a faster conduction velocity. 
This works as the axon only needs to depolarise at nodes of Ranvier. Ranvier and Saious 
suggested that myelin plays a role in nutrition and energetic support within the axon, this was 
supported by the work of Funfschilling and Lee125,134–136. 
The myelin sheath is a multilamellar structure composed of flattened myelin membrane, the 
integrity of which determines the speed of transmission (Figure 1.7)137. The sheath contains 2 
regions which can be identified by electron microscopy, the major dense line, which is formed 
by the adherence of the cytosolic surfaces of the plasma membrane, and the intraperiod line, 
which is formed by the extracellular surfaces88,137. 
 
Figure 1.7: Myelin sheath surrounding an axon. The oligodendrocyte extends its flattened process to make concentric 
layers of myelin. The major dense line is produced where 2 cytosolic regions of membrane adhere, whereas the 
intraperiod is produced by the extracellular surfaces of the membrane. The cytoplasmic content of the process is 
compacted and accumulates in small pockets, the pockets that are near the axon form the inner loop (IL), whereas 
pockets closer to the periphery produce the outer loop (OL). Image from Greer 2013138 
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1.4.5  Myelin Damage 
Damage to existing myelin (Demyelination) has profound effects on neurological function, and 
can lead to symptoms such as neuropathic pain, myasthenia, and spasms139. Traumatic spinal 
cord injury causes a disruption within the communication between glia and axons, leading to 
demyelination and loss of function. The primary trauma causes physical damage to the myelin, 
and compaction of the neurone. This leads to a disruption in ion dynamics in the CNS, which 
affects the conductivity within the trauma site140. Although the mechanical injury from the 
primary trauma causes damage, the secondary trauma which occurs a number of hours after 
this causes the most damage141. The secondary damage can occur due to a variety of reasons 
including ischemia, haemorrhaging, free radical production, and immune system activity, the 
result of which is more necrosis. Here the cascade of events causes the damage to spread 
from the original site of injury to adjacent sites, this forms an environment which is not 
accommodating to regeneration within the spinal cord, which ultimately leads to irreversible 
loss of function. This damage is self-propagating within and around the injury site142. For this 
reason the repair of myelin (remyelination) is key to pave the way for DNA regeneration143. 
This works via two mechanisms, firstly myelin restores impulse conduction by preventing 
signal loss, and secondly myelin reduces the vulnerability of axons by acting as both a physical 
barrier for the noxious signals within the tissue, and a source of trophic support. 
 
CNS inflammation itself is one of the most common causes of myelin damage; a prominent 
example of which is multiple sclerosis (MS). Multiple sclerosis is one of the most extensively 
researched demyelinating diseases, whose cause is still unclear142. It has previously been 
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found that patients suffering from MS exhibit lesions within the CNS, which lack myelinating 
OLs, and possess an immune response within these lesions against the myelin47,144,145. Both of 
these symptoms impede successful re-myelination within these patients. B cells and T cells 
have been shown to be involved in the pathogenicity of MS, with these cells entering the CNS 
by permeabilising the blood brain barrier, and producing an autoimmune response to myelin 
antigens24,146,147.Other immune cells are recruited through the release of pro-inflammatory 
cytokines which exacerbates the demyelination and OL death139.  
1.4.6  Remyelination 
Remyelination occurs in several stages, and is a response to demyelination143. Progenitor cells 
migrate into areas where demyelination has occurred, and differentiate into mature OLs, 
which are used to myelinate the exposed regions of the axon. The mature OLs extend 
processes towards the injured axon, using signals from the extracellular matrix. These 
processes produce myelin proteins and synthesise myelin membrane, which wraps itself in 
several layers around the axon. The myelin proteins are synthesised within the processes near 
the site of remyelination, rather than within the cell body, this is believed to occur in this 
manner to support the efficiency of the process of re-myelination90. Although remyelination 
does occur spontaneously, the quantity of this is inadequate to cause functional sensory and 
motor recovery in conditions such as traumatic spinal cord injury or MS142. This remyelination 
has also been shown to produce myelin which is not structurally the same as the original 
myelin sheath, with remyelination producing shorter and thinner internodes compared to 
those on normal axons148. These shorter myelin structures have a detrimental effect on the 
conduction speeds of the axon, as there are more nodes of Ranvier and therefore more of a 
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need for signal propagation (Figure 1.8). These myelin sheaths are adequate in restoring near 
normal function to the axons, however, a mild loss of ability is still apparent149.  
 
Figure 1.8: Depiction of axon myelination before and after remyelination. A) Depiction of myelination within an axon. As 
can be seen axons can be myelinated multiple times from a single oligodendrocyte and contain segments of myelination 
from multiple oligodendrocytes B) Depiction of remyelination of an axon. It can be seen that segments of remyelination 
(light Blue) form shorter than the original myelination (Dark Blue). Image was modified Franklin & ffrench-Constant 
2017150. 
 
1.4.7  Myelin Proteins 
Although the majority of the composition of myelin is lipids, proteins make up approximately 
a third of myelin88,130. These proteins play a key roles in the structure and function of myelin. 
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Cyclic-nucleotide-phosphodiesterase (CNP) constitutes 4% of the total myelin protein. It is 
known as a Wolfgram protein as its existence was suspected by Wolfgram when a group of 
proteins were found to be insoluble in a mix of chloroform and methanol88.  CNP is found at a 
high concentration in immature myelin, however, it is not found in mature compact myelin 
when immunocytochemically stained for88. It has been suggested CNP has a role in the 
formation of myelin through membrane expansion as overexpression of CNP has been shown 
to cause irregular membrane expansion in OLs151. 
Myelin Associated Glycoprotein (MAG) is a membrane spanning protein from the 
immunoglobin superfamily88. Within the adult rat CNS MAG is limited to the periaxonal collar 
of the myelin sheath, where as in the PNS it is largely distributed in the intermodal regions of 
myelin.  Knockouts of MAG have been shown to allow normal functioning myelin, however, 
abnormal formation of a periaxonal cytoplasmic collar, and has organelles within the lamellae 
152. Over expression of MAG has been shown in the PNS to cause over myelination, suggesting 
it has a role in surface detection, which is confirmed by studies using anti-MAG antibodies 
where it has been shown MAG plays a role in neurone, glia interactions153,154. 
Myelin Oligodendrocyte Glycoprotein (MOG) was first identified as an antigen for inducing 
demyelination88. MOG is a myelin protein which is only present in mammalian species, and is 
highly conserved. MOG is localised to the outer lamellae of compact myelin, and tends to be 
used as a marker for OL maturation88.  
Myelin proteolipid protein (PLP) corresponds to approximately 50% of myelin proteins88. PLPs 
are located on the major dense line and intraperiodic line of myelin. PLP knock out in mice 
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does not affect the competency of OLs to myelinate, however, the myelin formed is less stable 
shown with condensation in the intraperiodic lines155. PLP knock out also causes axonal 
swelling in the neurone suggesting that subtle alterations in myelin structure may affect 
axonal viability88. Over expression of PLP perturbs the formation of myelin and the viability of 
OLs156. It has also been shown that over expression of PLP reduces the quantity of other myelin 
proteins such as myelin basic protein MBP, which could account for the effects on OL 
viability157. 
The Myelin Basic Protein (MBP) content of myelin constitutes approximately 30% of the total 
protein88, and has been found to be expressed in mice as early as embryonic day 14158 .  
Deletion of the MBP gene in mice, such as that which occurs in shiverer mutant mice, results 
in a lack of a major dense line in the myelin structure due to its incorrect compaction 159. Post-
translational modification of MBP through methylation is believed to be important for the 
compaction role of MBP160. Recent findings have suggested that MBP drives myelin biogenesis 
using phase interactions161. These phase interactions are mediated by hydrophobic 
interactions from the phenylalanine residues in MBP, and have been implicated in forming a 
structural mesh within myelin to cause compaction161. This mesh is suggested to play a role in 
the extrusion of other myelin proteins to the periphery of the myelin leaflet, by making the 
myelin leaflet less permeable to molecules above a certain size161. MBP thus far is the only 
myelin protein known to be required for generating compact myelin sheaths162. 
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1.4.8  Oligodendrocyte Markers 
Antigenic markers are used to identify OLs, their phase of maturity and the cells leading up to 
mature OLs. There are several markers which can be identified for OLs, and their precursor 
cells (Figure 1.9). A few key myelin markers are addressed here. 
The OL transcription factors, Olig1/2, are useful in determining an OL lineage, as they are 
present from OL precursor stage throughout to mature OL stage163,164. Olig1/2 are both 
members of the basic helix loop helix family, with Olig2 producing a 323 amino acid long 
peptide, and olig1 producing one of 271 amino acids165–167. Both proteins are highly associated 
with chromosome 21, this has led Olig2 to be implicated with a role within Down syndrome, 
due to its actions to regions close to the Down syndrome critical region166,168. At this region 
transcription factors have been shown to have actions in the production of reactive astrocytes, 
neural repair, and OL precursor differentiation164,169–172. 
Prior to committing to an OL path, oligodendrocyte precursor cells (OPCs) express 
Neurone/glial antigen 2 (NG2). NG2 is a chrondroitin sulphate proteoglycan, a class of proteins 
known to be upregulated in neural regeneration, and cell adhesion173–175. NG2 itself has been 
shown to be involved in cell adhesion, motility, cytoskeletal organisation, and outgrowth, as 
well as repulsive to neurones174,176–184. It is first expressed at embryonic day 14, and can be 
seen throughout the hindbrain following embryonic day 16185. At embryonic day 17 NG2 
expression is concurrent with that of platelet derived growth factor α receptor 
(PDGFαR)185,186. Expression of NG2 reaches its maximum density at postnatal day 10, and then 
is lost from maturing OLs a few days later186–188. NG2 is not only expressed within OPCs but 
also within pericytes so PDGFαR tends to be used when immunopanning for mice OPCs189–191. 
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Platelet derived growth factor receptor α (PDGFαR) is a tyrosine kinase receptor with a high 
affinity to all isoforms of platelet derived growth factor192. Platelet derived growth factors are 
abundant throughout different parts of the body, such as smooth muscles, fibroblasts193, and 
within the CNS platelet derived growth factor A is expressed by neurones and astrocytes194. 
They play a role in processes such as angiogenesis, gastrulation, and alveolar development, 
and more specifically within OPCs they are involved in proliferation, migration, and 
maturation192,193. PDGFαR is expressed from embryonic day 15, and is expressed concurrently 
with NG2 at embryonic day 17185,186,192. 
A2B5 is a marker for gangliosides within OL lineage cells, in particular the GQ ganglioside, and 
used to mark the OPC phase. Gangliosides exist in large quantities within the CNS195. They 
have many intercellular roles including intercellular trafficking and cell signalling196–198. It is a 
commonly used OPC marker in vitro, but is also useful to mark neuronal progenitors, therefore 
A2B5 is not useful as a specific in vivo marker for OPC199–201. 




Figure 1.9: Marker timeline for cells in the oligodendrocyte lineage. Common markers utilised for detection are shown in 
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1.5  Multiple Sclerosis 
Multiple Sclerosis (MS) is a chronic demyelinating autoimmune disorder that affects the 
nervous system impairing a variety of functions. There are various different clinical 
pathologies accounting for the extent and progression of MS in patients. MS affects more than 
two million people worldwide, with no known cure203.  
1.5.1  Risk 
There is no know etiological trigger of MS identified, and the causes are still unknown. 
However, there are a number of risk factors which have been identified to increase chances 
of patients progressing to MS. Many proposed risk factors include Serum vitamins, 
vaccinations, surgical trauma, and environmental agents204–208. Trauma has been implicated 
in the development of MS, with premorbid injuries being associated with diagnosis of MS209. 
Surgery has also been implicated with MS, especially in surgeries involving lymphatic tissue at 
a young age206. However, the part of trauma and surgery in the development of MS is 
controversial, with most studies suggesting if it plays a part it is small203,206,209. Another risk 
factor which is suggested of MS is vitamin D levels,  with vitamin D intake being inversely 
related to MS onset, relapse rate, and clinical severity203,210,211. However, a number of these 
studies show that dietary vitamin D levels don’t exhibit an association with MS incidence210. 
This relationship of vitamin D may also play a role in the discrepancy of MS rates in different 
climates, with more temperate climates, like north America and northern Europe, showing a 
marked increase compared to more hotter climates, such as Asia and Africa212. Infection with 
viruses have been implicated, especially the Epstein Barr virus (EBV) 213,214. Patients with 
clinically active MS have a tendency to express antibodies against the EBV215–217. This 
seropositivity was found to be higher than individuals without MS who have been in contact 
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with the EBV, this was found to be the only virus seropositivity out of those tested which 
differs between those effected with MS and those not215,216. From Belbasis’s meta-analysis of 
risk factors for MS only three environmental causes were shown to be highly related with 
MS218. Two of these were linked to EBV, seropositivity to EBV and infectious MONO, the other 
factor being smoking. 
One key risk factor is sex, as females are almost twice as likely to develop MS than men212,219–
223. The exact reason of this yet to be determined, however, it has been suggested to be linked 
to testosterone levels, and in preliminary results by Chitnis testosterone replacement therapy 
has beneficial effects222. However it must be noted that the prevalence of MS is enhanced due 
to the premature mortality of men212,224. It has also been suggested this is due to the 
willingness of women to consult on health problems, as more benign cases are seen in women, 
however, from the work of Orton it is seen that the interval between onset and diagnosis on 
average is the same between sexes and therefore not due to male reluctance to consult212,221. 
Most of the genes implicated with MS susceptibility are associated with immune processes, 
and are genes related to other autoimmune diseases225. Approximately 200 genes have been 
identified which may play a role, with the HLADRB1*1501 haplotype being identified as the 
most significant genetic indicator for MS203,223. 
1.5.2  Presentation 
MS consists of two distinct occurrences, firstly there is diminishing neurological function, and 
reductions in cognitive processing ability203,226,227. The second occurrence is the episodes of 
disability, referred to as relapses, which may last anywhere between days to weeks. The 
   
36 
 
amounts of both these occurrences vary depending on the phase, and presentation of MS the 
patient exhibits. 
 
There are 4 types of presentation of MS, the most common of which is relapsing-remitting. 
Diagnostically there is no clinical test to distinguish between the different presentations, the 
only way to distinguish is through the clinical course from onset. Relapsing remitting MS 
(RRMS) constitutes about 85% of patients with MS228–231. This presentation is characterised by 
temporary relapses where new symptoms present, patients are normally otherwise able to 
progress within their lives as normal. This may develop into secondary-progressive MS (SPMS) 
over time, this is normally between 20-25 years from onset. With SPMS symptoms worsen, 
with a reduction in the amount of remission, or even an absence of remission. In addition to 
this 10% of patients presenting with MS have symptoms classifying them with primary 
progressive MS (PPMS)203. This is characterised by slowly worsening symptoms from the 
beginning without recovery228–231. The final presentation is progressive relapsing MS (PRMS), 
which is the rarest form effecting up to 5% of patients203,232. This is characterised by 
progressive neurological dysfunction, with acute relapses, and no remission.  




Figure 1.10: Myelination during multiple sclerosis. The figure shows patches of myelination from OLs with some cell 
debris from demyelination. This area of demyelination does not benefit from myelination, but remyelination can’t occur 
due to the existance of the cell debris. Image was modified Franklin & Ffrench-Constant 2017150. 
MS consists of 2 phases, the early phase which is defined by a focal inflammatory response, 
and a later phase which is independent of inflammation212. The median time from onset to 
death within patients varies from 24 years to 45 years depending on a range of factors, 
however, all studies suggest that life expectancy of patients is reduced by at least about 14 
years compared to the general population203,233–242. Within the first 20 years of the disease is 
it believed that survival rates are the same as with the general population, and that risk of 
death increases due to increase disability, and an increase in suicide rates203,233,238,239,241,243,244. 
Pathologically, MS presents with focal areas where demyelination, inflammation, and gliosis 
occur, referred to as lesions203 (Figure 1.10). Lesions present throughout the CNS, but vary in 
frequency. The most common location for lesions are perivascular areas within the brain, 
although subpial lesions, associated with leptomeningeal inflammation, and spinal lesions, 
associated with clinical disability, are also key in understanding the condition203,245–249. These 
lesions are more capable of repair within younger patients, corresponding to the increased 
severity of symptoms causing the progression of patients from RRMS to SPMS250–252. 
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Within these lesions both macrophages and microglia are abundant, in addition to astrocytes, 
all of which promote an immune response through the complement system, through the 
expression of complement C1q, as well as recruiting more immune cells through the 
expression of opsonising agents, such as complement C323,253–256. The blood brain barrier 
becomes leakier, allowing more macrophages to invade the plaques, exasperating the plaques 
and producing a self-propagating injury257,258. In addition to this the adaptive immune system 
also plays a role, as CD4+ and CD8+ cells have also been observed within the lesions259. Drugs 
which reduce T cell and B cell invasion into the plaque, have been shown to limit the formation 
of plaques within MS patients, however, it should be noted all disease modifying drugs thus 
far limit white matter lesions but do not seem to delay clinical progression203,260.  
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1.6  The Immune System 
The emergence of multicellular organisms posed a requirement to protect the organism 
from foreign material which could potentially disrupt the ability of the organism to work 
efficiently, and maintain homeostasis261. This foreign material, known collectively as 
pathogens, disrupt normal cell function in order to redirect resources to fuel the pathogen’s 
own replication and spreading. This not only aids the pathogen’s survival but also allows the 
pathogen to spread to other cells and possibly other organisms261–263. As the pathogens 
redirect the cellular resources to their own processes, the cells have less resources for their 
own functions, which has an effect on its functions within a multicellular system. Also by-
products from pathogen-related processes, known as toxins, can be harmful to the 
organism261,264. In order to combat this a set of cellular and molecular defences, known as 
the immune system, exists with the aim to eliminate these pathogens from the organism. 
This system is required to destroy the pathogens, and any toxins they may produce, with 
minimal damage to the host tissues261,265. It must also be able to tolerate normal tissue from 
the host (self tolerance) and commensal organisms262,265,266. In order to achieve the 
recognition of the vast array of pathogens, and combat their array of mechanisms the 
immune system has developed a range of complex tools. The mechanisms to recognise these 
pathogenic materials can be categorised within 2 categories, the innate responses which are 
genetically inherited and non-specific, and the adaptive responses which are clonally unique, 
highly specific, and change during the organism’s life span (Figure 1.11)261,262,267. 
1.6.1  Innate Immune system 
The innate immune system is encoded by genes which are existent within the host’s germ 
line265. The innate immune system consists of various components, including physical 
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defences such as the skin, cilia, tight junctions, and mucosal layers, chemical defences such as 
small protein and bioactive molecules, and cellular defences such as immune cells261,265. The 
physical defences are the first line of defence, they non-specifically restrict what may enter 
the body, and also play a role in preventing pathogens establishing themselves outside of the 
body261. When the physical defences fail to prevent pathogen entry the other defences are 
required261,265. The chemical defences include various small molecules, such as complement, 
defensins, cytokines, and enzymes, all of which play different roles in collaboration with the 
cellular defences265,268,269. The chemical defences can be categorised as the constitutively 
active molecules such as complement, defensins, and ficolins; and the molecules which must 
be activated, such as cytokines, chemokines, and enzymes265,268,269. All molecules play a key 
role in either attacking the pathogens, recruiting other immune entities to dispose of the 
pathogens. One of the key innate immune elements which are recruited by this are entities 
utilised in cellular defence such as the immune cells261,265. The immune cells at this level 
recognise and target structural features which are not common within mammalian cells 267. 
The receptors involved, referred to as pattern recognition receptors (PRR), help control not 
only pathogens, but also help control the levels of commissural organisms, and clear host cells 
which have died or are injured261,265,270. These receptors exist in all cell types, but the 
combinations vary between different cell types.  
1.6.2  Adaptive Immune system 
The adaptive immune system is the next line of defence for an organism. This is form 
developed by exposure of the organism to various pathogens261,265. The adaptive immune 
system is only utilised if a pathogen has been present for an extended amount of time, and is 
only evident in vertebrates271. Adaptive immune responses take a matter of days to mount a 
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defence as cells need to be proliferated to respond to the pathogen, whereas the innate 
immune system activates on the order of hours261,265. The response of the adaptive immune 
system is long lived, as immune cells which are formed for the pathogen may lay dormant 
following the eradication of the initial exposure, and can form an immune memory261,262,265,271. 
The adaptive immune system is more specific than the innate system, with many cells 
encoding a response to a single pathogen261,262,265,271. This is the stage where identification of 
the hosts own cells, self-identity, must occur. Responses here can either be mediated by an 
antibody or by the cell. Antibody mediated responses are occur when B cells are activated and 
secrete antibodies, which bind to a target on the pathogen referred to as an antigen261,271. 
This prevents the pathogen from binding to receptors to initiate its response, as well as 
marking pathogens to allow phagocytes to find and ingest them. These antibodies are highly 
specific and can distinguish antigens which differ by one amino acid or are optical isomers of 
each other271. Cell mediated responses occur when T cells react to a foreign antibody directly, 
the T cells then either recruit macrophages to dispose of the pathogen or kills the cells itself. 
This stage of the immune system is specific and allows immune memory, which is an 
advantage in dealing with more devastating viruses as it allows immune priming using 
immunisation. Immunisation involves exposure to inactivated pathogenic components, which 
activates the immune system, and allows the body to produce adaptive immune memory cells 
to response to the pathogen272,273. This system may also be detrimental if dysregulated as is 
the case with various allergies such as hay fever, and asthma265,274,275 
Both the innate and adaptive systems are required to combat the full plethora of pathogens 
encountered by the organism.  







Figure 1.11: Depiction of the innate immune system and the adaptive immune system. The innate immune system 
comprises of many different element including the dendritic cell (DC), macrophages, neutrophils, and natural killer (NK) 
cells. These all signal the adaptive immune system, whether it is the production of products like immunostimulatory 
liposomes (IF-liposomes), or production of secondary messengers such as interleukins (IL). These elements activate the 
adaptive immune elements such as the T cells. T cells may differentiate to form other cell types, such as T helper cells 
(Th1/2), or may signal the activation of other cells such as B cells. B cells when activated produce antibodies against the 
pathogen as well as producing memory cells to help combat the pathogen in the future. This figure was adapted from 
Faisal 2015276.  
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1.7  Complement system 
The complement system is a key element of the innate immune system, comprising of an array 
of molecules ranging from membrane proteins and receptors, to plasma molecules, all of 
which form a self-propagating cascade to attack pathogens268. Complement comprises of over 
30 molecules, which account for up to 10% of the total amount of proteins within serum. 
These molecules serve many functions within in the body including within tissue regeneration, 
synaptic pruning, homeostasis, and the adaptive immune response256,266,277–286. The term 
complement was originally coined by Paul Ehrlich in 1899, in reference to heat inactivatable 
substances in serum which were found to improve the antimicrobial immune response of 
antibodies275. Complement proteins generally are synthesised by hepatocytes within the liver, 
however , they may also be made locally, as seen in the CNS where astrocytes, microglia and 
neurones produce complement281,287–292. Inactive complement precursors circulate the body 
normally, and activates in response to a pathogen293. In addition to this expression of 
complement also increases during periods of infection and ischemia281. Alterations in the 
levels of complement proteins can lead to various pathologies, such as tissue/ organ damage 
in over activation294, and conditions such as lupus erythematosus when deficient295–297.  
Activation of the complement system can occur from 3 distinct pathways, the classical, lectin 
and the alternate pathway. All these pathways converge at the production of a factor C3 
convertase293. 
The classical pathway utilises complement protein C1q which binds to the Fragment 
crystallisable (Fc) binding site of the immunoglobulin (Ig), normally Ig M/Ig C, and C-reactive 
protein following antigen binding274,275,293,298. This forms a complex with complement C1r to 
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activate C1s, the activated C1s is used to cleave complement factors C2 and C4, Figure 
1.12275,293. The Lectin pathway has a number of recognition molecules, such as mannose 
binding lectin, collectins and ficolins. The recognition molecule forms a complex with a serine 
protease to form a C1-like complex, cleaving factors C2 and C4. Both the classical and lectin 
pathway lead to the conversion of factor C4 to factor C4a and C4b, and factor C2 conversion 
to C2a and C2b. The factors C4b and C2a then form the C3 convertase274,275,293,298. 
The alternative pathway activates spontaneously using complement factors B,D,H and 
properdin, in a process referred to as antibody independent hydrolysis, this is achieved by 
hydrolysis of factor C3 using factor B to form C3(H2O)FB, which is then further matured using 
factor D to form a C3 convertase, C3bBb275,293,298. 
The C3 convertases formed cleave factor C3 to factor C3a and C3b. The factor C3a is utilised 
as a chemoattractant to recruit more inflammatory cells, whereas the C3b is utilised as a tag 
for apoptotic debris clearance, and bind to the C3 convertase to form factor C5 
convertase299,300. The C5 convertase cleaves factor C5 forming C5a and C5b, C5a attracts more 
inflammatory cells, and triggers granule release299. Whereas, C5b initiates the membrane 
attack complex by binding to factors C6, C7, C8, and up to 18 molecules of C9264 (Figure 1.12). 
This complement cascade results in the formation of a membrane attack complex to kill cells, 
inflammation to attract phagocytes, macrophages and neutrophils to the area and the 
activation of the phagocytes to clear the foreign and damaged material produced256,301,302. 
C3b is a key opsonising agent, tagging pathogens for clearance and recruiting various 
macrophage cells to clear pathogens256,299. 
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Aberrant complement activity is associated with a number of autoimmune conditions such 
as glomerulonephritis, Sjögren’s syndrome, and rheumatoid arthritis268,274,295,303. Showing 
that complement cascade is important in fundamental immune processes. 
 
Figure 1.12: Depiction of the complement Pathways. This shows the Mannose binding lectin pathway, the classical 
pathway, and the alternate pathway. All these pathways converge at the formation of complement C4, which is used to 
form C5 and so on till the MAC complex is produced. This Figure was extracted from Rutkowski et al 2010 293 
 
As complement proteins are well conserved, viruses have also adapted in order to combat 
this crude system and to utilise it in infection304,305. Viruses such as the vaccinia, cowpox, 
and variola viruses have developed means to evade complement by mimicry of its 
regulatory proteins, for example the vaccinia virus produces a factor I like protein to cleave 
C4b and C3b, whereas some other viruses like human immunodeficiency virus incorporate 
complement proteins into their viral envelopes to evade immune response, or use 
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complement proteins as receptors for infection, an example of which is the Epstein–Barr 
virus which uses complement protein CD21 to infect B cells268,303,305,306.  
One of the other interesting functions of complement is its functions in neuroprotection and 
synaptic pruning (Figure 1.13)281–283. It has previously been shown that mice injured with kainic 
acid exhibit a greater injury if the mice were deficient in complement protein C5307,308. This 
role of complement is also supported by results in experimental autoimmune 
encephalomyelitis where C5 seems to provide an anti-apoptotic function309. To further these 
results, it has been shown that the MAC complex inhibits apoptosis in Schwann cells and OLs 
(Figure 1.12) 310,311.  
It has been suggested that the classical complement pathway plays a key role within 
synaptic pruning (Figure 1.13)281. Complement protein C3a has been suggested to play a role 
within neurogenesis, with blocking of C3a following ischemia inhibiting neuroblast 
migration and neurogenesis312. In addition to this, stimulation of complement protein 
receptor C5aR has been shown to inhibit caspase-9 driven apoptosis within granule cells in 
the cerebellum313. This is supported by the downregulation of C5aR mRNA in terminally 
differentiated cells, as occurs when OPCs mature into OLs314. Complement protein C1q has 
also been suggested to have a role in synaptic pruning, as C1q levels are upregulated in 
neurones and microglia in CNS diseases such as Alzheimer's disease, Huntington's disease, 








Figure 1.13: Functions of the complement cascade on various phases of the glial and neuronal life cycle. Complement 
promotes neuroinflammation in addition to supporting cellular development, cellular regeneration and viability 
following injury. Both neurones and glia produce a complete set of complement proteins which interact with a range of 
receptors to induce many functions. C1q exhibits a role in synaptogenesis by causing synaptic pruning in mice. Binding of 
complement C3a and C5a to their receptors in progenitor cells exhibits a role in maturation, and differentiation. 
Complement proteins have also been shown to play a neuroprotective role in cellular injury conditions, by inhibition of 
apoptosis and stimulation of growth. This stimulation of growth has also been seen within remyelination studies within 
the CNS. This Figure was extracted from Rutkowski et al 2010 293 
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1.8  Fluorescence 
In order to observe the effect of biological components, such as complement, there must be 
a means to tag the components. Fluorescence provides a means to do so. 
The term fluorescence was first used in Sir George Gabriel Stokes’ paper titled “On the change 
of refrangibility of light”, as a means to describe the property of the mineral fluorite which he 
observed319. Fluorescence is brought about by electrons within the singlet ground state 
absorbing energy, normally through photons, which causes a molecular transition that 
promotes electrons to raise to a higher energy state, referred to as the highest vibrational 
state320,321. From this point the electron falls through vibrational states, releasing vibrational 
energy, until it reaches the excited state. From here the electron releases the energy required 
to return to ground state. This energy manifests itself as light (Figure 1.14). This emitted light 
is of a higher wavelength and lower energy than the light utilised to excite the electrons. This 
difference in wavelength has underpinned fluorescence microscopy as the excitation and 
emission light can readily be separated320,321. 
 
Figure 1.14: Jablonski diagram of fluorescent protein activity. The excitation energy is normally provided by a photon of 
high energy, or multiple photons simultaneously to provide enough energy to reach the higher vibrational state. Some of 
this energy is lost, such that the electron enters the excited state, where the electron releases energy as light in order to 
return to ground state. Due to the energy loss between the higher vibrational state and excited state, the wavelength of 
emitted light is different to that of the excitation light. 
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1.8.1  Fluorescent protein (FP) 
Fluorescent proteins (FPs) have provided an important tool for use within biological 
imaging322. This has been useful as FPs are genetically encodable so can be introduced into 
cells without fixation of premiabilisation, this has allowed information on protein expression, 
and localisation to be performed with more reliability323.   
The first fluorescent protein which was studied was green fluorescent protein (GFP), which 
was first isolated from Jelly fish, Aequorea victoria , in the 1960s324. Prior to this work the only 
bioluminescent molecule identified was luciferin325, as all other cases of fluorescence 
observed were seen in mineral states such as fluorite. From Aequorea Victoria two proteins 
were identified, aequorin and GFP, both of which showed interesting properties324. Aequorin 
when purified was shown to emanate a blue glow, which was later found to work in a Forster 
energy transfer with GFP to make the jelly fish emit green light. It was not till 1992 that the 
chromophore for GFP was discovered326–328, which was later found to autocatylse329. Although 
the original attempts to synthesise GFP from its genes were not successful330, it was eventually 
achieved by the work of Chalfie in 1993 where GFP was established as a staple lab tool331. 
Following that many other fluorescent proteins have been generated through point mutations 
or discovered, such as monomeric cherry FP332, blue fluorescent protein329, and yellow 
fluorescent protein333. It was found that GFP does not affect function when fused to other 
proteins (fusions), allowing FP fusions to become useful in exploration in structure and 
function of proteins325,334–337 
1.8.1.1  Photoswitchable FPs 
Since the discovery of GFP many unique and peculiar fluorescent proteins have been 
produced with interesting spectral properties338. Some mutants of GFP such as citrine, 
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enhanced yellow fluorescent protein, and cyan fluorescent protein, showed the property of 
photoswitching, where following irradiation with certain wavelengths, the molecule 
undergoes a change in structure which allows the fluorescent signal to be diminished or 
salvaged reversibly339,  as shown with mIRIS FP (Figure 1.15). However, these original 
mutants of GFP showed poor contrast, as they did not photoswitch efficiently339. The 
discovery of kindling fluorescent protein provided the first utilisable signal for a 
photoswitchable protein within research. However, due to its existence as a tetramer it 
proved impractical for many research uses339,340. Following this the monomeric FP Dronpa 
was discovered341, which was a photoswitchable green protein with a baseline ‘on’ 
phenotype341. This allowed the discovery of other photoswitchable proteins through 
mutation such as Padron FP, where methionine at position 159 is converted to a tyrosine, 
which has a baseline ‘off’ phenotype342. Further understanding of the chromophore allowed 
new photoswitchable versions of previous FPs to be produced such as mApple322 and 
rsCherry343. Photoswitchable proteins tend to be 11 strand β-barrel structures, with an alpha 
helix in the centre344. The 4-(p-hydroxybenzylidene)-5-imidazole chromophore is generated 
auto-catalytically, and a cis/trans isomerization of the methylene bridge between these 2 
rings determines the state339. Dronpa FP is in the cis conformation at rest which is stabilised 
by hydrogen bonding between serine in position 142 and hydroxybenzylidene, providing it 
with a baseline ‘on’ state339. Padron FP, on the other hand, exists in a Trans geometry at rest 
as the tyrosine in position 159 interacts with the p-hydroxyphenyl ring stabilising the 
chromophore.  
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1.8.1.2  Photoconvertible FPs 
In addition to photoswitchable fluorophores, another key variety of FP exist, known as 
photoconvertible fluorophores338, which undergo an irreversible change in structure triggered 
by light. This is illustrated with mIRIS FP in Figure 1.15, where UV light induces the 
incorporation of a side chain into the π-bond system of the chromophore345, causing the 
chromophore to change from a 2 ring system into a 3 ring system346. One of the first examples 
of a photoconvertible was kaede FP, which upon ultraviolet irradiation irreversibly converts 
from its native green emission to a red emission347. Following this a number of 
photoconvertible proteins were produced such as mKIKGR348, Dendra2349, and mEOS2350, all 
with slightly modified spectral properties351. In addition to this, a number of jointly 
photoconvertible and photoswitchable FPs have been produced, such as Iris FP352, and Niji 
FP353 (and as also shown in Figure 1.15). This allow finer experimentation than either 
photoconvertible proteins, or photoswitchable proteins alone, as it allows control over both 
the emission wavelength, and the ability to activate the FP. 
  






Figure 1.15: Diagram of the photomanipulation of mIRIS FP. It can be seen that photoswitching occurs in both the red 
and green forms of the FP, causing a switch between the fluorescent form and the dark form. Photoconversion also 
occurs within mIRIS with 405 nm light, causing a conversion between the green and red form. This occurs as the photo 
conversion extends the π electron system of the chromophore to the third ring of the structure, effectively acting as a 2 
ring to 3 ring conversion of the chromophore354. This image was adapted from Wiedenmann et al 2011355. 
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1.9  Single molecule Imaging 
Traditional fluorescent imaging in the life sciences utilises imaging on the “ensemble average” 
level, which looks at the population as a whole. This has allowed a “break-neck pace of 
growth” within the life sciences as it has allowed us to make discoveries on the average 
behaviour of molecules quickly, helping smooth out any anomalous data356. However, the 
molecules in living cells undergo more dynamic behaviours and movements, with each 
molecule experiencing the behaviours at different time scales357. Ensemble techniques do not 
allow these kinetics, dynamics, and behaviours of molecules to be teased out. These 
behaviours are important in understanding the true interactions and consequences of 
molecular fluctuations in a sample358. Of exceptional importance is the understanding that 
genetically identical cell cultures, may show identical results on an ensemble level, however, 
the population is intrinsically heterogeneous with different cells showing variations in 
physical, chemical, and biological properties356. This intrinsic heterogeneity is valuable in the 
adaption of the cells to the environment, and therefore key to survival359–361. Also many of the 
conventional modalities require cells to be fixed which causes distortions on the true structure 
of proteins362. This is where the emergence of single molecule imaging has allowed further 
understanding in the field.  
Single molecule imaging (SMI) techniques allow the observation of the stochastic and 
probabilistic behaviours which drive biological reactions, and the interplay of molecular 
interactions and random collisions363. The pivotal point of SMI is the ability to identify 
individual molecules within the population, observe their precise location, and follow them in 
the cellular environment, which is not possible or necessary within ensemble averaged 
imaging323. Single molecule techniques can be split into 2 categories, Single molecule 
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localisation, and single molecule tracking364–366. Single molecule localisation techniques utilise 
single molecule information to quantify and locate molecules within a sample334,367. This 
requires high resolution imaging, such as super resolution techniques, and normally is 
performed at the cost of temporal resolution, as many higher resolution modalities are slower, 
or require fixed samples367. Localisation experimentations allow information on the number 
of the labelled particle, structure of the system, particle interactions in terms of co-
localisations, and distribution of particles within the system to be derived from the 
experiments. Single molecule tracking on the other hand focuses on the dynamic behaviour 
of a system, by following a particles point spread function368. As samples are being tracked, 
faster imaging modalities are required, and live samples must be imaged. With tracking 
experiments information on the molecular dynamics, interactions in terms of dwell times, and 
movement of the particle can be derived 369.  
When designing single molecule experiments there are several considerations which must be 
addressed, such as the choice of probe, the labelling methods, and the microscope setup. The 
biggest challenge for SMI is the generation of a signal which must be detected above any 
biological background luminescence364. The choice of probe is instrumental to producing 
viable results within single molecule modalities. The probes composes of 2 elements, the 
specificity molecule, for targeting the molecule of interest, and the label. In order to reduce 
the labels effect on the target molecule, a 1 to 1 ratio of reporter to target is normally utilised. 
The targeting molecule and reporter are normally conjugated to ensure the target can’t be 
lost. In terms of photophysical characteristics, inorganic fluorophores (such as Quantum Dots) 
provide stronger reporter signals, which bleach less and can be smaller reducing their effect 
on the target. However, these probes need to be applied exogenously, and require many 
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additional steps to conjugate them to the molecule of interest and ensure that they do not 
alter the behaviour of the molecule being studied. On the other hand organic fluorophores, 
such as fluorescent proteins, can be expressed by the cell of interest, conjugated to the protein 
of interest, with little effect on the function of the proteins they are conjugated to, these tend 
to be larger which allows a greater signal to noise ratio, however, they are easily 
photobleached relative to quantum dots325,334–337.   
The next key consideration is the imaging modality being utilised. Here the resolution of the 
images both spatially and temporally must be assessed. Imaging with high spatial resolution 
require high signal to noise ratios, which can be gained using longer exposures, and normally 
require stationary particles370. Whereas modalities with high temporal resolution tend to 
sacrifice spatial resolution to do so, as more sensitive detectors are required371. Next the 
penetration distance of incident light must be assessed, in terms of membrane proteins or 
single cells lower penetration imaging like total internal reflection fluorescence, may be 
utilised. On the other hand for thicker samples, like tissue slices, require techniques such as  
light sheet microscopy, or confocal microscopy372. In addition to this, the level of 
photobleaching and toxicity must be assessed, as techniques requiring higher laser powers, or 
longer exposures, will lead to more rapid photobleaching of samples and even damage to the 
sample, especially if imaging is needed for extended time periods373. Here the level of signal 
must also be assessed. Imaging techniques such as confocal microscopy allow greater 
penetration of the excitation beam into the sample. However, this will lead to greater 
background as fluorophores in layers above and below the plane of imaging will be 
activated374,375. This can be remedied using planar imaging such as light sheet microscopy, 
however, particles outside of your field of view will also be activated376. 
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Following imaging analysis of the images is the next concern. Particles within the images must 
be detected to allow downstream processing323. There are a number of detection algorithms 
each with their own advantages and disadvantages. Otsu thresholding utilises a cluster based 
thresholding, assuming the system is bimodal, consisting of background and foreground377,378. 
This is computationally efficient, however, deals poorly with photobleaching, poor contrast, 
or halo effects. The watershed method for particle detection deals with the image as a 
topographic map, with the intensity of each point being a height378,379. Although this deals 
better with poor contrast images than the Otsu method, it tends to over segment the image. 
Wavelet spot detector utilises wavelets to remove high frequency noise from the images, and 
identifies particles through local maxima380,381. However, it deals poorly with non-circular 
objects. The choice of the correct particle detection method of the images obtained is key to 
ensure downstream processing is reliable. 
The next step for single molecule experiments is post processing. This ranges from tasks such 
as observing the level of co-localisation within the sample, or clustering, or linking particles 
for track formation. In terms of tracking there are a number of algorithms which can be utilised 
for particle tracking, depending on the amount of prior information, the properties of the 
particles being tracked, and the amount of computational power available. Global 
optimisation linking is a robust method, which requires a large computational power382,383. It 
relies on the ability to link all detected particles in all frames with each other, to determine 
the most likely particles track for each particle energetically, determined using a global scoring 
system. This is computationally intensive, and requires high performance systems for large 
data sets. The multiple hypothesis linking technique (MHT) utilises deferred logic to reduce 
the computational power required compared to the global optimisation technique384,385. The 
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MHT utilises data from subsequent frames to reduce the number of possibilities which exist, 
producing a likelihood ratio to assess the viability of a track. Although this reduces the amount 
of computation power compared to the global optimisation technique, it is still a 
computationally heavy technique. The nearest neighbour technique reduces the amount of 
computational power further as it tracks particles based on a unique feature, this requires 
each particle to have a unique feature, whether it is the intensity, shape, or colour386. This 
works well if particles are well separated and have a unique feature which can be used to 
identify the particle easily. The least computationally heavy tracking technique is the 
probabilistic data association technique, this utilised prior knowledge on the dynamics of the 
particle to refine particle tracking results, however, this requires some knowledge on the 
particle dynamics to be known386,387.   
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1.10  Single Molecule Microscopy techniques 
SMI can utilise many different types of imaging modalities, to provide different levels of 
resolution, sample penetration, bleaching/phototoxicity, and signal388. When choosing an 
imaging modality consideration needs to be placed into selecting the right modality, as 
different modalities preferentially enhance one or two of these aspects at the cost of the 
others374. 
1.10.1  Confocal Microscopy 
Confocal microscopy is one of the key microscopy techniques within biology, which utilises 
apertures to remove out of focus signal389 (Figure 1.16). Within confocal microscopy two 
apertures are utilised, one to spatially reject the excitation beam focusing the light path, and 
another to filter out the emitted light to reduce any stray signals from planes, other than that 
being imaged364. Confocal microscopy requires either the stage or the laser beam to move in 
vertical and horizontal directions to scan the sample389. Confocal microscopy has a higher 
signal to noise ratio than a wide-field fluorescent microscope, as out of focus light is rejected 
by the apertures, improving the contrast within the image, allowing finer activities to be 
imaged, such as DNA repair 390, and viral activities391. However, classical confocal microscopy 
is known to rapidly induce photobleaching and phototoxicity within samples391, and due to 
the precision of the pinholes and mirrors it is known to have slow imaging speeds374. In order 
to circumvent these issues other implementations have been utilised, such as Spinning disk 
confocal microscopy392 and Airyscan364. Spinning disk confocal microscopes utilise a pattern 
of apertures in order to filter out of focus light, this allows faster acquisition rates than classical 
confocal microscopy as multiple points are recorded in parallel, this also allows each point to 
be illuminated for longer, allowing lower intensity light to be used, and thus reducing the 
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phototoxicity and photobleaching392. However, spinning disk modalities suffer from lower 
spatial resolution than classical confocal, meaning the depth at which images can be taken is 
lower364,392. Airyscanners utilise an array of small detectors to collect all the emitted light from 
the sample, each detector behaves like a small pin hole in the confocal microscope393. This 
provides greater resolution images, with lower signal to noise ratios than seen with confocal 
microscopes394.  
 
Figure 1.16: Diagram illustrating the principle of confocal microscopy. The light source is focused by the aperture to filter 
out any stray excitation light. This passes through a dichroic mirror, which allows the light from the source to pass 
through but to reflect the emitted wavelength, this may also be a beam splitter in order to allow observation from an 
eye piece and detection using the detector. The light before the detector is filtered using an aperture to remove out of 
plane signal. This figure has been extracted from Gramatikov 2014395 
1.10.2  TIRF Microscopy 
Total internal reflection Fluorescence (TIRF) microscopy utilises an excitation beam at a 
narrow incident angle to the sample. This angle is finely tuned to produce an evanescent 
wave396. If the angle is too large, the period of refraction is too long leading to reflection of 
the light, whereas if the angle is too shallow the period of refraction is too short so the light is 
transmitted396. When the beam of light is correctly tuned the light produces an evanescent 
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field in a region of interface between the two surfaces have different refractive indices, such 
as the cell membrane, the angles utilised are directly related to the refractive indices of the 
two surfaces, and can be determined through Snells law323. The evanescent field produced 
can extend as far as 100 nm before it is lost, this allows illumination of a small section of the 
surface, and only activates probes on the surface of the sample as the wave only penetrates 
as far as 150nm into the sample, providing a high signal to noise ratio as little background is 
produced323,396. Although TIRF produces great axial resolution, ~50 nm, it has poor sample 
penetration, which has led to the production of highly inclined laminated optical light sheet 
microscopy397. 
1.10.3  HiLo Microscopy 
Highly inclined laminated optical light sheet (HiLo) microscopy, often referred to as “near 
TIRF” microscopy utilises a thin optical sheet of illumination with a sharp imaging angle398. The 
sharp angle of HiLo microscopy allows penetration of up to 300 nm into the sample, double 
that which is possible with TIRF microscopy, with the light sheet compensating for the loss of 
light arising due to the lack of the correct angle to produce an evanescent field398. HiLo 
microscopy has a slightly lower signal to noise ratio compared to TIRF398,399. The image 
produced is constructed from two components, which are recorded separately: the in focus 
high-frequency imaging components, derived from a high pass filter with uniform illumination, 
and the low frequency components, obtained through local contrasting with grid 
illumination399. 
1.10.4  Light Sheet Microscopy 
Light sheet microscopy, like HiLo microscopy, utilises a low power light sheet, however, the 
illumination plane is orthogonal to the imaging plane365,376. The light sheet tends to be thin, 
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and the samples need to be either optically clear or close to optically clear365,376,388. The sample 
is illuminated one plane at a time, which leads to a high signal to noise ratio, as little 
background is produced from out of focus planes. A low power illumination is used, which 
leads to a low phototoxicity, and little photobleaching, this is especially advantageous with 
thicker samples as unlike HiLo or confocal microscopy the path of the illumination beam does 
not pass through other layers of sample376. Resolution of light sheet microscopy depends 
greatly on the set up used, with the resolution being highly dependent on the numerical 
aperture of the lenses374,376. 
1.10.5  Super resolution techniques 
Normal light imaging is limited in the resolution it can achieve by the diffraction limit, which 
is a limit of microscopy caused by the diffraction of light, meaning that when two objects which 
are being imaged are less than 200 nm apart they can’t be distinguished as two separate 
objects. This limit is a big challenge within SMI where there could be a requirement to image 
objects on this scale, or smaller. In order to combat this a number of imaging paradigms have 
been established in order to overcome this limit, these techniques are referred to as super 
resolution techniques. These techniques utilise the discrepancies between particles in terms 
of their blinking, bleaching, emission and excitation spectra to localise individual fluorescent 
probes and construct images in a pointillistic manner. 
1.10.5.1  STORM 
Stochastic optical reconstruction microscopy (STORM) is a super resolution technique which 
utilises the blinking properties of fluorophores400. Reporters are made to switch on and off 
using a UV laser, occasionally fluorophores will stochastically enter a triplelet state which is 
non-fluorescent401. In order to return from this state the fluorophore utilises oxidation from 
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the buffer it is in. This occurs at different rates for each molecule, allowing them to be 
separated such that the locations of the molecules can be reconstructed. STORM can provide 
a spatial resolution up to 20 nm400,402. As imaging requires observation of single molecules 
over extended periods of time, live imaging is not possible, and it deals poorly with non-
stationary samples388,403. 
1.10.5.2  PALM 
Photoactivated light microscopy (PALM) utilises photoswitchable fluorophores to provide a 
sparse signal. Fluorescent probes are subjected to a low power of the activation light, which 
stochastically causes molecules to convert to their on state404. These molecules are subjected 
to a high intensity illumination beam to photobleach them. This process is cycled thousands 
of times in order to get a representation of all the molecules within the sample. This allows 
PALM to provide resolution of particles up to 20 nm apart367,398,404. 
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1.11  Semliki Forest Virus 
In order to express the fluorescent tags within cells, a vector is required. Viruses are a useful 
vector as they are designed to bypass the cells natural defences to pass their genetic material 
to the cell. 
The Semliki forest virus (SFV) is an Alpha virus of the togaviridae family. It was first isolated 
from mosquitoes originating from the Semliki forest, Uganda, in 1942 263,405. Its symptoms are 
similar to that of malaria or the flu, with individuals suffering from headaches, fever, joint 
pain, abdominal pain, and diarrhoea263,405. All alpha viruses are arboviruses, so are spread by 
arthropods, most surviving in nature by replicating alternatively within vertebrate hosts and 
hematophagous arthropods, like mosquitoes405. For this reason these viruses thrive in tropical 
regions where many appropriate transmission vectors like mosquitoes exist. For SFV this 
vector is more commonly mosquitoes of the Aedes genus263,405,406. 
The alphavirus genome is composed of single positive stranded RNA, enclosed by a capsid 
structure, and a lipid bilayer derived from the host, seen in Figure 1.17.405,407 Alphaviruses are 
small viruses, consisting of 4 structural proteins; known as E1-3, and capsid protein; and 4 
non-structural proteins (nsP), known as nsP 1-4272,405. The virus particle identifies the cell 
through the use of its transmembrane proteins, such as the E1/E2 proteins which identify 
surface proteins on the cell, such as laminin and heparin, causing cell entry and fusion, 
allowing the RNA genome to be delivered into cells for immediate RNA replication, as seen in 
Figure 1.18272,405. Upon translation the virus shuts down host transcription through the use of 
non-structural protein 2, which inhibits RNA polymerase II by inducing degradation of the 
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RNAPII complex, Rpb1408. Alpha viruses typically contain two initiation sites, one of which 
tends to be inactive409.  
 
 
Figure 1.17: The structure of an alpha virus. This shows the RNA genome, the icosahedral structure composed of capsid 
protein, host membrane, and E1/E2 transmembrane structural proteins for cell fusion, receptor binding, and cell entry.  
Figure was adapted from Carossino et al 2014272. 
The alpha viruses SFV and Sindbis have both demonstrate the ability to induce encephalitis 
within mice406,410,411. Avirulent versions of SFV exhibit the ability to induce demyelination 
within mice, and foetal death within pregnant mice, this is believed to be due to the ability of 
SFV to preferentially infect glial cells406,410,411. The SFV genome consists of approximately 1300 
base pairs (bp)405,406,412. The most commonly used strands of SFV used in research are the 
A7(74) strain derived from the avirulent A7 stain produced by Bradish, or the prototype strain 
derived from the L10 strain produced by Glasgow 1991, an example of which is pSP6 SFV4413–
415. Although the L10 strain consists of a longer genome, both strains amplify equally well 
within baby hamster kidney (BHK) cells, however they vary in their ability to multiply in 
neurones416. The SFV itself shows a gender discrepancy in sensitivity, with male mice being 
more sensitive to SFV than female417. 
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Although most work on SFV concentrates on mice, as it mainly effects small mammals, it has 
been shown to also effect humans, leading to outbreaks of mild febrile illness, for this reason 
SFV is classified as a biosafety level 2 virus, with a Lethal dose (LD50) of 1-2 plaque forming 
unit of the virulent strain418,419.  
 
Figure 1.18: The life cycle of Alphaviruses. The virus enters the host cell using the spike proteins, allowing fusion to the 
plasma membrane. RNA is released from the viral particle into the cytoplasm, this allows the expression of new spike 
protein (SP), caspid protein (C), and the replication of the viral RNA. New viral RNA and caspid protein form the 
nucleocaspid. The spike proteins undergo modifications within the rough endoplasmic reticulum (RER) and are 
transported to the membrane. At the membrane the nucleocaspid assembles with the spike proteins, and the plasmid is 
released through membrane budding.  Figure was extracted from Lundstrom 2015405 
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1.12   Aims and hypothesis 
 
The work presented in this thesis addresses the behaviour of MBP during oligodendrocyte 
differentiation and following myelin injury. These behaviours will be probed by imaging of a 
chimeric protein, containing a photoconvertible fluorescent protein (dendra2) attached to the 
MBP molecule. SFV was chosen as the vehicle to deliver the protein into cells, rather than 
methods such as lipid transfection, as infection with SFV allows efficient transgene expression, 
in both cells and tissue samples. The dendra2 MBP fusion protein will also be used to explore 
myelin injury, both induced by complement mediated methods in brain slices, and through a 
chemically induced injury in dissociated cell cultures. These injuries were selected as early 
presentations of MS have been found to possess complement-mediated myelin injury, while 
chemically induced injury was utilised as these models provide a fast acting, efficient injury 
suitable for SMI studies420. These studies will provide information on the behaviour of MBP 
following various types of myelin injuries, and may provide insight into the earliest stages of 
myelin disruption during oligodendrocyte and myelin injury. 
1.12.1   Hypothesis 
It is believed that the response of MBP to injury will vary according to the level of 
differentiation of the cells. These believes are as follows; 
MBP within mature OLs will show less mobile behaviours than MBP within immature cells 
When observing MBP on a single molecule level it is believed that MBP within mature myelin 
would be highly confined with little to no particle diffusion, as MBP would be interacting with 
other elements of the cell and other MBP molecules as observed in the literature161,421,422. This 
will be contrasted with the OPCs, where it is believed MBP will be highly mobile with its actions 
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being defined by Brownian motion, as these cells should not express the mature proteins 
which MBP would interact with.  
The behaviour of MBP within mature OLs will be more mobile following injury, but 
immature cells will not show a change in behaviour 
Following injury to mature myelin it is believed that the MBP interactions will be broken, 
leaving MBP more mobile such that it will closely resemble the particle behaviour of immature 
cells. This is believed as following injury and remyelination myelin is shown to change 
morphology148, suggesting the MBP interactions may change161,421,422. In the case of immature 
cells it is hypothesised that the behaviour of MBP will not change following injury, as there are 
little to no interactions to be broken. 
Complement injury will produce demyelination in OLs 
It is hypothesised that the complement induced injury will produce a myelin injury analogous 
to that seen within MS, with a strong myelin injury and little to no injury to neurones. It is 
believed that this injury will be achievable with a lower concentration of complement and 
antibody than used in previous work. It is believed that this injury would induce a 
reorganisation of MBP, which would cause an alteration in the shape of the cell. 
1.12.2   Aims 
The aim of this research is to investigate the behaviour of MBP during oligodendrocyte 
differentiation and injury, which may further the understanding of the processes which occur 
within demyelinating conditions such as MS, and neuromyelitis optica. To achieve this the 
following aims must be achieved;  
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Establish protocol to label MBP 
A protocol to label MBP had to be established, which may be extended to other myelin 
proteins at a later point. This labelling approach should be achieved such that individual 
molecules can be observed, and in a way that allows presentation of MBP in mainly 
oligodendroglial cells. To achieve this MBP will be fused with dendra2, and this fusion protein 
will be encoded within an SFV vector for delivery to oligodendrocytes in brain slice cultures, 
immortalised cell lines, and primary cultures of OLs. 
Establish and characterise a model of myelin injury 
A myelin injury model shall be established, which represents one of the immune initiated 
components seen within demyelinating conditions, such as MS, and optimised such that a 
neuronal injury does not present in response to the treatment. This model shall be supplied 
by the use of complement induced injury, which can be made to target myelin through the 
use of the classical pathway, where antibodies against myelin proteins induce the formation 
of a complement complex. 
Observe the behaviour of MBP in response to injury and differentiation. 
The SFV based vector established previously will be used to observe the behaviour of MBP 
following myelin injury, and at various stages of differentiation in cultured OLs to see how 
differentiation status and injury alters these behaviours at the level of single MBP molecules. 
The understanding of these behaviours, and how they change, may provide new information 
on the molecular interactions of MBP during OL differentiation, and a new model in which to 
analyse the effects of OL injury on myelin integrity. 
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1.12.3  Chapter outline 
The work performed within this thesis is divided into three parts. 
The first section (Chapter 2) will outline some of the general methods utilised across all results 
chapters within this work. This includes the culture techniques for the cells used, the 
compositions of cell culture media used, and other general protocols used in multiple studies 
within this thesis. 
Chapter 3 explains the design and characterisation of the SFV vector used to observe the 
actions of MBP. The design of the chimeric protein, the infection rate, the expression 
behaviour, and the viral timeline will be addressed within this chapter.  
Chapter 4 will explore the use of an immunological myelin injury utilising the complement 
system. This chapter will address the concentrations to be used, the treatment time, the 
mechanism of action, as well as utilising the treatment in collaboration with the SFV vectors, 
described in Chapter 3, to observe myelin injury within cultured brain slices.  
Chapter 5 describes the single molecule studies, which explore the behaviour of MBP in 
cultured OL cells. Utilising the SFV vector this chapter will look at the effects of OL 
differentiation, and injury on the behaviour of MBP by looking at protein diffusion, and 
confinement within various cells. 
The final section (Chapter 6) will address the work in this thesis as a whole, in order to produce 
conclusions, identify work that could be performed to further the presented results, and 
identify how this work fits in within the field. 
  






"Research is what I'm doing when I don't know what I'm doing"  
- Wernher Von Braun  
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2.1  Overview of methods 
The experiments described within this thesis utilised both in vitro tissue and cell culture 
techniques. Specific details on individual experimental groups and specific methods for the 
work performed will be addressed within the experimental chapters 3-5. Within the work 
presented the majority of the cell based work was performed on Oli-neu and baby hamster 
kidney (BHK-21) cell lines. These cell lines were maintained throughout the duration of study, 
and utilised to test imaging conditions, staining conditions, and injury conditions when 
deemed necessary. A number of culture solutions were produced to maintain the cell and 
tissue samples, these were composed of different components, optimised for the samples 
being studied. Many studies throughout the work utilised SFV vectors, of various 
concentrations, both within tissue and cell samples. While cell samples could be transduced 
with SFV by addition of the vector to the culture media, tissue cultures had to be injected with 
the vectors to ensure cells within the deeper layers of the slice were infected. In order to test 
for certain phenotypes immunostaining was performed in both tissue and cell samples. This is 
a method underpinning a large amount of the work within chapter 4. 
2.2  Oli-neu culture 
Oli-neu cells were cultured for use within various experiments within this work, these cells 
were kindly supplied by Prof Jacqueline Trotter (University of Mainz). These cells were 
cultured as follows. Sato media was developed as outlined in Trotter et al423. This media 
contained all the agents required to cultivate Oli-neu cells, formula of which is shown in Table 
2.1 . Cell stocks were defrosted and diluted using an excess of SATO media, to remove the 
DMSO used as a cyroprotectant, and centrifuged at 150 x g for 5 minutes at 4oC, to pellet out 
the cells, following this the solution was aspirated out leaving the cell pellet. The resulting cell 
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pellet was resuspended in 4 ml SATO media and seeded into a T25 plate (430639, Corning). 
After 2 days the cells were passaged, the media was removed from the cells, and the cells 
were submerged in 3ml 1x trypsin. The cells were left to trypsinise for 5 minutes at 37oC and 
then the trypsin was inactivated by addition of 3 ml SATO media, following this the cell 
solution was collected and centrifuged at 150 x g for 5 minutes at 4oC. The cells were 
resuspended in 10ml fresh SATO media and plated into a T75 plate (3276, Corning). The cells 
were passaged every 3rd day following that, and split at a 1:3 ratio into T75 flasks. Oli-neu cells 
were maintained like this until used for experiments. 
2.3  Baby Hamster Kidney (BHK-21) cell culture 
BHK-21 cells were cultured for use within the production of SFV, the optimisation of imaging 
conditions within the SMI experiments, and for the confirmation of immunofluorescent 
staining. BHK-21 cells were procured from the University of Warwick, School of life sciences, 
and were cultured as follows: BHK media was produced as outlined in Basic Concept of 
Biotechnology 2015424. Cell stocks were defrosted and diluted using an excess of warmed BHK 
medium, and centrifuged at 150 x g for 5 minutes at 4oC, following this the solution was 
aspirated to isolate the cell pellet. The cell pellet was resuspended in 8 ml BHK media and 
seeded into a T75 plate. After 2 days the cells were passaged, the media was removed from 
the cells, the cells were washed in sterile PBS (P4417, Sigma) and then were submerged in 3ml 
1x trypsin (15400054, Thermofisher). The cells were left to trypsinise for 5 minutes at 37oC 
and then the trypsin was inactivated by addition of 3 ml BHK media, following this the cell 
solution was collected and centrifuged at 150 x g for 5 minutes at 4oC. The cells were 
resuspended in 24ml fresh BHK media and plated into a three T75 flasks. The cells were 
passaged every 3rd day following that, and split at a 1:3 ratio into T75 flasks. These cells were 
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maintained like this until used for experiments. Any excess cells were pelleted out as described 
previously, then resuspended in 1ml of freezing media, and stored at -70OC. 
2.4  Sacrificing Mice 
Within the work C57 black 6 mice (C57BL/6) were sacrificed for the procurement of primary 
cells, and cerebellar brain slices. All mice were bred by the Biomedical Services Unit at the 
University of Birmingham. All animals were killed according to home office approved methods 
listed in the schedule one methods prescribed within chapter 14 of the Animals (Scientific 
Procedures) Act 1986. 
2.5  Infection with SFV 
In order to infect OLs within cultured brain slices with the SFV construct, the viral solutions 
had to be injected into white matter tracks. To achieve this the brain slice was transferred to 
a shallow tissue bath mounted to an upright microscope (Zeiss Axioscope 1), and submerged 
in approximately 1 ml pre-warmed injection media. The slice was surveyed at 20x to locate 
white matter tracks. The viral solution was diluted 1 in 10 in pre-warmed injection medium, 
and 10 to 20 µl of this was loaded into a glass micropipette which was then attached to a 
micromanipulator. The micropipette was lowered into the tissue bath and positive pressure 
was applied via a 1 ml syringe connected to the pipette to ensure a clear flow of injection 
solution. The micropipette was then lowered into the white matter track under visual 
guidance so that the tip penetrated the tissue by approximately 10 to 50 µm. The syringe was 
depressed for approximately 2 seconds to release virus (approximately 2-10 nl) into the 
sample, with successful injection signalled by a slight expansion of the tissue upon solution 
ejection. Multiple injections were made to provide an even distribution of injections along 
each white matter track in the slice. Following injection of the white matter tracks the slice 
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was washed in warmed injection wash media and returned to incubate at 37oC. Samples were 
observed 6-12 hours following injection to ensure expression of the chimeric protein. 
2.6  Immunostaining 
In order to test samples for expression of various markers, such as NG2 within the single 
molecules samples, or MBP within cultured brain slices, immunostaining was performed. This 
was performed with a standardised protocol with minor modifications to incubation times to 
allow staining of both cells and tissues. Samples were fixed using 4% paraformaldehyde (PFA) 
(F003, TAAB) for up to 16 hours at 4oC, following which the samples were gently washed with 
PBS three times to ensure any excess PFA is removed. Samples were then permeablised with 
a solution containing 0.2% triton (X100, Sigma) and 10% goat serum (S1000, Vector 
Laboratories) diluted in PBS, at room temperature for 4 hours for tissue samples, and 1 hour 
for cells. These samples were then stained with a primary antibody against the target marker, 
with the antibody diluted to appropriate levels in carrier solution containing 10% goat serum 
and 0.05% triton. Samples were left to incubate with the primary antibody at 4oC for 
approximately 16 hours. Following this the samples were washed in PBS 4 to 5 times to 
remove all unbound primary antibody. The samples were then treated with secondary 
antibody diluted 1 to 400 in antibody carrier solution as detailed above. The cells were left to 
incubate for 2 hours at room temperature, whereas the slice cultures were incubated for 5 
hours.  The samples were then washed in PBS 4 to 5 times and stained with a 300 nM DAPI 
solution (D9542, Sigma) at room temperature for 20 minutes. All incubation steps were 
conducted in dark conditions to minimise the amount of photobleaching which may occur 
during the protocol. 
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2.7  Media Compositions  
Table 2.1: Compositions of media used within these studies performed. 
SATO/ Imaging Sato DMEM (Phenol red free for imaging) 
(10569/21063, Thermofisher) 
Apo-Transferrin 10ug/ml  
(T2252, Sigma) 
Insulin 10 µg/ml  
(I5500, Sigma) 
Putrecine 100 µM 
(P5780, Sigma) 
TIT 500 nM  
(T6397, Sigma) 
Sodium Selenite 220 nM  
(S5261, Sigma) 
L-Thyroxin 520 nM  
(T1775,Sigma) 
Horse serum 1%  
(H1270, Sigma) 
Progesterone 6 µg/ml  
(P8783, Sigma) 




Freezing media DMEM  
(10569, Thermofisher) 










Penicillin-Streptomycin 50 units/ml 
(15070, Thermofisher) 
FGF2 20 ng/ml 
(PHG0266, Thermofisher) 
IGF1 100 ng/ml 
(PHG0078, Thermofisher) 
PDGF-AA 20 ng/ml 
(PHG0035, Thermofisher) 
Hydrocortisone 360 ng/ml 
(H0888, Sigma) 
Glutamax 2 mM  
(35050061, Thermofisher) 











Penicillin-Streptomycin 50 units/ml 
(15070, Thermofisher) 
TIT 500 nM 
(T6397, Sigma) 
Hydrocortisone 360 ng/ml 
(H0888, Sigma) 
Glutamax 2 mM  
(35050061, Thermofisher) 
Dissection media DMEM:F12 
(D6421, Sigma) 
Glutamax 2 mM  
(35050061, Thermofisher) 
Penicillin-Streptomycin 50 units/ml 
(15070, Thermofisher) 
Injection media DMEM  
(10569, Thermofisher) 
MgCl2 10 mM 
(M8266, Sigma) 
Penicillin-Streptomycin 125 units/ml 
(15070, Thermofisher) 
Tetrodotoxin 500 nM 
(AB120054, Abcam) 
Injection wash media DMEM  
(10569, Thermofisher) 
Penicillin-Streptomycin 125 units/ml 
(15070, Thermofisher) 
Slice culture media/ 
Imaging Slice Culture media 
MEM 50% (Phenol red free for imaging) 
(42360/51200, Thermofisher) 
EBSS 20% (Phenol red free for imaging) 
(24010/14155, Thermofisher) 
Glucose 36.46 mM  
(G7528, Sigma) 
Penicillin-Streptomycin 50 units/ml 
(15070, Thermofisher) 




All serums utilised within these studies were heat inactivated to reduce native complement 
activation. This was performed by incubating the media in a water bath at 56OC for 30 minutes, 
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with occasional inversion to ensure mixing within the serum. This serum was placed on ice for 
approximately 10 minutes in order to allow any precipitating material to settle, then was 
filtered sterilised using a 0.2 µm filter. These stocks were stored at -20OC until needed. 
  








“we only see easily the facts on which one's attention is already 
attracted. ”  
- Louis-Antoine Ranvier 
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3.1  Introduction 
All the work in subsequent chapters required the use of fluorescent myelin protein constructs 
in order to understand responses of myelin proteins. This construct must contain a suitable 
fluorescent protein for the required experiments and must be associated with a myelin 
protein, whose analysis may provide insight into the dynamics of myelin proteins during 
myelin development and injury. It was decided that a photoswitchable or photoconvertable 
protein would be used as they allow more information to be derived on protein dynamics such 
as diffusion, or local protein tracking. The choice of myelin protein used was driven by the 
available literature, for which there is just a single report describing SMI of the myelin protein 
MBP.  Finally, the construct would be delivered to OLs in brain slices using a SFV based vector. 
The concentration of this viral construct must be quantified, its expression properties must be 
understood and its toxicity must be explored, to ensure the resultant construct will be viable 
for the experiments performed in subsequent chapters.  
3.2  Fluorescent protein development 
pRSET B expression Plasmids encoding several fluorescent proteins (FP) were obtained from 
Katholieke Universiteit Leuven (KU Leuven). These proteins consisted of various enhanced or 
photoconvertable/switchable FPs, including eGFP, Dendra2, mEOS, Dreiklang, rsGFP, NIJI, and 
Dronpa, the characteristics of which are summarised in Table 3.1. All the plasmids were 
amplified using the K12 E.coli Stain, NEB® Turbo Competent E. coli (High Efficiency) (New 
England Biosciences) and extracted using a miniprep format, QIAprep Spin Miniprep Kit 
(Qiagen), to produce DNA stock solutions of 300 ng/µl. These FPs were then sequenced using 
Sanger sequencing, within the Functional Genomics, Proteomics and Metabolomics Facility 
(University of Birmingham). 




Table 3.1: Summery for the photo physical characteristics of obtained Fluorescent proteins. Within the cohort is a mix of 
photoswitching FPs, such as Dreiklang, which has wavelengths to convert between the on and off states, and 
photoconverting FPs, such as Dendra2, which has a wavelength to change the emission profile from Green to red. The 












Dendra2  486 505 405 558 578 N/a 
mEOS  482 516 390 571 581 N/a 
Dreiklang  500 529 N/A N/a N/a On 365 
Off 405 
RS GFP  493 510 405    
NIJI  469 507 405 526 569 Green 





Dronpa  503 518    On 
400425,339,341 
Off 490 
eGFP  488 509 N/A N/a N/a N/a 
 
 
From the photophysical data shown in Table 3.1 it was deemed that from the photoswitchable 
FPs only Dreiklang was suitable, as the others would undergo photoswitching at wavelengths 
close to their excitation wavelength. In addition, from the spectra of the photoconverting FPs, 
Dendra2 was the most compatible with the filters and lasers available in the microscopes 
which were planned to be used. Although NIJI possessed both traits, it was deemed unsuitable 
as, at the wavelengths available within the imaging systems which were to be used, the 
excitation beam line would induce photoswitching making imaging over an extended period 
in both channels difficult.  
In regards to the myelin protein incorporated into the construct, the aim was to analyse the 
dynamics of a myelin in OL cells at different stages of differentiation, and during injury. Human 
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and Murine myelin consist of approximately 30% protein, and to understand the mechanisms 
within myelin one of the key proteins should be explored65. The key proteins which could be 
explored are MBP, PLP, and CNP88. MBP and PLP constitute 80% of the proteins within 
myelin65,88 so these proteins would be good candidates for use within the construct. PLP is the 
most abundant myelin protein, constituting 50% of the proteins within myelin. It is a 
membrane protein coded on the X chromosome, and well conserved between human and 
murine species. Gene deletion and transgenic studies in mice have revealed important roles 
for PLP and MBP in myelin function. Knock out of the gene encoding PLP in mice does not 
prevent the formation of compact myelin, however, the myelin is less stable88,426. PLP 
knockdown also resulted in axonal swelling and degeneration suggesting that PLP plays a key 
role in the maintenance of myelin. Overexpression of PLP is linked to Pelizaeus-Merzbacher 
disease an X linked disorder which is associated with diffuse hypomyelination within the CNS 
and a reduction of mature OLs88,427,428. MBP constitutes approximately 30% of the protein 
within CNS myelin. Its role within the myelin is related to myelin folding and compaction. The 
importance of MBP function within myelin is seen in an MBP deficient mouse strain, the 
shiverer mouse strain, which exhibits hypomyelination and presents with a generalised tremor 
429,430.   In contrast to MBP knock out, overexpression of MBP results in immature OLs, and so 
has been suggested to impede maturation and myelination431. The work of the Simons lab161 
has revealed that homotypic interactions between MBP proteins play a role in the structuring 
of myelin. Based on these findings we hypothesised that MBP molecules may undergo a 
change in behaviour, for example decreased confinement, following injury. PLP is a 
transmembrane protein and thus its dynamics are likely to be greatly confined88. On the other 
hand, while MBP exhibits interactions with membrane bound molecules such as 
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Phosphatidylinositol 4,5-bisphosphate, PIP2, it is not physically integrated into the plasma 
membrane. MBP is therefore likely to exhibit a greater range of dynamic behaviours and so is 
more suitable as a target for these novel imaging studies.   MBP was therefore chosen for 
incorporation into the construct.  
3.3  Generation of FP-MBP vector cDNAs 
3.3.1  FP selection and Modelling 
Dendra2 was chosen as the fluorescent reporter for MBP. This was mainly due to its 
compatibility with the microscopes being used, as well as its ability to be photoconverted, 
which could be utilised to obtain a sparse signal for tracking within a different channel.  
Previous work from the Simons lab161 using MBP-FP fusion proteins reported that it was 
necessary to introduce a spacer sequence between MBP and the FP to maintain the native 
function of MBP in the modelling of compacting myelin. Constructs containing MBP directly 
fused to an FP fail to exclude MAG and MOG from compacting myelin, a known function of 
MBP161. However, when MBP is separated from the FP by a spacer sequence it retains the 
ability to exclude these proteins161. Based on these findings we decided to follow the construct 
design described by the Simon’s group (see Figure 3.1). The Simons group used a spacer 
fragment containing either Oligodendrocytic Myelin Paranodal And Inner Loop Protein 
(OPALIN) or Proteolipid protein (PLP) within their studies on MBP161, with the choice of spacer 
sequence depending on the FP used.  Both OPALIN and PLP are transmembrane proteins and 
the Simons group utilised the intracellular regions of these proteins to act as a spacer. We 
designed two chimeric protein constructs containing the PLP fragment (PLPFRAG): (1) mCherry 
(mCherry-PLPFRAG-MBP); (2) GFP (GFP-PLPFRAG-MBP); and one construct containing the OPALIN 
transmembrane fragment (TM); Dendra2-TM-MBP).  
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Following experimentation with the Dendra2-TM-MBP construct it was found aberrant cell 
death occurred within infected cell cultures. It was determined that this cell death was related 
to the presence of the OPALIN fragment, which appeared to increase the toxicity of the MBP 
fusion protein, making infected cells exhibit signs of reduced viability (rounding up, retraction 
of processes) much earlier than seen with other FP constructs. Typically cells infected with SFV 
exhibit signs of reduced viability after approximately 48 hours as the vector effectively takes 
over the host cells protein synthesis machinery limiting production of essential native 
proteins. In the case of Dendra2-TM-MBP cell viability was impaired as early as 6 h.  This 
severely limited the window for experimentation and imaging, and provided doubt within the 
single molecule experiments as to whether observed changes in MBP dynamics were 
physiological or pathological. Another consideration was whether the OPALIN fragment, as a 
transmembrane protein, may exert additional influences on the behaviour of MBP (e.g. 
localisation, confinement), that may confuse the analysis of MBP dynamics. Based on these 
considerations the construct was deemed unacceptable for use within the single molecule 
work discussed in chapter 4. The effect of the transmembrane region on the observed 
behaviour of MBP may not have been as important to the Simons group, as many of their 
experiments were observing proteins on an ensemble level, where the effect of a small 
fragment of membrane protein would not be so apparent. It was therefore decided that a new 
construct where MBP was directly conjugated to Dendra2 (Dendra MBP) would be adequate 
for the single molecule work, where the focus was on monitoring MBP behaviours such as 
confinement / diffusion, rather than its functions in the modelling of compacting myelin as 
investigated previously161.   
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The choice of producing a directly fused Dendra2-MBP protein is supported by other work 
from the Simons lab where directly conjugated FP MBP constructs were used to investigate 
the role of PIP2 in the formation of associations between MBP and the cell membrane432,433. 
 
Figure 3.1: DNA maps of FP MBP Constructs in A7(74). (A) GFP construct containing PLP and MBP fragments. Enhanced 
GFP (eGFP) was used instead of GFP due to increased quantum emission, increasing the signal to background ratio. (B) 
mCherry construct containing PLP and MBP. (C) Dendra2 construct containing OPALIN and MBP. (D) Dendra2 construct 
containing MBP. Key enzyme restriction sites are shown: XhoI, ApaI, BamHI represent the cloning sites used in the 
generation of all of the fusion constructs. During subsequent SFV production, either SapI or NruI were used to linearize 
the recombinant vector cDNAs to enable their use as templates in in vitro RNA synthesis reactions.  
 
3.3.2  Template cDNA preparation 
Production of the MBP-FP constructs required well defined DNA templates of the individual 
components including the fluorescent proteins and MBP. The original DNA templates for the 
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fluorescent proteins were obtained from Dr Peter Dedecker (Ku Leven, Leuven, Belgium),  and 
templates for MBP bound to either the transmembrane proteins, OPALIN or PLP, were kindly 
provided by Prof Mikael Simons (Max Planck Institute for Experimental Medicine, Göttingen, 
Germany). All of these cDNA plasmids were provided as dried stocks on filter paper.  These 
were eluted in 10µl nuclease free water, enough to submerge the paper, and left overnight to 
produce low concentration stocks of DNA. These DNA stocks were then used to transform 
chemically competent E.coli (NEB Turbo) to allow amplification of the cDNAs. Aliquots of E.coli 
in 1.5 mL Eppendorf tubes were incubated with 1-2 µl of eluted DNA, depending on the elution 
volume, and left to stabilise for 30 minutes, this allows the calcium chloride in the solution to 
neutralise the negative DNA backbone. In order to get the DNA inside, the cells are stressed 
through heat shocking in a water bath at 42oC for 30 seconds, this makes the membranes 
permeable allowing DNA to enter the cell. Transformed E. coli were then allowed to recover 
by placing tubes on ice for 5 minutes. E. coli were then incubated in Super Optimal broth with 
Catabolite repression (SOC) medium (S1797, Sigma) at 37oC in a shaking incubator for 1 hour. 
This step is necessary to promote cell growth and allow time for cells to express the resistance 
proteins encoded by the cDNA plasmids (required for subsequent clone selection steps). 
Following this incubation this solution was used to inoculate culture plates by spreading a 
range of dilutions (25 µl, 50 µl and 300 µl) of solution on to Luria-Bertani (LB) plates. LB plates 
were produced using LB agar (L2897, Sigma) with 100 µg/mL ampicillin to enable selection of 
clones expressing the desired cDNAs. Preparation and inoculation of the LB plates were 
performed within a laminar flow hood to maintain sterility. Inoculated plates were incubated 
overnight at 37oC, in order to provide optimal conditions for the E.coli to produce bacterial 
colonies. The next day plates were inspected for colonies and well isolated colonies were 
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picked using a sterile 200 µL pipette tip. Selected colonies were then used to inoculate 5 mL 
preparations of LB broth (L3022, Sigma) containing 100 µg/mL ampicillin. These 5 mL 
preparations were then shaken to encourage mixing, then left to incubate at 37oC on a shaking 
incubator for 16-20 hours. The duration of this incubation varies depending on when the 
solution reaches an optical density at 600nm of about 0.6, indicating optimal E.Coli growth. 
Glycerol stocks were made from a small proportion of the E. coli stocks using 50% glycerol 
(50% glycerol, 50% PBS) and stored at -80oC, to ensure that samples from the same colony 
could be used to re-produce DNA in the future. The remainder of the cell solution was pelleted 
by centrifugation at 3500 rpm for 12 minutes to collect the cells. The media supernatant was 
aspirated out and cDNA isolated from the pellet using a GeneJET Plasmid Miniprep Kit (K0502, 
Thermofisher) as per the kit instructions. The Pellet was suspended in the supplied 
resuspension solution and the pellet dissociated thoroughly by trituration and vortexing to 
ensure efficient mixing. The cells were then lysed using the cell lysis solution to release the 
cell contents, and the samples then treated with the neutralisation solution, to neutralise the 
solution, and bind any nuclear DNA or free proteins. This produced a white precipitate 
containing bound material.  This precipitate was pelleted using centrifugation and the 
supernatant was added to the purification column, which was then washed using the supplied 
wash solution to remove any free floating material which had not passed through the column, 
and dried to remove any excess ethanol from the wash solutions. At this stage the desired 
plasmid DNA should be adhered to the column and be free of the ethanol present in the wash 
solution. The bound cDNA was then eluted from the column using 30 µL of nuclease free water 
to produce a high concentration stock of template DNA. The exact concentration of the 
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resulting cDNA was then determined using a nano-spectrometer (Figure 3.2) and adjusted to 
300 ng/µL using nuclease free water.  
 
Figure 3.2: Nano spectrum of template DNA amplification. The spectrograph shows the DNA has a good purity. 
3.3.3  Preparation of FP cloning inserts 
3.3.3.1   PCR synthesis of FP inserts 
Oligonucleotide primers were designed to synthesize new versions of the FP constructs 
containing enzymatic restriction sites suitable for the subsequent cloning steps.  The DNA 
sequences of the expression vectors, the coding DNA for the protein, and the final vector were 
taken into account to identify the possible restriction enzymes to use. Three unique restriction 
endonucleases were found to be ideal for use with the protein and the final SFV A7(74) vector: 
Bam HI , Xho I, and Apa I (Figure 3.1) as they did not exist in the coding sequences, and were 
present as unique sites  within the multiple cloning region of the vector. These sites were also 
chosen as they produce sticky ends following restriction, which are typically more convenient, 
and provide good specificity, in ligation reactions. 
Having identified the restriction enzymes to be used, the primers were designed. These 
primers must overlap with the sequence of interest enough to be specific without having an 
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exceptionally large melting temperature.  Based on literature434 it was decided that primers 
of between 14-28 bases would be ideal. These sequences were carefully chosen to have GC 
contents between 45-60% to ensure the primer binds well to the template, but is not too 
difficult to remove, and that no hair pin structures or self-annealing regions would be 
present435,436. In accordance with advice from an established supplier of restriction enzymes 
(NEB), a sequence of bases was added to the 5’ end of the primer to provide the enzymes an 
overhang to bind to and ensure optimal restriction enzyme activity434,437. This sequence was 
carefully selected to ensure that it did not increase the GC content too much, or induce 
annealing, and that the new sequence did not induce new restriction sites for any of the 
enzymes to be used in the work. 
The structure of the primers (Figure 3.3) consisted of, from the 5’ end, the enzyme support 
sequence, the restriction site, and the overlapping sequence of at least 14 bases. The forward 
primer and the reverse primer consisted of different restriction sites to allow a unique site to 
be at each end of the sequence. The primers for the fluorophores had Bam HI within the 
forward primer and Xho I on the reverse primer, whereas for the MBP and TM-MBP fragments, 
primers were designed such that the forward primer contained Xho I, while the reverse primer 
contained Apa I. This design would allow the FP and MBP fragment to join, to produce a fusion 
construct that could subsequently be cloned into other vectors containing these Bam HI, and 
Apa I. The Xho I site, also allows the FP or MBP fragments to be interchanged with other FPs 
or myelin proteins if required in the future using either Xho I and Apa I or Bam HI. 




Figure 3.3: PCR Primer sequences. These primers were used for the addition of Bam HI (top) to the front of the sequence, 
and Apa I (bottom) to the end of the sequence. These sequences have a 4 base overhang to ensure optimal restriction. 
Coding sequence (Red) is handled in the reverse complement configuration for the second primer to allow it to bind to 
the complementary strand. Bam HI (blue) is attached to the forwards primer, whereas Apa I (yellow) is bound to the 
reverse primer 
  
New DNA sequences were synthesized from these primers by using the polymerase chain 
reaction (PCR). Template DNA was mixed with reagents for the hot start Q5 polymerase kit 
(M0493, NEB) for PCR amplification, on ice to prevent enzyme and primer degradation as well 
as to prevent non-specific polymerase binding, as shown in Table 3.2 A. This solution was mixed 
and placed in a thermocycler programmed with the settings in Table 3.2 B. The program starts 
with a prolonged initial denaturation step to induce a single stranded morphology within the 
template DNA, and to activate the polymerase. Subsequent denaturation steps are shorter as 
they only aim to make the DNA single stranded. The temperature is then reduced to the 
annealing temperature, which is the temperature at which the PCR primers bind loosely to 
the template strands, thus determining the specific loci at which PCR will occur. The 
temperature is then increased to the extension temperature where the polymerase works 
most efficiently. This pattern of denaturation, annealing and extension steps were cycled 34 
times (see Table 3.2 B for justification of cycle times). Further cycles would likely be sub-
optimal due to exhaustion of enzymes, degradation of the primers, and an increased chance 
of producing non-specific DNA strands.  
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Table 3.2: PCR reaction conditions. A) PCR reaction recipe, all components were added in order on ice, to reduce the 
amount of non-specific binding of the enzyme. B) Thermocycling conditions for the PCR reaction. 34 cycles were chosen as 
this produced the most beneficial results in previous PCR reactions using Q5 polymerase within the lab, in terms of 
sequence accuracy and amount of product 
A  
                         
Reagent Volume 
NEB Q5 Reaction 
Buffer 
10 µl 
dNTP 1 µl 
Forward Primer (10 
µM) 
2.5 µl 
Reverse Primer (10 
µM) 
2.5 µl 
Q5 Enzyme 0.5 µl 
Template DNA 0.5 µl (1ng) 








 Temperature Time 
Initial 
Denature 





98 15 Seconds 
62 45 Seconds 
72 45 Seconds 
Final extension 72 4 minutes 
3.3.3.2  Purification of PCR FP inserts   
In order to remove free nucleotides and the DNA template from the PCR mix, the Sigma 
GenElute PCR Clean-Up Kit (NA1020, Sigma) was used. The columns were prepared by the 
addition of Sigma GenElute Column preparation solution, which was run through the column 
by centrifugation at 14000x g for 30 seconds. The DNA to be purified was then mixed with 
DNA binding solution, which contains guanidine chloride to reduce the hydrogen bonding, 
helping the DNA elute out of solution and bind to the silica column. This solution was added 
to the centrifuge tube and spun for 1 minute at 14000x g. The silica columns were then washed 
twice with GenElute wash solution, which is ethanol based, to prevent the DNA from eluting 
off the column. The columns were then centrifuged without any contents to ensure all the 
ethanol from the wash solution was removed, as this interferes with the UV spectra of the 
DNA, and with any enzyme activities required in subsequent cloning steps. Next, the DNA was 
eluted in approximately 50 µl nuclease free water, which was incubated with the columns for 
approximately 2 minutes prior to centrifugation to maximise the recovery of isolated DNA. 
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Finally the DNA solution was thoroughly mixed, and quantified using a nano-spectrometer 
(BioSpec-nano, Shimadzu). 
3.3.3.3   Agarose gel electrophoresis  
Having produced purified DNA the size of the DNA had to be determined to provide initial 
validation that the correct sequence was synthesized. In order to do this agarose gel 
electrophoresis was performed, where DNA is separated by size within an electric gradient, 
with the agarose providing physical hindrance on the DNA movement, so larger molecules will 
not move as far as smaller molecules, and non-linear molecules would move differently to 
linear molecules of the same size. In this case the agarose was made at 1% in 
Tris/Acetate/EDTA (TAE) buffer (B49, Thermofisher). The agarose was heated in the 
microwave and swirled occasionally, to dissolve the agarose, this solution was then allowed 
to cool in a water bath set at 60oC (a temperature where agarose remains in solution), and 
Gelgreen nucleic acid stain (41005, Biotum) was added to the solution and mixed. The gel 
mould was then assembled and levelled to ensure the gel produced would be homogenous in 
thickness. The gel solution was poured into the gel mould with a comb providing either 14 or 
20 wells ( depending on the number of samples being tested), foil covered to protect the green 
DNA probe, and left for 20 minutes to set completely. The comb was then removed from the 
mould and the gel submerged in the electrophoresis tank filled with TAE (1X). DNA was then 
prepared by mixing approximately 300 ng of DNA, with gel loading buffer (B7024, NEB). 
Importantly, this buffer contains a dye which migrates within a 1% gel at the same rate as a 1 
kB linear DNA fragment, thus enabling easy assessment of protein migration during 
electrophoresis. The DNA was then loaded into the wells with a 2-log DNA ladder (N0550, NEB) 
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in the first and last lane of the gel, and the gel run at 90 v for 1 ½ hours in the dark. The gel 
was then removed and imaged on a trans-illuminator (Figure 3.4). 
 
Figure 3.4: Agarose electrophoresis gel of PCR products. Left is the ladder, followed by the crude PCR product, and right 
the PCR product following clean up. Smears in the band for the crude product are believed to be a mixture of enzymes, 
dNTPs and primers. 
Following electrophoresis, the PCR amplified DNA solutions were restricted with either Fast 
digest Bam HI and Xho I, or Xho I and Apa I depending on the restriction sites added to the 
DNA, for 1 hour to produce DNA fragments with sticky ends (all digestions were performed 
with Fermentas Fast Digest enzymes (Thermofisher). The digested PCR products were then 
subjected to further PCR clean up, using a Genelute PCR clean up kit as previously described 
to remove the overhang fragments which were excised from the DNA, and concentration was 
confirmed on a nano-spectrometer (Figure 3.5). 




Figure 3.5: Spectrum of DNA insert following digestion with restriction enzymes to produce sticky ends. 
3.3.4  Construction of vector cDNA 
In order to prepare the SFV A7(74) vector DNA for insertion of FPs, the multiple cloning site 
was digested using Bam HI and Apa I, leaving a DNA backbone with sticky ends complementary 
to the FP inserts. After enzymatic digestion the vector DNA was purified by gel electrophoresis. 
Specifically, the DNA was run within an agarose gel to separate the DNA fragments by size, 
and the resulting bands visualised using a blue light trans-illuminator to reduce the possibility 
of DNA damage from the visualisation. To further protect the DNA the trans-illuminator was 
used as briefly as possible, whilst the DNA band of interest was excised from the gel using a 
scalpel. The excised band was weighed in an Eppendorf, with the derived weight used to 
identify the volume of binding buffer to be used during the gel extraction process. Gel 
extraction was performed using the GeneJET Gel Extraction Kit (K0691, Thermofisher) as 
directed by the manufacturer’s protocol.  As the extracted DNA was larger than 10kb the 
solubilised gel solution was diluted as directed in the manual, and an additional binding step 
was performed. The final elution step was also performed at 65oC to aid elution. The eluted 
DNA was then cooled on ice before being quantified using a nano-spectrometer (Figure 3.6). 




Figure 3.6: Spectrum of DNA Vector following Digestion, and gel excision and purification. 
 
DNA Fragments were ligated together using a T4 DNA Ligase (M1801, Promega). The reaction 
solution, Table 3.3, was incubated at room temperature for 2 hours, or in the case of some 
more troublesome constructs, overnight at 4oC. The quantity of insert and vector to use for 
the reaction was determined by one of two equations depending on the number of inserts 
used and the vector. The first of these equations determines the concentration of DNA in 
picomoles for both the insert and the vector. From this the ratio of vector to insert must be 
considered as recommended by New England Biolabs, these normally provide an excess of 
insert to bind to the vector. The second of the equations was a simplified equation to 
determine the nanograms of insert DNA to be used if 30 ng of SFV A7(74) vector DNA was 
used within the reaction. Both equations were used depending on the reaction being 
performed. When the ligation involved a single insert, for example Dendra2-MBP, where the 
A7(74) vector used already contained a MBP sequence (one of the previous FP-MBP vectors 
being used as a vector), Equation 3.2 was used.  However, when the reaction involved two 
inserts, as was the case for Dendra2-TM-MBP where sequences for both Dendra2 and TM-
MBP were ligated simultaneously, then Equation 3.1 was used. In this example 
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recommendations from New England Biolabs suggested that a molar ratio of 1:5:5 (vector : 
insert : insert) would provide the greatest probability of successfully producing the required 
construct, so the equation was used to determine the amount of insert required to heed the 
advice. 
𝑝𝑀𝑜𝑙𝑒 =  
1000
𝑁𝑜. 𝐵𝑎𝑠𝑒 𝑝𝑎𝑖𝑟𝑠 𝑥 650𝐷𝑎𝑙𝑡𝑜𝑛𝑠
 
Equation 3.1: Equation to calculate the moles of DNA produced. Used for multiple inserts or experiments where a 
different vector was used 




Equation 3.2: Equation to determine the amount of insert required in a reaction with 30 ng SFV A7(74) vector and only 1 
insert, requiring only a 1:3 ratio. 
Table 3.3: Composition of ligation reactions, all produced on ice, before reaction at room temperature. V+I indicates a 
reaction with both vector and insert, V+ indicates a reaction with vector and ligase but no insert, V- indicates a reaction 
with vector but no insert or ligase.  
Dendra TM V+I V+ V- 
V 0.67 0.67 0.67 
I 0.79 0 0 
Buffer 2X 5 5 5 
H2O 2.54 3.33 4.33 
T7 1 1 0 
Total 10 10 10 
3.3.5  Transformation 
As with the original vectors the ligated DNA had to be amplified to a usable quantity, as the 
quanitity produced would be too low to detect the correct construct. In order to amplify the 
amount of plasmid DNA, the DNA was transformed in to competent E. Coli. 1 µl of ligated DNA 
solution was added to 25 µl of NEB Turbo Competent E. coli (C2984) on ice, mixed by light 
trituration. The same was done with the vector only controls. The DNA was then amplified as 
previously mentioned in the DNA amplification section. The plasmid DNA generated from 
ligations would be compared to controls to ensure no/little growth, showing that there are no 
contaminates that cause the plasmid to reform, or that intact DNA is not within the vector 
solution. Following this verification, 10-15 colonies presenting with differing morphologies 
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were selected out to be grown (Figure 3.7). Part of these colonies were tested with colony PCR 
to ensure it contained the gene of interest, whilst the rest were inoculated into 5ml of LB Broth 
with Ampicillin for growth, and placed in a shaking incubator. The colonies which yielded 
positive confirmation from the colony PCRs were left to incubate for 10-18 hours, depending 
on the turbidity of the solution measured using the optical density at 600nm, whilst the other 
colonies were abandoned. The cell solutions were then pelleted out by centrifugation at 5400g 
at 4oC, these pellets were then minipreped using a GeneJET Plasmid Miniprep Kit (K0503, 
Thermofisher) to extract the DNA as per the kit instructions. The DNA was quantified using 
the nano-spectrometer (Figure 3.8), and verified using restriction digest and sequencing 
 
Figure 3.7: Colonies of Ligated product, utilised for amplification, showing optimal colony spacing for selection. 
 
Figure 3.8: Nano-spectrum of construct DNA following transformation. 
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3.3.6  DNA verification 
3.3.6.1  Colony PCR 
Following transformation of the ligated plasmid into E. Coli, the plates were checked for 
colonies, summarised in Figure 3.10. Some of these colonies were selected out for further 
growth in LB amplicilin. Part of each of the colonies selected were used to verify the DNA 
produced in the ligation. These colonies were selected out using a pipette tip. The tip was 
swirled within a PCR solution, prepared on ice, as described in Table 3.4, this is similar to the 
mix used for the PCRs performed previously, however, more water was added as the template 
DNA is provided here from the colony. The mixture was thoroughly mixed, then placed in the 
thermocycler with the thermocycling conditions in Table 3.4. The thermocycling conditions 
have an extended denaturation step compared to PCRs performed previously, this is to 
promote plasmid release from cells. Following the thermocycling protocol, DNA was purified 
using Sigma PCR clean up kit as was performed previously, and electrophoresis was performed 
using an agarose gel (Figure 3.9). The results of this were compared to the expected size of the 
fragment generated, calculated by identifying where the plasmid would bind to the DNA. 
Colonies which produced fragments of the expected size were carried forward and purified. 
Table 3.4: Colony PCR reaction conditions. (Left) colony PCR master mix composition. (right) Colony PCR thermocycling 
conditions with an extended initial denaturation step, to induce the expulsion of DNA from the cells. 
Reagent Volume 
NEB Q5 Reaction 
Buffer 
10 µl 







Q5 Enzyme 0.5 µl 
Nuclease Free Water 33.5 µl 
 
 
 Temperature Time 
Initial 
Denature 






98oc 15 Seconds 
62oc 45 Seconds 
72oc 45 Seconds 
Final 
extension 
72oc 4 minutes 




Figure 3.9: Agarose gel of colony PCR products. In this case all colonies were probed for both MBP alone, and MBP with 
Dendra2. All colonies tested here showed the results desired, except colony 2 which showed an additional product when 
tested with Dendra2 and MBP together, 
  





Figure 3.10: Schematic of colony PCR workflow, starting at bacterial colonies expressing the plasmids. These are 
transferred to PCR tubes with PCR master mix. The resultant product from PCR is run within a gel to identify the correct 
colonies from the profile seen. 
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3.3.6.2  Restriction Digestion 
Following DNA purification the DNA was verified using restriction digest. Restriction sites were 
selected to probe different parts of the DNA, such as the whole insert, the FP coding part of 
the insert and the MBP part of the insert. In all cases 500ng of DNA was incubated with 0.5ul 
of enzyme (0.5 unit) for 1 hour. All the enzymes were also tested individually to ensure that 
the enzymes cleave the DNA leaving a linear product, this ensures that there are the sites 
within the DNA and the enzymes are still functioning. Electrophoresis was performed on the 
solutions to determine the restriction pattern, and the size of the DNA fragments (Figure 3.12). 
 
 Figure 3.11 Molecular models of Dendra TM MBP and Dendra MBP. According to molecular modelling the 
transmembrane version has interactions with the membrane, although it is not completely anchored in the membrane. 
The Dendra MBP complex does not have this interaction due to the lack of the transmembrane element. For the 
structure of the molecule it should be noted that Phyre2 did not have sufficient reference material to be confident in the 
structure of MBP. 




  Figure 3.12: Restriction digest results.  A) Double digests of all possible constructs with Bam HI and Xho I, wells are ordered from the Ladder on the left, Bam HI digest, 
Xho I digest, Double digest. B) Restrictions of all plasmids with Xho I and Apa I, again using the pattern Xho I single digest, Apa I single digest, double digest C) 
Restrictions of all plasmids with Bam HI and Apa I, again using the pattern Bam H I single digest, Apa I single digest, double digest. D) Signle digests utilising the 
linearization enzymes. Ordered Rru I, Lgu I, Bam HI. 
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3.3.7  Sequencing and Protein Modelling 
DNA sequences for the chimeric proteins which were produced needed to have their 
sequences verified before they could be transferred to a virus. This was achieved through the 
use of Sanger sequencing. The samples were selected for sequencing from the results of the 
restriction digest, if the restriction pattern for the DNA was correct, both the right number of 
bands and the right size of the DNA fragments, the DNA would be sequenced. DNA was 
prepared by mixing 3.2 pmol of the primers with 400 ng DNA, and made to 10 µl using nuclease 
free water. Sample solutions were submitted for Sanger sequencing performed by the 
Functional genomics services, University of Birmingham. Following retrieval of the sequencing 
results, the data was imported into Snapgene® viewer to visualise the spectra (Figure 3.13), the 
corresponding sequence was also compared to the predicted DNA sequence using the 
comparison software, Jalview2 (Figure 3.14)438. From the Jalview results it can be seen that the 
predicted sequence of the construct matches the sequencing results very well, with 800-
1000bp of alignment for both the forwards and reverse primers, the loss of alignment after 
this could be attributed to the loss of accuracy in sequencing for long fragments439. Between 
the 2 fragments enough overlap exists to determine the full sequence the construct, and show 
that the sequenced DNA matches the predicted sequence. Following this the DNA sequences 
were also submitted for Blastx440 analysis, to ensure the MBP and FP sequences map well with 
their recognised peptide sequences (Figure 3.15).  From the blast results it can be seen that the 
peptide sequences match well with both the GFP superfamily, which corresponds to GFP and 
all its mutants, and MBP superfamily, this is further supported as the top matches from the 
blast library were Dendra, and an mouse MBP isoform, confirming the correct construct was 
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designed and that the final protein was not lost through the DNA formation. Once the DNA 
sequences were confirmed, the DNA was prepared to produce the viral genome. 
 
 
Figure 3.13: Sequencing results 
 
Figure 3.14: Sequencing comparison using Jalview. The top 2 rows refer to the forward sequence, with high consensus 
between the sequenced data and the predicted sequence of dendra. The bottom 2 rows refer to the reverse sequence, 
showing a high consensus with the predicted reserve MBP sequence.  
 
Figure 3.15: Blast results confirming the presence of Dendra2 from the GFP superfamily, and the presence of a MBP 
isoform. 
   
104 
 
Having confirmed the DNA sequences of the chimeric proteins the protein sequences were 
inputted into the protein modelling software, Phyre2441, to provide an approximation of the 
conformation of the protein. The Phyre2 modelling showed, that the existence of the FP does 
not obstruct MBP in either the Dendra2-TM-MBP or the Dendra2-MBP construct, however, it 
should be noted due to the lack of reference material, within the Phyre2 library, it could not 
confidently identify the structure of MBP (Figure 3.11). However, this could also be due to 
MBPs unstructured organisation137,442The Phyre2 platform identified that Dendra2-TM-MBP 
has an interaction with the cytoplasmic surface of the plasma membrane which corresponds 
with the position of the transmembrane region within the sequence, this interaction was not 
discovered in Dendra2-MBP, supporting the suggestion that the interaction was due to the 
transmembrane fragment, as it is not apparent when it is removed.  
3.4   Generation of infectious recombinant SFV particles 
SFV particles were generated from SFVA7(74)-FP-MBP vector cDNAs according to methods 
described by Ehrengruber et al412. Detailed steps are described in the following sections and 
summarised in Figure 3.17. 
3.4.1  Plasmid linearization 
Following sequencing of the DNA, the plasmid was linearized to prepare the DNA for in vitro 
transcription to make the RNA genome of the virus. Linearization is required as transcription 
proceeds to the end of the DNA template, so linearizing the DNA serves to define the length 
of the transcript. SFV vector cDNAs contain unique restrictions sites (Nru I and Sap I) located 
close to the SP6 promoter whose activity drives in vitro transcription443. To linearize the 
plasmids the restriction enzymes Nru I, and Sap I were identified, as these left the gene of 
interest intact as well as leaving the chimeric protein in frame with the SP6 promoter412. To 
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produce sufficient DNA 15 µg of plasmid DNA was mixed with fast digest buffer (1x) and 10 µl 
(10 units) of enzyme, this was incubated at 37oC for 40 minutes. Following this an additional 
5 µl of enzyme was added to ensure the DNA was restricted, and left for 20 minutes. The DNA 
was then tested using gel electrophoresis to ensure the plasmid was linearized (Figure 3.16). 
 
 
Figure 3.16: Gel showing linearized cDNA (middle) compared to intact plasmid (Right). The intact plasmid has multiple 
bands reflecting the multiple conformations common to plasmid cDNA such as coiled, and nicked. 
 
 




Figure 3.17: Schematic of the construct formation workflow. The vector (Left) is digested and gel extracted to produce a 
linear vector molecule with sticky ends, the insert (right) undergoes PCR to produce sticky ends and isolate it from its 
vector. This is cleaned up to remove any fragments of vector and dNTPs, and mixed with the linear vector. These are 
ligated to make the next construct. 
 
3.4.2  Phenol Chloroform precipitation 
Following linearization digested cDNA should be purified for downstream processes. In 
addition, the subsequent in vitro transcription step requires a high concentration of DNA, as 
half the reaction volume required is provided by the transcription buffer (2x buffer). Phenol 
chloroform precipitation provides a useful method to remove impurities such as restriction 
enzymes and concentrate the cDNA. First, the DNA of interest was mixed in a 1 to 1 manner 
with the phenol chloroform mixture (phenol / chloroform / isoamyl aclohol (25:24:1)). This 
solution was then mixed well by vortexing to facilitate dissociation of proteins and DNA in the 
respective solutions, before centrifugation at 24,000g for 5 minutes at room temperature. This 
caused the formation of 2 layers, the aqueous phase on top containing the nucleic acids, and 
the organic phase at the bottom containing proteins, and hydrophobic lipids. The top layer 
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was the transferred into a new tube and mixed in a 1 to 1 ratio with 100% chloroform to 
remove the remaining phenol, and increase the purity of the resultant solution. The top layer 
of this was removed and mixed with an excess of ethanol (2.5x) as well as sodium acetate 
(1/10) to reduce the hydrophilicity of the DNA, making it easier to precipitate out. This mixture 
was stored at -80oC for 20 min (or -20oC overnight), to reduce the activity of nucleases which 
are potentially existent, as well as increasing the yield of DNA by precipitation. The DNA is 
then spun at 4oC for 30 minutes at maximum speed. The tube was then inverted carefully to 
remove the ethanol ensuring the pellet was not disturbed, the tubes were then filled with 75% 
ethanol to remove any residual salts existent with the DNA. The tubes were centrifuged and 
the ethanol was removed by inversion. The pellet was left at room temperature for 2 hours to 
remove any residual ethanol, then resuspended in 11µl nuclease free water, 1µl of which was 
used to determine the DNA concentration using a nano-spectrometer (Figure 3.18). 
 
Figure 3.18: Spectrum of precipitated DNA following ethanol precipitation.  
3.4.3  In vitro transcription of SFV vector cDNA 
SFVs possess RNA genomes, thus the genetic material produced thus far (e.g. cDNA) were 
incompatible with viral production. To enable the generation of infectious SFV particles from 
the vector cDNA, this must be converted into RNA via an in vitro transcription reaction. The in 
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vitro transcription was performed using the Ambion mMESSAGE mMACHINE® SP6 
transcription kit (AM1340, Thermofisher) and was performed as directed in the instructions. 
Reactions were performed using 1 µg of the template cDNA. The reaction mixture was 
prepared, as shown in Table 3.5, at room temperature to prevent precipitation of the supplied 
buffer.  Once the reaction was assembled it was mixed thoroughly and incubated at 37oC for 
2 hours. Following this the RNA was kept on ice to reduce any possible nuclease activity. The 
resulting RNA was verified using both the nano-spectrometer, where the 260/280 absorption 
ratio was observed as pure RNA solutions would produce a ratio close to 2444, and gel 
electrophoresis where RNA are found to run faster on the gel than the linearised template 
cDNA (Figure 3.19 A). Following these checks the RNA was stored at -80 until pending further 
use. 
Table 3.5: Composition of the in vitro transcription reaction, added in order on ice. 
Reagent Quantity 
NTP/CAP 10 µl 
Reaction Buffer 2 µl 
Nuclease free Water to 20 µl total 
DNA template 1 µg 
GTP 2ul 
Enzyme 2 µl 
 
3.4.4  SFV generation 
3.4.4.1  Packaging cell line electroporation 
Baby hamster Kidney (BHK-21) cells are used as the packaging cell line for the protocol used 
in this thesis412. BHK-21 cells must be electroporated with solutions containing two distinct 
RNA molecules to initiate SFV production. The first RNA solution contains the newly cloned 
SFV vector encoding the SFV genes for replication and the inserted transgene. The second RNA 
solution contains Helper2 RNA which encodes the packaging information required to produce 
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infectious SFV particles. Division of replication and packaging genes into separate RNA 
molecules provides an important safety feature in this SFV system412,443. Prior to 
electroporation BHK-21 cells were grown in 75cm2 tissue culture flasks (430725U, Corning) 
until reaching the late log-growth phase, approximately 1-day post inoculation, where the 
cells are at 80% cell confluency 406. Electroporation was performed using Cell Line 
Nucleofector® Kit L (VCA-1005, Lonza) according to the manufacturer’s instructions.  
Specifically, electroporation media was mixed consisting of 82% Special solution and 18% 
supplement from the Nucleofector® Kit L. These solutions were assembled on ice. The media 
from the BHK-21 cells was then aspirated, and the cells were washed in PBS to remove any 
residual media from the flask, to prevent inactivation of the trypsin enzymes required for cell 
detachment. The cells were then covered in 1x trypsin and incubated for up to 5 minutes to 
remove them from the surface of the flask. The cells were then resuspended in an excess of 
BHK media, (see Chapter 2 for recipe), to inactivate the trypsin. The cell solution was 
centrifuged at 150xg for 10 minutes, and the resulting supernatant aspirated. Cells were 
suspended in BHK media and counted on a haemocytometer. The solution was divided into 
units containing 1 million cells each and the cells were pelleted out by centrifugation as 
mentioned previously, and each unit was suspended in 100µl of special solution/supplement 
mixture. Immediately before electroporation 5ul of the SFV A7(74) construct RNA (1µg/µl) for 
the viral genome and 5ul of helper solution (1µg/µl) to provide the packaging information for 
the virus were added in, and the solution was transferred into the nucleofector cuvettes. 
These were electroporated in the Nucleofector device on program A-031 as suggested by 
Lonza445. Following electroporation cells were diluted with warmed BHK media and added to 
a T25 flask containing 4ml of pre-warmed media at 31oC. Electroporated cells were then 
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incubated at 31oC 5% CO2 for two days to allow the virus to be produced and packaged. 
Monitoring of the cells during this stage provided evidence of successful electroporation and 
SFV activity. First, expression of the FP-MBP transgenes was assessed by observing FP signals 
in the flasks using an inverted fluorescent microscope. Second, production of SFV particles 
leads to reduced cell viability as packaged particles are released from the cell leading to 
membrane budding and alterations in cell morphology (rounding up, detachment). Once these 
signs were confirmed the media was harvested, and the virus was activated as described 
below. 
3.4.4.2  SFV particle activation 
SFV A7(74) possesses a point mutation in the p62 precursor protein, which produces the E2 
and E3 spike protein on the virus412,443. This renders the SFV replicons cleave deficient and 
therefore non-infectious. This provides an additional safety feature in protecting users from 
the virus. In order to activate the virus and make it infectious, the viral solution had to be 
incubated with 100 µL Alpha chymotrypsin (20 mg/mL) at room temperature for 30 minutes, 
which cleaves p62 at a leucine residue rending the viruses infectious412,443. This activates the 
virus by cleaving the p62 cleavage site of the virus446. The reaction was then stopped by the 
addition of 100µL aprotinin (10mg/ml). The activation reaction was stopped as it has been 
shown that the maximal infectivity is achieved when about only about 40% of the virus is 
cleaved413,446,447. The virus was aliquoted out to reduce the freeze thaw cycles of the virus 
during usage, and stored at -80oC. 
3.4.4.3  Virus quantification 
Once the virus was successfully produced, the viral titre had to be determined to ensure that 
similar amounts of viral units would be utilised between viruses. This was achieved by seeding 
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BHK-21s into 6 well plates, allowing them to achieve approximately 100% confluence, and 
then infecting BHK-21 cells with various dilutions of virus, 1 in 10, 1 in 50, 1 in 100, 1 in 500, 1 
in 1000, 1 in 10000 all in 1ml of solution. Cells we incubated with viral solution at 37oC for 1 
hour, and then washed and placed in fresh media. Observations of transgene FP expression 
were performed 24 hours later to estimate the number of infectious units/mL. Dilutions where 
observed under the microscope to identify wells with expression which were neither too 
dense nor sparse to enable easy and accurate counting of infected cells. These wells were then 
sampled for 15-25 fields of view on the microscope to quantify the number of cells expressing 
the fluorescent protein construct (Figure 3.19). These numbers were averaged to give the mean 
count/field, and this number multiplied by the factor required to scale up the field size (µ2) to 
the total number of fields possible given the surface area of the well (Equation 3.3). Using this 
calculation to provide the amount of infectious SFV units in 1 well it was then possible to 
determine the number of infectious SFV units/mL of viral solution by multiplying by the 
dilution factor used for that well (e.g. 1:10, 1:100 etc). 
  




Figure 3.19: Quantification and verification of FP-MBP. (A) Agarose Gel to compare DNA and RNA for GFP-TM-MBP. The 
first lane (left) contains the linearised construct DNA, the final well contains  RNA products from the in vitro transcription 
reaction.  (B) Image of cells infected with a 1 in 10 dilution of the virus solution, taken with spinning disk confocal 
microscope. Imaging was performed with the following parameters:  10x objective, 800ms exposure time, excitation 
485nm. Within the image, 9 cells were identified as infected.  This count was utilised within Equation 3.3 , giving the 
concentration of 3.5x105 infectious particles/mL in the viral stock solution.   
𝒗𝒊𝒓𝒂𝒍 𝒖𝒏𝒊𝒕𝒔/𝒎𝒍 = 𝒎𝒆𝒂𝒏 𝒄𝒐𝒖𝒏𝒕 𝒑𝒆𝒓 𝒇𝒊𝒆𝒍𝒅 × 
𝒂𝒓𝒆𝒂 𝒐𝒇 𝒕𝒉𝒆 𝒘𝒆𝒍𝒍  (𝒎𝒎𝟐)
𝒇𝒊𝒆𝒍𝒅 𝒂𝒓𝒆𝒂 (𝒎𝒎𝟐)
×  𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓 
Equation 3.3: 𝐓𝐢𝐭𝐫𝐞 𝐜𝐚𝐥𝐜𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐟𝐢𝐧𝐝 𝐭𝐡𝐞 𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐯𝐢𝐫𝐮𝐬 𝐰𝐢𝐭𝐡𝐢𝐧 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 . 
 
3.4.5   Validation and characterisation of SFV vectors in oligodendroglial cell 
lines 
 
Having produced SFV vectors expressing the chimeric proteins it was then necessary to 
confirm the ability of the vector stocks to infect an appropriate cell type. In order to achieve 
this Oli-neu cells were grown to about 70% confluency, after which they were infected with 
SFV A7(74) GFP-PLP-MBP at a 1 in 10 dilution (1 hour incubation at 37oC). Oli-neu cells were 
used for this experiment as they are a well characterised model of OPCs448–450. In addition, 
large numbers of Oli-neu cells can be grown in the lab, thus they provide a more convenient 
model for this validation work than primary cells or brain tissue cultures, where there is a large 
burden of animal work and time involved. Infected cells were left for 24 hours at 37oC to allow 
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expression of the chimeric proteins to reach maximum expression. These cells were then fixed 
overnight at 4oC using paraformaldehyde (PFA), then stained with the nuclear stain DAPI to 
provide an additional cell marker. The cells were then observed on a spinning disk confocal 
microscope, on widefield mode. Images of cells containing GFP-PLP-MBP were overlaid on the 
DAPI images to identify cells containing GFP-PLP-MBP (Figure 3.20). From the images 
produced it could be seen that the virus did not infect all the cells within the dish, and that 
the transgene is present throughout the entire cell except the nucleus. These are positive 
results for this work as it confirms that the vector produces fluorescent signals of an intensity 
suitable for imaging, and that it enables a level of infection that is sparse enough to allow 
proficient resolution and imaging of single cells. 
  
Figure 3.20: Preliminary images depicting Oli-Neu cells expressing the GFP chimeric protein (Green). Blue counterstain 
indicates cell nuclei as labelled with DAPI. Images taken at 20x, with excitation at 485nm and 351 nm. It can be seen that 
many cells are in frame but only one is expressing GFP. 
Following this result, the infection rate of cells was investigated for the viral construct. For this 
work Oli-neu cells were grown until they reached approximately 80% confluency within a 35 
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mm imaging dish with a circular 14mm2 glass bottom (P35GC-0-14-C, Mattek). The media 
within these dishes was then carefully aspirated, and A7(74) FP-MBP was added such that 
7500 viral units were delivered to the well. These cells were left for 16-20 hours to allow the 
construct to be expressed and mature. The cells were then stained to identify the plasma 
membrane by incubating them briefly in CellMask Deep Red Plasma membrane Stain (C10046, 
ThermoFisher). Cells were then fixed and stored in PBS pending imaging.  The cells were then 
imaged on the spinning disc confocal microscope, with 40 fields of view captured. Within these 
images the number of CellMask positive cells (red cells, providing the total number of cells), 
and transgene expressing cells (green cells) were quantified. Using this data it was possible to 
determine that the efficiency of infection with the Dendra2-MBP vector, when used under the 
current infection conditions, was 23%.  
3.4.6  Kinetics of transgene expression in Oli-neu cells 
The kinetics of transgene expression were explored to understand the length of time required 
for cells to express the fluorescent MBP construct, and the time it takes for the expression to 
reach its maximum. Cells were cultured in imaging dishes until they were approximately 70% 
confluent. The cell medium was then aspirated to remove the culture media and infected with 
7500 units of A7(74) construct suspended in fresh imaging SATO media. These cells were 
incubated for 1 hour at 37oC 5% CO2, after which the virus solution was removed and the cells 
washed with fresh medium to ensure as much virus was removed as possible. Cells were then 
imaged on the spinning disc confocal microscope (either on Confocal or Widefield mode) to 
collect a baseline image where FP signals could not be observed. Images of the cells were 
taken for every 1.5 hours until the level of fluorescent signal could not be seen to change. One 
final image was also taken at 24 hours as a positive control to ensure cells were infected. From 
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the images it was observed that the SFV A7(74) construct is expressed at approximately 3 
hours post infection with expression reaching a peak at 6 hours. 
It should be noted that these times are approximate, as the timeline can be slightly quicker or 
slower depending on the resilience of the cells being infected.451 
3.4.7  Viability of infected cells 
Survival of the cells were a key point to explore when considering the utility of the new SFV 
vectors. If the construct is toxic to the cells this would alter the interpretation of any results 
obtained when imaging MBP in live cell experiments. In addition, the approximate length of 
time before activity of the SFV vector produces significant signs of reduced viability in cells 
(rounding up, process retraction) is important to know as it determines the maximum length 
of time available to image cells following infection. In order to investigate this, Oli-neu cells 
were infected with SFV A7(74) Dendra2-MBP. In the case of Dendra-TM-MBP, cells were 
imaged to collect a baseline image approximating the first detection of fluorescence (referred 
to as 0 hours in Figure 3.21). Images of the cells were then taken approximately every 3 hours 
using both bright field and fluorescent imaging. When no fluorescence was observed imaging 
was terminated. It was seen that upon expression of the construct cells began to appear 
injured (rounding up, retraction of processes), and this phenotype became more apparent up 
to 6 hours at which time all infected cells appeared to show this injured phenotype. By 9 hours, 
all infected cells had retracted their processes, and un-infected cells started to migrate into 
the field to occupy the newly vacated spaces. By 24 hours no fluorescent cells could be seen 
and the field was populated with uninfected cells only. These results suggested the Dendra2-
TM-MBP virus possessed an additional level of toxicity compared to the other viruses. This 
was contrasted with results from the Dendra2-MBP virus (Figure 3.22), where following virus 
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expression up to 24 hours only a small number of infected cells show an injured phenotype, 
this number slowly increases until 36 hours, where many of the infected cells died and were 
replaced by other fluorescent cells which had migrated within the dish. By 48 hours many of 
the infected cells were lost with few fluorescent cell bodies visible within the dish, leaving only 
uninfected cells.  
  
Figure 3.21: Viability assay of Dendra2 TM MBP. Cells are shown to possess an injured morphology with loss of processes 
and rounding up as early as 1 hour post expression. The infected cells die off within 9 hours and are replaced by 
uninfected cells. 
 
Figure 3.22: Viability assay of Dendra2 MBP. Here a small number of cells are shown to be injured from expression of the 
protein, however, cells are shown to be expressing the protein up to 2 days where all infected cells are shown to have 
died and been replaced by uninfected cells. 
3.4.8  Virus expression profile 
Previous work in the field found that MBP protein expression occurs mainly by free polysomal 
synthesis in OL processes, with MBP mRNA being transported to processes through granules 
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452–454. This expression profile was tested in the MBP constructs, to see if MBP shuttling is 
changed when expression is mediated by the SFV A7(74) vector. For these experiments the 
MBP-Dendra2 construct was used. MBP-Dendra2 expression started 3 hours following 
infection of cells (Figure 3.23). The expression started in small clusters within the perikaryon of 
the cells with little to no expression observed in the processes at this point. As time progressed 
the cells expressing MBP-Dendra2 started to change in morphology. This may reflect the 
normal migratory behaviour of cells of this type such as OPCs, where forward motion involves 
cell and process extension455. Another possibility is that these changes in morphology actively 
facilitate protein transport to the processes of Oli-neu cell, inducing the processes themselves 
to compact. The bulk of the fluorescence was still observed within the perikaryon of the cells 
following expression, suggesting that expression is driven by cell machinery within the cell 
body, and not via free polysomes within the processes. This result contradicts the results of 
previous studies within the field using MBP, where Nucleoside triphosphate labelling showed 
that MBP RNA is shuttled to the processes452,453.  
3.5  Conclusion 
This chapter describes the creation of a number of new SFV vectors encoding various FP-MBP 
proteins designed for the exploration of the behaviours of MBP (Table 3.6). This construct was 
designed and created de novo from the DNA template, and made into viral particles. These 
viral particles were tested to see their expression properties, such as expression localisation, 
expression timeline, the infection rate, and the virulence. It was concluded that the new SFV 
vectors produce a pattern of infection with suitable efficiency to infect approximately one 
quarter of cells in a given culture, leading to FP-MBP expression lasting three hours to two 
days following infection.  
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Table 3.6: Summery of SFV A7(74) viruses produced. All viruses, other than the Dendra2-TM-MBP virus, showed viral 
expression up to 2 days following infection. The GFP-PLPfrag-MBP virus was shown to be the most tolerable construct out 




Time till expression 
(Hours following infection) 
Last observed expressing cell 
(Hours following infection) 
Dendra2-TM-MBP 3.66x105 3 12 
GFP-PLPfrag-MBP 3.5x105 3 60 
mCherry-PLPfrag-MBP 3.4x105 3 39 
Dendra2-MBP 3.9x105 3 39 
 
 
Figure 3.23: Virus expression over time. It can be seen that expression starts within the cell body at 3 hours, and that 
expression is accompanied by a change in morphology that appears over time with the cell, progrerssing from a 















“How can a three-pound mass of jelly that you can hold in your palm imagine 
angels, contemplate the meaning of infinity, and even question its own place in 
the cosmos?” 
- Vilayanur Ramachandran  
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4.1  Introduction 
Myelin plays an essential role within the brain, providing trophic support to neurones, 
protection to axons from pathological conditions within the environment, and by providing an 
insulation to the axons, allowing saltatory conduction67,68,88,121,132. Conditions where 
demyelination occurs, such as MS, neuromyelitis optica, and central pontine myelinolysis, can 
have detrimental effects on brain function, leading to a myriad of symptoms such as pain, 
visual deficiencies, poor homeostatic control, and loss of motor coordination203,212,456–458. 
When demyelination occurs the functional effect on the neurone is the same, with the loss of 
trophic, environmental, and signalling support. However, the mechanisms by which these 
injuries propagate may vary greatly. For example, demyelination in the CNS can be induced by 
a number of causes, including physical trauma, such as spinal cord injury, immune mediated 
attack, as is the case with MS, and excitotoxicity, like what happens within Stroke, to name a 
few.  
Complement proteins have been shown to be implicated in the progression of MS, with 
complement activation being heavily localised to areas of active myelin destruction in MS 
patients459. Of key interest is complement C3 which has been linked with the progression to 
clinical disability within MS patients460. Complement C3 and C1q have also been found to be 
elevated in areas near demyelinating plaques in secondary progressive cases of MS, as well as 
complement C3 being present within the CSF of patients with relapsing remitting MS in 
association with an increase in Complement C4a 23,256,460–462. Reduction of serum complement 
using cobra venom factor has been shown to reduce the severity of EAE, an experimental 
model of MS463–466. For this reason within this study we chose to focus upon immune-
mediated damage involving the complement system. For this injury an anti-MOG antibody 
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was chosen to make the injury specific to myelin, as this is an injury which has previously been 
shown to produce demyelination similar to that seen in MS467,468. This gives us a chance to 
apply live-imaging approaches to determine how the myelin injury progresses at the level of 
myelin proteins. To date the analysis of myelin injury has relied on static methods, for example 
electron microscopy and immunofluorescence469,470. These methods do not provide detailed 
temporal resolution of myelin injury. In contrast, a live-imaging approach has the potential to 
provide greater insight into the temporal development of the injury, thus it could help to guide 
the development of pharmacological interventions for the protection of OLs and myelin in the 
face of ongoing demyelinating conditions.  
First discovered in serum as a system which complemented the roles of antibodies, the 
complement system is a key element in the innate immune system298. The complement 
system has three key roles in the immune response, providing an early line of defence against 
pathogens via formation of the membrane attack complex on targeted cells, initiating the 
recruitment of the adaptive immune system in the form of various types of T-cells, and 
participating in mechanisms of cellular waste clearance297,298. In the case of these experiments 
the interest is in the early attack function, as this activity provides a means to induce external 
physical damage to OLs and myelin membranes (demyelination), and the generation of myelin 
debris that may trigger the recruitment of an adaptive auto-immune response that could set 
the stage for the development of a demyelinating disease state. 
Antibody treatment with complement has previously been established as a means to induce 
demyelination in brain slices, which is considered to be reversible, e.g. remyelination is 
possible 467,468,471–473. This injury was considered to be myelin specific leaving axons un-injured, 
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and when utilised with antibodies against MOG, presents a phenotype analogous to certain 
aspects of MS pathology468,474–477. The aim of this work is the development of an imaging 
system capable of resolving the earliest stages of myelin injury, thus it was important to 
characterise the kinetics of complement activation. In addition, to avoid studying secondary 
effects due to axonal injury it was also important to confirm that the model selectively induced 
myelin injury with minimal effects on axons.  
Previous work on the complement injury modality utilised 7% complement and 100 µg of 
antibody, both utilised in excess. 
4.2  Methods 
4.2.1  Level of complement needed to induce injury 
The first aspect of the complement injury which was considered for optimisation was the level 
of complement required to obtain a myelin injury within organotypic slice cultures. Previously 
it was shown that a treatment of 7% complement combined with 60 µg/mL of an anti-MOG 
antibody produced effective demyelination 467,471,473,478. However, this work did not provide 
optimisation data to explain the choice of this concentration of complement and anti-MOG. It 
is therefore possible that lower concentrations of both compounds may provide an equally 
effective demyelination treatment. This is important for two reasons. First, as noted above, it 
was desirable to produce a selective myelin injury with minimal axonal injury. Second, anti-
MOG is expensive, thus optimisation of the concentrations required to induce demyelination 
would provide a useful modification to the protocol. Previous work within the lab determined 
that concentrations as low as 20 µg/mL of antibody produced effective demyelination when 
combined with 7% complement. For this reason the effects of 20µg/mL anti-MOG was 
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investigated when combined with 7%, 3% and 1% complement to determine the level of 
complement necessary to facilitate myelin injury. 
4.2.2  Cerebellar slice cultures 
Cerebellar slice cultures were produced by Dr Daniel Fulton according to the methods 
described by Fannon et al 2015120. Six-well culture plates were prepared 1 day before the 
acquisition of cerebellar tissue slices. Millicell-CM organotypic culture inserts (PICMORG50, 
Millipore) were placed in the required wells containing 1ml of culture medium (Table 2.1). 
Sterile confetti membrane discs (FHLC01300, Millipore) were added on top of each culture 
insert (five to eight segments per insert) to provide a substrate for stable adherence, and to 
enable easy transfer of individual slices during experiments and subsequent staining 
procedures. The plates were then maintained in a humidified cell culture incubator (37°C, 5% 
CO2) overnight120. To obtain brain tissues, postnatal 9-10 (P9-10) days old C57BL/6 mice were 
sacrificed by Home Office approved methods according to Schedule 1 of the Animals (Scientific 
Procedures) Act 1986. After this procedure brains collected and placed immediately in 
oxygenated ice-cold slicing solution. Cerebella were dissected out in slicing media and 
attached to the vibrotome stage using super glue. Cerebella were sectioned at 350 µm thick 
slices and then observed under a light microscope to detect and remove slices of uneven or 
irregular cuts, and to trim away unwanted pieces of brainstem.  Slices were then transferred 
on to pieces of confetti membrane. The slices were cultured in this way for 7-14 days, with 
media changes every second day. Slices were regularly observed to monitor viability, through 
the observation of slice integrity and white matter tract continuity, preceding the initiation of 
an experiment slices were judged on quality, and viable slices were selected. 
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4.2.3  Slice Selection 
Prior to experiments slices were surveyed and selected based on their viability. This was 
performed on a bright field microscope using the 4x objective to assess the slice quality and 
10x objective to assess the white matter track quality (tracks being the central regions of folia 
white matter containing myelinated purkinje cell axons). Slices were classified by a 3-point 
system based on the quality of the white matter tracks as observed at 4 and 10x (Figure 4.1). 
+++ represented slices with clearly defined white matter with mainly continuous tracks. ++ 
represented slices with clearly defined white matter with some continuous tracks. + 
represented slices containing white matter which had lost some definition and contained few 
continuous tracks. – represented slices which had lost all traces of white matter structure. 
Typically only slices of +++ / ++ where used for experiments.  
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Figure 4.1: Brain Slice Ranking examples of slice conditions meeting each rank. It can be seen that slices with lower ranks (+/++) have 
a greater amount of granularization and are less continuous. Whereas the higher ranks are more continuous with less granularization 
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4.2.4  Complement concentration assay 
Selected slices were arranged to ensure an equivalent number of slices of similar quality within 
each group. Typically experiments used a minimum of 3 slices per group. Wells within a 6 well 
plate were prepared with the treatment conditions outlined within Table 4.1. A stock of sterile 
filtered complement solution was prepared by dissolving lyophilised baby rabbit complement 
(CL3441, VH Bio) in 1 ml of ice cold culture medium, this was further diluted 1 in 10 in culture 
media to make a 10% stock to minimise variation through pipetting errors. 1ml of this solution 
was then added to each well, and culture inserts holding the slices were added to the wells to 
start the complement treatment. Treatments were performed at 37oC for 24 hours, following 
which, the slices were fixed for 16 hours at 4oC with 4% paraformaldehyde (PFA) solution. The 
fixed slices were stained with Rat anti-MBP (MAB386, Merck Millipore), with a secondary stain 
utilising a Goat anti-Rat antibody conjugated to alexafluor488 (A-11006, Thermofisher) to 
detect myelin, and 4',6-diamidino-2-phenylindole (DAPI) (D1306, Thermofisher) to visualise 
nuclei, then mounted on microscope slides with aquamount (18606, Polysciences).  Slices 
were imaged on an inverted microscope (Zeiss) equipped with a spinning disk confocal module 
(Andor Technologies). Confocal images were collected with a 20x Air objective (N.A. 0.5) with 
an exposure time of 800ms. Z stacks containing the complete myelin track (as defined by anti-
MBP staining) were produced with an image every 5µm.  These images were then imported 
into FIJI for processing. 
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Table 4.1: Complement concentration assay injury conditions. 
4.2.5  Neuronal Injury validation 
Six slices were selected to evaluate the level of neuronal injury arising from treatment with 20 
µg/mL anti-MOG plus 3% complement. Here 3 groups were analysed: two groups utilising 3% 
complement treatment with 20 ng/ml of an antibody (1) anti-MOG with 3% Complement (anti-
MOG/Complement); (2) mouse IgG isotype control (m IgG control) plus 3% complement (IgG 
control/Complement); and one slice with no complement or antibody (3). Anti-MOG / 
complement treatments were initiated as previously described (4.2.4), after which slices were 
fixed and labelled against MBP, with a goat anti-rat antibody conjugated to Alexafluor 488 ( 
A-11006, Thermofisher), to detect myelin, and against the 200 dA isomer of neurofilament 
(anti-NF200), with a goat anti-chicken antibody conjugated to Alexafluor 594 (A-11042, 
Thermofisher), to label axons.  Slices were then mounted and imaged as described in section 
4.2.4 before being imported into FIJI for processing and ranking. 
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Analysis of injury progression and repair 
In order to see how the injury progressed over time, and whether remyelination was possible 
in this protocol, a time course examining myelin injury was performed. The aim of this 
experiment was to find the optimal time to observe the myelin injury. In order to achieve this 
slices were arranged in 3 groups: two groups utilising 3% complement treatment (1) anti-
MOG/Complement treatment; (2) IgG control/Complement; (3) no anti-MOG / no 
complement. Time points for analysis were 1 day, 3 days, and 10 days after exposure to the 
treatment. Previous experiments (4.2.4, 4.2.5) had used a 1 day time-point for analysis, thus 
3 days allowed time for a greater degree of myelin injury to occur, while 10 days represented 
the amount of time by which  remyelination had previously been reported to occur479. 3 Slices 
were allocated to each group, with the quality of slices between groups adjusted to ensure 
homogeneity across the groups. Treatments were performed as described in 4.2.4 and 
allowed to continue for 24 hours, after which they were terminated by replacement of the 
media with fresh culture media. Slices were then incubated in culture medium for the required 
amount of time, with the 1 day time-point classified as 1 day after the removal of the 
treatment. Slices were then subjected to fixation, anti-MBP/anti-NF200 staining, imaging and 
analysis as described previously. 
In order to understand whether the responses seen were due to the combination of the 
antibody with complement, and not the individual components, this experiment was repeated 
with the following additional groups: (1) m IgG isotype control only; (2) anti-MOG only; (3) 
complement alone. These additional groups were designed to probe the effect of each of the 
components in isolation. These samples were treated, stained and mounted as described 
previously.  
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4.2.6  C9 stain 
To investigate whether the myelin injury produced by anti-MOG/complement treatment are 
a result of the formation of the membrane attack complex, slices were stained with anti-C9 
which recognises complement complex. For this work we used a custom polycloncal anti-C9 
raised in rabbit, provided by Prof Pranab Das (School of Immunity and Infection, University of 
Birmingham). Four groups of slices were studied: (1) no treatment (providing a background 
control for C9 levels in the slice system); and three groups using 3% complement, (2) 
complement alone; (3) m IgG control/complement; (4) anti-MOG/complement. Slices were 
treated for 24 hours, after which slices were labelled with anti-C9 and MBP, and with DAPI 
used as a counter stain against the nuclei. These samples were mounted and imaged as 
described previously. 
4.2.7  C9 Time course 
To determine how complement activation progresses following initiation of the treatment, a 
time course study was performed, looking at the levels of the C9 complex at each time point. 
Slices were treated as described previously (4.2.7) with either anti-MOG/complement, or m 
IgG control/complement.  Slices were then fixed in PFA at the following time-points: 30 
minutes, 3 hours, 6 hours, and 12 hours following exposure to the treatment. After fixation 
slices were labelled using antibodies against the C9 complex and MBP, plus DAPI as a nuclear 
counterstain. Samples were then mounted and imaged as previously described (4.2.4). 
4.2.8  30 minutes injury condition 
In order to see if the C9 complex activation observed following 30 minutes of anti-
MOG/complement exposure would be sufficient to induce myelin injury within the brain 
slices, an injury condition was tested where exposure to anti-MOG/complement was 
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performed for only 30 minutes. 3% complement treatments were prepared as conducted in 
4.2.8, with slices treated with either anti-MOG/complement, or m IgG control/complement. 
Following 30 minutes of exposure all slices were carefully washed in warm culture media to 
remove any residual complement or signalling molecules. Slices were then transferred into a 
well of fresh slice medium, and incubated for a further 24 hours at 37oC. Following this slices 
were fixed using PFA, stained with anti-MBP and anti-NF200, and mounted as described 
above. Slices were then imaged and analysed as described in 4.2.4. 
4.2.9  Live imaging  
4.2.9.1  Evaluating the ‘bubble’ setup for live-imaging 
The conditions required for live imaging of slices were investigated.  Imaging could not be 
performed with slices on culture inserts, as although the inserts are optically clear, they place 
the slices in a position outside of the focal distance of the lenses on the microscope. For this 
reason ‘bubble imaging’ was performed, where slices were imaged in imaging dishes (Mattek) 
submerged in a small bubble of media, approximately 100 µL of imaging media. Bubbles were 
used to achieve a balance between the need to provide nutrients to the slices via the culture 
medium, and the requirement for adequate levels of dissolved gasses (O2/CO2), which would 
not be possible if slices were submerged in large volumes. To test the viability of OLs within 
slices maintained under these conditions we used a previously generated farnesylated 
mCherry (mCherry-f) virus, SFV A7(74) mCherry-f to label and image OLs, as fernesylation 
leads to membrane localisation making it easy to track changes in cell morphology480,481. First, 
slices were examined carefully to select slices with sections of viable white matter tracks. 
These slices then received intra-white matter injections with SFV A7(74) mCherry, after which 
they were left to incubate for 7 hours at 37oC/5% CO2 to allow expression of the reporter 
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proteins. Slices were surveyed for fluorescence, and live imaging was performed using the 
Andor spinning disk system. Confocal Z stacks were collected at 564nm (800 ms exposure) 
with a 20x Air Objective (0.5 N.A.) at 5µm intervals covering the entire range of the cells. Based 
on the appearance of imaged OLs under these ‘bubble conditions’ it was determined that 
slices could be imaged for periods of up to 6 hours (Supplementary Figure S4.1).  
4.2.9.2  Live-imaging of anti-MOG/complement injury  
Live imaging was performed using the ‘bubble’ setup tested previously (4.2.10.1). The slices 
were carefully selected such that slices with at least 1 highly continuous white matter track 
were selected. These slices received intra-white matter injections with the SFV A7(74) 
mCherry MBP virus after which they were incubated for approximately 7 hours to ensure 
expression of the reporter protein. These slices were then exposed to anti-MOG/complement 
and Z stacks of a selection of mCherry MBP positive OLs were collected every 1.5 hours 
between 3 and 12 hours after initiation of the treatment. Imaging parameters were as 
described in (4.2.10.1). In between imaging sessions slices were returned to the culture insert 
/ culture well and maintained at 37oC/5% CO2. Target OLs were located in multiple imaging 
sessions based on their appearance within a map of the slice that was prepared prior to the 
start of the treatment. After the experiment images were exported and assessed in FIJI.  
 




Figure 4.2: NF200 staining for 20 µg MOG with 7% complement. Clear neuronal degeneration is visible within the MOG 
treated sample compared to the complement control which is highly continuous with little blebbing. N=3 
4.2.10  Image processing 
A custom Image J macro (appendix), was used to load images in Fiji, perform contrasting, and 
produce maximum intensity projections from the z stacks. During the operation of this macro 
the Bio formats function was used to separate the imaging channels, which were then saved 
as individual tiffs to allow reference to an unmodified image if required at a later date. Images 
were contrasted using the Fiji brightness/contrast module, by setting the upper limit of the 
intensity histogram to the point of 35% saturation. Then the single channel image stacks were 
Z projected, using the maximum intensity within the stack, to produce a singular image for the 
analysis where all the OL processes were visible. Maximum projections were then saved in 
individual folders for each channel. To allow easy implementation of the macro all images 
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were taken with MBP in the first channel position of the stacks. DAPI images were not taken, 
but only used for initial focusing during imaging setup. 
4.2.11  Ranking of Slice injury  
To assess myelin and axonal injury in images taken from the brain slices a ranking scale 
(ranging from 1 to 4) was developed, where a score of 1 represented the greatest degree of 
injury, and 4 represented healthy / non-injured tissues (Figure 4.4). Rankings for myelin were 
performed by assessing the anti-MBP signal, whilst rankings of axonal injury were performed 
using the anti-NF200 signal (Figure 4.3). Both of these were chosen due to the morphology of 
the signals they produce, with both labelling the processes of either myelin or neurones in a 
continuous fashion, and thus providing an easy means to detect injury. In both cases ranking 
scores of 4 were assigned for processes which are continuous and show only a small amount 
of blebbing/ disruption. In contrast a ranking score of 1 was assigned where processes were 
barely evident and were mainly replaced by cell debris. Ranking scores of 3 and 2 were used 
where the processes were found to be partly discontinuous to highly discontinuous, with the 
amount of blebbing/ disruption and cell debris increasing. 




Figure 4.3: Scale for Injury rankings. The varying levels of discontinuity and blebbing can be seen with 1 having the most 
of both and 4 having the least. 
 
4.2.12  Matlab blinding of Ranking  
In order to ensure ranking of the images were done in a non-biased and a consistent manner, 
the images to be ranked were displayed to the ranker in a blinded manner. This was achieved 
through the use of a Matlab™ function (appendix). Following processing within Fiji, the Z 
projected images were fed into Matlab, where they were stripped of their names and 
displayed in a randomised order for the individual to rank. The order was then stored in a 
matrix with the original filenames, and ranking, for analysis at a later point. Once all of the 
images had been analysed the matrix was exported as an excel file. This blinded ranking was 
repeated 3 times, non-consecutively, to reduce bias to the rankings caused by the 
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confounding variables such as the state of the ranker, time of day, mood of the ranker, which 
may affect the rankers ability to rank images consistently. 
Following ranking of the images, the images were separated out into experimental groups, 
and then assigned a label of either injured (rank scores 1 or 2), or uninjured (rank scores 3 or 
4), based on the ranking scores they received. These data were then collated and graphed and 
a chi squared statistical test was performed to determine whether differences in the 
distribution of injured and non-injured images achieved a level of significance (P<0.05). 
4.3  Results 
4.3.1  Complement concentration assay 
Analysis of the proportion of images exhibiting myelin injury revealed a dose-dependent effect 
of complement. Comparison of the proportion of images assigned as injured in m IgG and anti-
MOG treated slices incubated with 1% complement did not reveal a statistical difference 
(p=0.06). However, the same comparison for slices treated with both 3% and 7% complement 
detected an increase in the proportion of images ranked as injured (3%: m IgG control 6%, 
anti-MOG 81%, p=0.000019; 7%: m IgG control 10%, anti-MOG 83%, p=0.0006) (Figure 4.4). 
This data indicates that 3% complement is the lowest usable concentration to produce a 
significant degree of myelin injury, thus 3% complement was selected for use in all subsequent 
experiments.  




Figure 4.4: Complement concentration assay results. IgG show little injury to myelin within these experiment, whereas 
MOG with concentrations of complement greater than 3% showed significant injury. N=3 
 
4.3.2  Investigation into the level of axonal injury 
Having selected the combination of 3% complement with 20 µg/ml anti-MOG antibody as the 
optimal treatment to produce myelin injury by 24 hours, the effect of this treatment on axonal 
viability was then investigated. In agreement with the previous experiment (4.2.1) anti-
MOG/Complement treatment resulted in a significantly greater proportion of myelin images 
ranked as injured when compared to the m IgG control/Complement treatment (m IgG control 
9%, anti-MOG 50%, p=0.0267) (Figure 4.5 A). In contrast a similar comparison of axonal images 
did not reveal a difference in the proportion of images ranked as injured (m IgG control 90%, 
anti-MOG 89%, p=0.716) (Figure 4.5 B). This data shows that the level of axonal injury resulting 
from the 24 hour treatment with anti-MOG/3% complement is very low, thus providing 
confidence that this injury is myelin selective. 




Figure 4.5: Rankings of Myelin and neuronal injury for 3% complement. From the tests with NF200 to look at neurone 
damage it was seen that 3% complement does not significantly injury axons (p=0.72 from chi2) and does significantly 
affect myelin (p=0.03 from chi2). N=3 
 
4.3.3  Analysis of myelin and axonal injury progression 
In order to determine the peak level of injury that would be observed with the conditions 
determined, a time course of injury was performed (Figure 4.6). The time points of 1 day, as 
performed in previous experiments, 3 days and 10 days, as it is suggested that remyelination 
should occur by this point, were used. From the results the injuries to the myelin between day 
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1 and day 3 were not seen as different (Day1 anti-MOG 66%, Day 3 anti-MOG 67%, p=0.941), 
this was supplemented with the results of the neurone injury, which showed that no 
difference (Day1 anti-MOG 17%, Day 3 anti-MOG 15%, p=0.912). However at day 10 it was 
observed that slices were significantly more injured in terms of the myelin (Day3 anti-MOG 
67%, Day 10 anti-MOG 90%, p=0.018), this could also be seen when observing the signal from 
neurones which are notably more injured (Day3 anti-MOG 15%, Day 10 anti-MOG 100%, 
p=1.46E-11). In terms of injuries within each group, day 1 and 3 both showed significant myelin 
injury when IgG control/complement and anti-MOG/complement were compared (Day1 IgG 
Control 13%, Day 1 anti-MOG 66%, p=2.48E-5, and Day3 IgG Control 12%, Day3 anti-MOG 67%, 
p=5.15E-7), whereas at day 10 no significant difference is seen between the treatments (Day10 
IgG Control 80%, Day 10 anti-MOG 100%, p=0.201). 
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Figure 4.6: Rankings of injury following axonal and myelin injury progression. From these results it can be seen that 
myelin and axonal injury does not vary between days 1 and 3. Whereas after 10 days of injury myelin and axons both are 
severely injured in both injury conditions. N=3 
 
4.3.4  C9 stain 
To confirm that the complement system plays a role in the myelin injury produced by anti-
MOG/complement treatment slices were stained with anti-C9 to label membrane attack 
complexes. From the anti-C9 staining it can be seen that untreated slices (no anti-MOG/no 
complement) and complement only slices showed a small amount of C9 labelling 24 hours 
after initiation of the experiment (Figure 4.7 A,B). This C9 signal likely reflects a basal level of 
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endogenous complement activity within the slices. In contrast, both m IgG 
control/complement and anti-MOG/complement treated slices showed a greater level of C9 
Labelling at 24 hours. Interestingly, the m IgG control/complement condition showed strong 
levels of C9 activation  with more pronounced cellular localisation when compared to the 
anti-MOG/complement condition (Figure 4.7 C), where the activation was more diffuse 
(Figure 4.7 D).The intense C9 activation seen at 24 hours in the m IgG control/complement 
group suggested non-specific binding of the m IgG, which is further supported by the stains 
shown in Supplementary Figure S4.1. To test this possibility slices exposed to a 24 hours 
treatment of m IgG control/complement were fixed and probed with anti-mouse secondary 
antibodies. These experiments revealed a low level of diffuse m IgG binding on slices that 
was not localised to specific regions (e.g. white matter / grey matter) (Supplementary Figure 
S4.1 A). This contrasted with signals from anti-MOG/complement treated slices where 
distinct immunosignals were apparent on cellular processes as expected for a myelin 
targeting IgG (Supplementary Figure S4.1 B). 
 
Figure 4.7: Complement C9 activation following treatment. No treatment (NT) shows a low level of residual activation, 
complement only treated slices (comp) show the same residual level activation as NT. complement with IgG (Comp IgG) 
shows localisation with cell bodies and processes, whereas MOG with complement (Comp Mog) shows localisation of C9 
all across the slice. N=3 
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4.3.5  Analysis of C9 activation kinetics 
Anti-MOG/complement treatment induced a more diffuse C9 signal at 24 hours when 
compared with m IgG control/complement (4.3.4, Figure 4.7 C-D). These observations appear 
to be at odds with the effects of these treatments on myelin viability, with anti-
MOG/complement providing a significantly greater myelin injury (4.3.2, Figure 4.5). This 
discrepancy may be explained if anti-MOG induced a stronger and faster complement 
activation than the m IgG control treatment. In this scenario the peak of C9 activation may 
have occurred earlier than the 24 hour time-point, with diffuse levels at this time reflecting a 
loss of C9 from terminally damaged cells. To test this idea a time course was performed to 
analyse the progression of C9 activation following initiation of the anti-MOG/complement and 
m IgG control/complement treatments (Figure 4.8). For anti-MOG/complement it can be seen 
that C9 activation starts as early as 30 minutes after the injury had begun (Figure 4.8 A), while 
C9 levels remain low at this time within the m IgG control/complement treatment (Figure 4.8 
B). C9 activation can be seen to progress across the sample in the anti-MOG/complement 
group as time passes, with the C9 signal localising to the white matter tracks, increasing to a 
peak intensity at 6 hours, before diminishing so that it is barely visible at 12 hours. In contrast, 
in the m IgG control/complement condition C9 complex formation is first seen at 3 hours, 
when it is present at a low levels, increasing over the subsequent time points, and remaining 
visible at 24 hours, as seen with the C9 staining done previously (4.2.4). 




Figure 4.8: C9 activation during various treatment times of complement injuries. With the MOG/complement treatments 
(Row A) activation can be seen as early as 30 minutes (0.5 hours) can is seen to tail off around 12 hours of treatment. 
During this time C9 complex staining (Red) localises more around the myelin tracks (Green), until 12 hours where C9 
complex activation dissipates and few myelin tracks are apparent. Whereas with the IgG control/complement 
treatments (Row B) activation is not seen till about 3 hours, with activation still being at high levels at 12 hours following 
treatment. N=2 
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4.3.6  30 minute injury experiment 
Following the C9 time course experiment (4.2.5) it was questioned whether the degree of C9 complex 
formed after 30 minutes in the anti-MOG treated slices would be sufficient to induce a significant 
myelin injury within the slices. As shown in Figure 4.9 A, slices exposed to anti-MOG/complement for 
30 minutes group showed a significantly greater proportion of images ranked as injured compared to 
those from the m IgG control/complement group ( m IgG control /complement 12.5%, anti-
MOG/complement 79.6%, p=6.51E-21). Although a significant injury was seen for myelin, there was 
little to no injury to axons (Figure 4.9 B), with a similarly low level of images ranked as injured in the 
two groups (anti-MOG/complement 0%, m IgG control/complement 0%, p=1). This data indicates that 
a 30 min treatment with anti-MOG/complement induces a C9 activation of sufficient intensity to 
induce significant myelin injury without affecting axonal viability.  
 
Figure 4.9: 30 minute complement injury. Left) Myelin injury, showing a significant injury between the MOG with 
complement group and the IgG with complement group. Right) Neuronal injury, showing that neurones were unaffected 
by the treatment. N=4 
4.3.7  Live imaging  
Live imaging of 28 OLs expressing A7(74) mCherry MBP provided insights into the kinetics of OL injury 
(Figure 4.10). OLs imaged from slices treated with anti-MOG/complement showed a loss of processes 
within 12 hours of treatment induction. The morphology of cells investigated did not show significant 
alterations at 6 hours, but between 6 to 7.5 hours of treatment OL morphology began to alter, with 
the loss of their thinner processes, and thickening / shortening of the remaining processes. By 9 hours 
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the cells had lost most of their processes, and by 11.5 hours all that remained were cell bodies and 
cellular debris.  
 
Figure 4.10: Live imaging study of MBP stained Oligodendrocytes. The process imaged here responds to the injury 
originally by trying to move away from the noxious stimulus, this is followed by cell injury, which by 9 hours leaves a lot 
of cell debris, as this cell debris is lost new cells migrate into field. N=3 
4.4  Discussion 
4.4.1  Brief summary 
The work presented here was performed to identify a means to induce a myelin selective injury, which 
does not harm axons. This was in aim to have a model for demyelinating conditions, which could be 
comparable with conditions such as MS and central pontine myelinolysis where myelin damage is seen 
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long before neuronal damage is visible. In order to produce this injury a complement injury induced 
by immunoglobulins against a myelin protein, MOG, was utilised, and its injury was investigated. It was 
found that injuries can be performed using as little as 3% complement with 20 ng of immunoglobulin, 
and that this injury only needs 30 minutes treatment in order to produce an effect. This injury was 
found to preferentially injure myelin, and no recovery from the injury was observed within this work. 
4.4.2  Optimisation of complement concentration 
The aim of this work was to develop a myelin specific injury model which could be used within 
subsequent live imaging experiments. MOG complement injury has previously been utilised 
to induce myelin injury, with concentrations of complement of approximately 7% and 60 
µg/ml of anti-MOG antibody with incubations of 2 days onwards467,468,473,478. These studies 
focused solely on the myelin injury induced and did not take into consideration the effect of 
these treatments on neurones. Although these studies suggested that only myelin injury is 
observed when using complement at 7%, this was a concern within the experiments presented 
in this chapter, as axonal injury would lead to myelin being falsely identified as injured as there 
are less neurones to myelinate, so this property of the treatment was explored within the 
work presented. Winter et al467 suggested that concentrations of complement between 3 % 
and 12% can induce a similar injury to that seen in previous work with 7% complement, so the 
complement concentrations within this work were manipulated to reduce the potential risk 
to neurones. The quantity of complement was chosen to be manipulated rather than the 
quantity of antibody, as the antibody provides a key step in determining the targeting of 
complement to cells, but does not play a direct role in the injury itself. Reducing the level of 
complement reduces the amount of damage which can occur, as this reduces the level of 
spontaneous complement attack possible, this property of complement can be seen within 
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the C9 time course experiments (4.2.4), as well as reducing the amount of attack complexes 
which can form as a whole. It was important to maintain the concentration of antibodies at 
20 µg/mL as this value had previously been validated as effective by our lab, and so 
represented an appropriate concentration for ensuring adequate complement/antibody 
interaction within the slice system. The experiments reported in 4.3.1 indicated 3% 
complement as the lowest concentration where a statistically significant injury was observed. 
Interestingly this value is within the bounds suggested by Winter et al467. 3% complement was 
selected for all subsequent experiments in this chapter. 
4.4.3  Acute complement activation provides a selective myelin injury  
Findings from experiment 4.3.2 showed that complement injury from anti-MOG/complement, 
when applied for 24 hours, did not induce a statistically detectable axonal injury. However, 
from the results of all the injury experiments taken together, it can be seen that axonal 
rankings are poorer only for the longest incubations with the MOG complement injury. This is 
highly apparent following the 30 minute injury experiments which show a reduced level of 
neurones with an injured phenotype compared to the other incubation times (0% injured with 
30 min treatment, 10% with 24 hour treatment, and 15% with 3 day treatment). This may be 
a result from the formation of large quantities of the C9 complex, which may also interact with 
neurones if overly abundant within the experiment. The number of neurones with an injury 
phenotype did not show a significant disturbance for the time points compared within this 
chapter until the slices were left to incubate to about 10 days following complement 
treatment. This suggests that the injury either takes many days to induce an axonal injury 
phenotype, or further injury processes are engaged beyond the direct complement induced 
injuries. Whether these injuries are due to complement action or some other mechanism is 
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yet to be understood. However, from the 10 day time point both axons and myelin are 
observed to be severely injured, whereas before this time point injury to neurones is not seen 
as significant. Since no additional exposure to complement is seen by the slices after 
termination of the treatment this injury may be due to the loss of myelin, which is expected 
to be the main change occurring within the slice environment, as all complement proteins, 
and metabolites should be removed with the subsequent media changes. If this injury is due 
to a demyelination induced neuropathy it is an interesting phenomenon, which may be used 
to develop a greater understanding to how myelin and neuronal viability interact. 
4.4.4  Involvement of the classical complement cascade in the myelin injury  
Results from this chapter (4.3.4/4.3.5) clearly show that the myelin injury involves the 
complement pathway. The complement system involves 3 main pathways, the classical, the 
alternative, and the Lectin pathways all of which activate a cascade of events converging at 
the production of the C3 convertase298,482. The classical pathway involves the use of 
immunoglobulins, which induces the cascade ultimately resulting in the membrane attack 
complex. The lectin pathway recognition molecules, such as mannose binding lectin, collectins 
and ficolins, bind to mannose binding lectin associated serine proteases, which leads to 
activation of the complement cascade. The alternative pathway activates spontaneously 
causing the hydrolysis of the C3 thioester bond, which leads to the activation of the cascade 
and production of the attack complex483. In the case of these experiments myelin injury was 
associated with robust and early complement C9 activation, while a delayed C9 activation was 
associated with a non-specific IgG/complement treatment that did not induce myelin injury. 
Although, activation of complement was seen within the controls this was of low basal levels. 
The pattern of results seen with both treatment conditions is most consistent with the classical 
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complement pathway, as it was greater than basal activation, and the key difference between 
the experimental and control groups is the addition of antibody(e.g. myelin specific vs isotype 
control), and the classical pathway is the only antibody dependant pathway. This explains both 
the greater anti-C9 signals seen within the antibody conditions, and the different activation 
profiles between the anti-MOG and m IgG control antibody conditions.  
4.4.5  Kinetics of C9 activation and myelin injury 
Results from the C9 activation time course (4.3.5) and live-imaging experiment (4.3.7) indicate 
that the OL/myelin injury phenomenon develops in anti-MOG/complement treated slices 
several hours following the initial complement c9 activation. From the C9 activation 
experiments it is seen that levels of activated complement complexes steadily increase up to 
6 hours following the treatment, while the live imaging experiments show that injury is not 
apparent until around 7.5 hours following the initial exposure. This suggests that there is a lag 
between C9 formation and injury presentation during which time the injury process is 
established. This lag time could be the time it takes for enough activated C9 to puncture the 
cells to induce an injured phenotype, or it could indicate that the injury to the cells is induced 
through an indirect means other than direct C9 induced membrane lysis484–486. The idea that 
an injury can’t be seen until the complement complexes reach a critical threshold is supported 
by observations from the m IgG control/complement group, as although the levels of C9 
elevate within the first 12 hours of treatment there is a clear lack of observable injury 
following 24 hours, up to 3 days. This effect could be due to the diffuse nature of m IgG control 
binding compared to the MOG binding, as shown in Supplementary Figure S4.1 as the IgG 
control injury may not provide enough localised damage to lead to an observable myelin 
response. This is because the C9 complexes within the IgG control/complement condition 
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show a level of cellular location, within the granule layer, although the cells this localises to 
has yet to be confirmed. The absence of an observable NF200 or MBP injury at 24 hours, 
although complement levels are high suggest either MBP and NF200 staining may not be 
sensitive enough to detect acute myelin injury, or that tolerance for the injury is high, such 
that the cells can resist showing an injured phenotype when the injury is not focused on it. 
The findings from the 30 minute exposure experiments suggest that the critical threshold for 
C9 activation is lower than the peak threshold as observed a 6 hours (3.3.5).  Certainly further 
complement activity is unnecessary for myelin injury as any messaging molecules and 
complement would be washed away during the washes that mark the end of the exposure. It 
should be noted that the live-imaging experiments involved only a few cells (28), thus further 
replications are required to confirm the kinetics of the injury. None the less, these 
observations provide strong evidence that the injury presentation at 7.5 hours is not directly 
related to the peak in complement C9 concentration. Instead this delay likely reflects the time 
it takes for the cells to respond to the damage induced by initial complement activation. 
  







“There’s as many atoms in a single molecule of your DNA as there are stars in 
the typical galaxy. We are, each of us, a little universe.” 
- Neil deGrasse Tyson, Cosmos 
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5.1  Introduction 
Imaging of fluorescent signals in living cells and tissues is a key utility used to investigate the 
structure and function of biological machinery. Various fluorescence modalities allow efficient 
observation of numerous physiological activities within the cell, including cell death, using 
agents such as propidium iodide and NucviewTM 487, ion mobility, with agents such as Fura-
2488, to  the distribution and trafficking of proteins via transgenic animal models489,490, and 
lipid transfection and viral vector mediated delivery of FP tagged fusion proteins172,401,491,492. 
In the context of live-imaging fluorescence imaging is also advantageous since it enables 
greater spatial resolution than magnetic resonance or ultrasound techniques493. 
Fluorescent investigations can be divided into 2 groups, ensemble-averaged imaging and SMI, 
both of which have their uses in understanding biological systems. Ensemble-averaged 
experiments look at the sample as a whole, allowing analyses of cell to cell interactions, 
intracellular structures, and distributions of groups of molecules by considering the averaged 
behaviour of the molecules within the sample and not the full spread of molecular activities 
and their interactions with each other within the system338. Although averaging of these 
behaviours reduces the level of information available, it permits a rapid and relatively 
uncomplicated analysis that can be useful for many applications, for example the study of 
active C9 complement complexes seen in the previous chapter. However, as these 
methodologies look at the sample as a whole the results only depict the averaged behaviour 
of the molecules within the sample, and not the full spread of molecular activities and their 
interactions with each other within the system338. Single molecule studies, unlike ensemble 
imaging, look at individual molecules within the system allowing observation of less 
conventional behaviours within the system that would not be apparent when the averaged 
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behaviour of the systems is analysed. The main requirement of any SMI methodology is to 
resolve individual molecules within a population, and therefore see the full range of 
behaviours which occur within the sample. In order to understand a system, and define its 
activities, and structure, both ensemble-averaged imaging and SMI should be used. Within the 
field of glial biology much work has been done at the ensemble level, providing us with many 
useful insights338,494. To date few SMI methodologies have been utilised within the OL and 
myelin biology field, thus the ambition of the work presented within this chapter is to develop 
SMI methods for the analysis of myelin protein dynamics both during OL development and 
injury. 
SMI methodologies can be divided into 2 categories, localisation and tracking, each with their 
own requirements and benefits, summarised in Table 5.1.  Single molecule localisation utilises 
high resolution microscopy techniques, such as STORM or PALM, to provide precise spatial 
information on individual molecules within the system364,400,495. Due to this, and the 
algorithms used within localisation methodologies, samples tend to be fixed. This allows 
localisation experiments to derive information on the amount of molecules within the system, 
the structural organisation of the sample, and particle interactions through co-localisation. In 
contrast to this are the tracking methodologies which utilise live samples, and conventional 
optical imaging323,388,496. Super resolution imaging would be preferred within this modality, 
however, this provides a large level of complexity to imaging, which super resolution 
techniques have yet to address, so instead temporal resolution is prioritised over spatial 
resolution as this dimension is more important within tracking497. Tracking provides 
information on the molecular responses following an event, and allows observation of 
molecular movements and dynamics, and short-lived particle interactions. As much of the 
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ensemble-averaged work has been performed previously on the structure of myelin, and the 
role of MBP within it, single molecule tracking was chosen for the work within this chapter as 
little is known on the motility of MBP molecules, and therefore any reference to single 
molecule imaging hence forth within the chapter shall be a reference to single molecule 
tracking338. 
Table 5.1: Comparison of Single molecule tracking and Localisation methodologies 
 
Localisation Tracking 
Type of Resolution needed Spatial Temporal 
Microscopy used Super resolution/ Optical Optical 
Fixation Yes No 





Interactions (Dwell times) 
Movement 
The most widespread single molecule techniques within biology are those which utilise 
fluorescent probes, which may be either inorganic or organic. Inorganic probes provide a high 
quantum yield and are normally more photostable than organic probes. A key disadvantage 
of these probes is that they must be applied ectopically, and can potentially be toxic to 
cells321,498. Organic fluorescent probes, e.g. FPs, on the other hand have the potential to be 
genetically encodable, and are generally well tolerated by cells, however, their quantum yields 
are lower than organic probes, providing them with poor signal to noise ratios in imaging499.  
One of the strategies to cope with poor signal to noise ratios is through an exceptional 
category of FPs, known as photoswitchable FPs339,400. These proteins may be converted 
between a fluorescent on-state, and a non-fluorescent off-state where fluorescent emission 
is prevented, thus allowing direct control over the fluorophore351. Photoswitching allows the 
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isolation of single molecules through the inactivation of the majority of fluorophores in the 
sample, leaving the remaining emitters as distinct point sources that can be resolved 
individually and tracked over time. This is also useful when performing super-resolution 
imaging, where fluctuations in the signal are used to improve the contrast of the image, as the 
protein signal can easily be manipulated, and therefore fluctuations can easily be controlled. 
Many photoswitchable proteins can also undergo photoconversion, where the protein enters 
an extra fluorescent state in which their emission converts from one wavelength to another339. 
These photoconvertible proteins increase the efficiency of SMI applications as they allow 
monitoring of multiple individual groups of molecules simultaneously. 
For the work conducted within this chapter all SMI work was conducted on monocultures of 
adherent cells, rather than tissue explant samples such as the organotypic slice cultures as 
used in Chapter 4, as it allowed more flexibility, and reduced complexity for imaging the 
samples. Two types of cells were used within this work, the Oli-neu cell line, and primary 
extracted OPCs. 
OPCs are an embryonically derived NG2 positive glial subtype, sometimes referred to as NG2 
cells177,500. These cells are proliferative, migratory cells, unlike OLs, and are commonly 
identified antigenically by probing for the surface marker proteins NG2, A2B5, and 
PDGFαR202,501. The quantities of these markers vary within species, an example of such is the 
marker A2B5, which is key for cellular identity within rat OPCs, however, within mice  OPCs 
the quantity of A2B5 is lower, so NG2  or PDGFαR are utilised instead336,502. In vitro studies 
have shown that OPCs are pluripotent cells with the potential to make OLs, type 2 astrocytes, 
and neuronal cells. Their lineage plasticity in vivo appears to be narrower, with astrocytes and 
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some neurons being generated in the embryonic CNS, but not in the postnatal or adult CNS503. 
In vitro, OPCs when exposed to high serum conditions produce type 2 astrocytes, referred to 
as such as they are produced from a different  precursor cell origin than type 1 and show a 
neuron-like morphology, however, functionally they have not been observed to have different 
activities to type 1 astrocytes202,336,504,505, while In low serum conditions OPCs produce OLs. 
Despite evidence for astrocytic fate in the embryonic CNS, and the generation of small 
numbers of neurons the majority of cells produced by OPCs in vivo are OLs500. Morphologically, 
OPCs have small soma compared to astrocytic and neuronal cell lineages, and are further 
characterised by the possession of fine processes. 
Following differentiation of OPC cells, the cells progress through 3 different stages (Figure 5.1). 
The first stage is referred to in the literature as the late OPC/preoligodendrocyte stage 
(pOL)506–509. At this stage the cells are still migratory, and proliferative, however, they have a 
multipolar morphology, with thicker processes, and larger soma than OPCs. pOL cells start to 
express antigens recognised by the O4 antibody510, suggesting a commitment to the OL 
lineage. Following this the processes of the cells start to become ramified and lengthen, these 
processes are normally compared to a spider’s web. The cells stop expressing NG2 and A2B5 
and start to express Gal C, at which point the cells are normally referred to as premyelinating 
oligodendrocytes (PMOL). These cells then progress to extend the membranes of its processes 
to make flattened ensheathing sheets, while expression of classical myelin proteins, such as 
MBP, PLP, MAG and MOG begins, at which point these cells are referred to as myelinating 
oligodendrocytes (MOL). 
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Oli-neu cells are a mouse immature OL cell line, which has been shown to be useful in looking 
at OL behaviours, and interactions449,511–513. The Oli-neu cell line was developed through the 
induction of the t-neu oncogene in OPC isolated from neonatal mouse cerebellum. The t-neu 
oncogene carries a point mutation causing tyrosine kinase to be constitutively active450. This 
causes Oli-neu cells to remains in an immature proliferative state where the expression of 
myelin proteins is suppressed. However, Oli-neu cells have the potential to differentiate to a 
more mature phenotype449. This differentiation is achieved through exposure to dibutyl 
adenosine 3′,5′-cyclic monophosphate (dbcAMP)449, and has been shown to induce a mature 
protein array within the Oli-neu cells, with myelin proteins such as PLP and MBP being 
expressed450. 
In order to understand MBP dynamics during various stages of OL maturation, SMI tracking of 
MBP was performed in  Oli-neu cells, primary OPCs, and  primary OPCs cultured under 
differentiating conditions. This allows further understanding on the behaviour of singular MBP 
molecules, and through the use of parameters such as confinement and diffusion, it allows 
inferences into MBPs interactions with itself as well as other OL proteins, such as PLP and CNP.  
In order to understand how MBP behaviour changes during injury, the tracking data from 
healthy cells will also be compared to that obtained from Oli-neu cells subjected to a cellular 
injury involving exposure to a toxin that disrupts the lipid structure of the plasma membrane 
(lysolecithin). These conditions are expected to disturb the localisation of MBP  producing a 
more mobile MBP phenotype, as MBP is known to interact with membrane proteins such as 
PLP and PIP2 with its behaviour well represented by Brownian motion432,514.  
   
157 
 
It is also believed MBP would be more mobile in the immature cells, such as the OPC cells and 
Oli-neu cells, with little difference between the two, as both cell types will not be expressing 
the mature complement of proteins, which MBP interacts with. 
 
Figure 5.1: Depiction of markers expressed by OPC cells at different levels of maturity. The bars below the list of marks 
depict that as the maturity of cells increase the cells become less migratory and proliferative. This figure was adapted 
from Barateiro et al 2014202 
5.2  Methods  
In order to perform single molecule tracking an imaging modality with a high spatial resolution 
was required to reduce the amount of particle cross-over events observed within the images. 
This work was therefore conducted using cells rather than slices, as methodologies which can 
penetrate samples further tend to sacrifice spatial resolution to do so, and of the imaging 
systems available for this work it was seen as more feasible. Utilising cells also allowed more 
samples to be imaged, as they can easily be prepared and treated with the virus. 
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5.2.1  Oli-neu plating 
Oli-neu cells were cultured as described in Chapter 3.  Cells were then seeded into 3 imaging 
dishes (Mattek, P35GC-0-14-C) at a density of 30,000 cells per dish. The remainder of the cells 
were seeded into T75 flasks with approximately 500,000 cells per flask. The cells within 
imaging dishes were then submerged in 1ml SATO solution and gently swirled to ensure an 
even distribution. Cells were then incubated at 37oC for up to 2 days at which point they were 
assessed for infection with SFV vectors. 
5.2.2  Oligodendrocyte precursor cell (OPC) culture 
Neonatal mice (postnatal day 0 -2) were sacrificed using Home Office approved methods 
(described by the Animals Act, 1986). Brains were then dissected out and submerged in ice 
cold dissection medium. The cortices were separated from the midbrain and the meninges 
were removed using fine forceps. The cortices were then minced into 1mm3 chunks and then 
incubated with trypsin and DNase for 20 minutes at 37oC, to liberate as many cells as possible, 
with agitation every 5 minutes to prevent aggregation. DMEM with 10% FBS was added to 
inactivate the trypsin, and the tissue was dissociated by trituration through a 10 mL serological 
pipette. This solution was then filtered using a cell strainer with mesh size of 70 µm, and 
centrifuged at 200 x g for 7 minutes at 10oC. The supernatant was removed and resuspended 
slowly, by trituration in 1 mL DMEM/10%FBS with a P1000 pipette, after which an additional 
8.5 mL DMEM/FBS was added. 3 ml of this cell solution was transferred into a Poly-L Lysine 
coated T25 flasks pre-filled with 3 mL of pre-equilibrated DMEM/10%FBS, resulting in a total 
volume of 6 ml. The flasks were then incubated at 37oC for 16 hours.  The next day a complete 
media exchange  was performed to remove as much cell debris as possible, and the cells were 
left to culture for 9 days with ⅔ media changes being performed every third day, with insulin 
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supplementation to produce a final concentration of 2 µg/ml. Flasks were visualised each day 
to monitor cell growth. Positive signs include the steady formation of an astrocyte monolayer 
and the appearance and proliferation of putative OPC (small round cells with bright 
appearance) atop the astroglial cell layer. Once glial cell growth had reached an acceptable 
level, normally around 9 days, the flasks were shaken on an orbital shaker at 160 rpm for 30 
minutes, following which the media was changed and the cells were placed on the shaker for 
a further 16 hours at 220 rpm. All shaking steps were performed within the culture incubator. 
Shaking in the second step detaches OPCs from the flasks. These suspended cells were then 
transferred into a non-coated 10 cm dish, and left to incubate at 37oC for 30 min with gentle 
swirling every 10 min to prevent adhesion of OPCs. The cell suspension from these dishes were 
then collected and centrifuged at 1000 rpm for 5 minutes at 10oC. The pellet was then 
resuspended in 1ml of fresh OPC media and 1-5 x105 cells were seeded into imaging dishes 
(P35GC-0-14-C, Mattek).  
OPC Differentiation 
In order to differentiate the OPC cells, the cells were exposed to OPC media lacking fibroblast 
growth factor 2 (FGF2), PDGFαR, and Insulin-like growth factor 1 (IGF1), and supplemented 
with Triiodothyronine (T3), this media was referred to as differentiation media. The cells were 
maintained with media changes every other day for 1 week. This provided the cells with the 
conditions needed to induce differentiation of OPC into OL. 
The maturity of these cells were examined through the use of immunocytochemistry for a 
marker for immature OPC cells, NG2. No signal was observed for NG2 from any of the 
differentiated cells, compared to undifferentiated cells where a strong NG2 signal can be 
observed (Figure 5.2). This confirms that cells observed progressed to a level of maturity 
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beyond the OPC phenotype. This also suggests that the pOLs observed in this work were more 
mature than those within the literature, as expression  of NG2 could not be observed within 
these cells202,509. 
Following the maturation process, 3 stages of cells were observed all of which were NG2 
negative cells (Figure 5.2): (1) POL: multipolar cells with few ramifications which were 
analogous with POLs from the literature202,506,509,515; (2) PMOL: multipolar cells which were 
heavily ramified and were analogous with PMOLs from the literature; (3) EMOL: Multipolar cells 
with regions of flattened membranes similar to the flattened myelin sheets observed for 
myelinating oligodendrocytes in vitro. Of note the flattened membrane areas observed in our 
cultures were not continuous like that seen in the literature, hence these regions will be 
referred to as myelinating bubbles202,506,509,515. In this thesis the 3rd type of cell is defined as 
early myelinating oligodendrocyte, as there are regions analogous with myelination, but the 
cells were not at the level of maturity where these regions are continuous. For imaging 
purposes only the myelinating bubbles were recorded from EMOLs. Unfortunately, no cells 
presented with the mature myelinating phenotype presented in the literature after 1 week of 
differentiation202,506,509,515. 




Figure 5.2: NG2 Staining of OPC cells, before and following differentiation. A) OPC before differentiation show robust 
staining for NG2. Following differentiation (B) NG2 staining is not detected within the dish indicating that OPC in the 
culture have differentiated beyond the OPC stage. NG2 staining was performed on a upright microscope at 100x 
magnification. 
5.2.3  Infection with SFV 
When the cultured cells were approximately 60% confluent, and more than 20% of cells 
possessed processes approximately 1.5 times the length of the soma, the dish was regarded 
as ready to image.  An example of such a culture is shown in Figure 5.3. For OPC or 
differentiated OPC cells, it was decided that when the cells possessed processes that were 1.5 
times the size of their soma they were ready to image. To prepare the dish for imaging, the 
cells were infected with the SFV A7(74) Dendra2 MBP virus to induce the production of 
fluorescent particles for tracking. This was achieved by removing all the media from outside 
the wells within the imaging dishes, and half of the media from within the well, leaving 100µl 
of media submerging the cells within the well. The residual media in the well was left to 
prevent both drying of the cells and reduce disruption to the cells, both of which could affect 
their viability. 25µl of virus solution was then added to produce a 1 in 5 dilution of the virus 
providing approximately 7500 infectious units of SFV to the dish. The media / SFV mixture was 
gently mixed, and left to incubate at 37oC for 1 hour. Following the incubation the cells were 
promptly washed with fresh Imaging SATO media to remove any remaining viral units, and to 
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remove any metabolites existent in the media. This wash was performed 3 times to remove 
as much phenol red and virus from the dish as possible. These cells were left to acclimatise at 
37oC for 6 hours to allow sufficient protein expression, after which the cells were taken for 
imaging. 
 
Figure 5.3: Oli-neu cells at stage of growth considered ready for imaging.  The sample contained many cells with 
processes that are much larger than their soma, and a cell density of at least 60% confluent. These conditions were 
considered optimal for imaging of Oli-neu cells. Of note, many processes within this sample overlap which may be 
disadvantageous for imaging individual processes if overlapping cells are successfully infected. 
5.2.4  Cellular imaging 
For imaging, a focus was made on imaging processes of the cells examined, as this is the 
functional region in terms of MBP, and therefore where the most significant differences were 
most likely to occur. Also, as it had previously been observed MBP from the SFV vector is 
centrally expressed (Chapter 3), therefore a large amount of particles and movement would 
be seen, there would be a large amount of obstructive data to mask any real changes which 
may occur between samples if the soma were to be observed. 
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Imaging dishes containing the infected cells were imaged on an inverted widefield microscope, 
using a 100 x magnification with 1.4 numerical aperture. The cells were first surveyed under 
bright-field to find cells with processes, after which the microscope was converted to TIRF 
mode. Upon discovery of a process, the cells were viewed using 488 nm excitation to ensure 
the cells produced a fluorescent signal. The fluorescent cells were then primarily irradiated 
with 405 nm light for 5 seconds to induce dendra2 photoswitching from a 488nm excitation 
to 561nm, producing a spectrally sparse red signal, which could be tracked. Time-lapse 
imaging was performed on the selected region of interest with a 561nm excitation 
wavelength, and 30 ns camera exposure times for 2500 frames. In the case of exceptionally 
sparse signal, or rapidly photobleaching samples, an image was taken at 488nm to produce a 
reference image to compare the detected particles to, ensuring the particle tracks produced 
are existent within the processes of the cell, and are not likely to be due to free floating 
material within the dish. Following this, a new process was identified for imaging, till 
approximately 2 hours had passed. All resultant timelapsed-image stacks where processed 
following this using ICY bioanalysis 516. 
5.2.5  Lysolecithin injury 
Once baseline cellular images had been performed, the processes were injured using 
lysolecithin. This was achieved by first irradiating the imaged processes with 405 nm light for 
30s each to promote further photoswitching from 488 nm to 561 nm. The cells were then 
treated with lysophosphatidylcholine (LPC) to produce an injury. For the Oli-neu cells 0.5 ng 
of LPC was used, and for the primary cells 0.5 pg was used as the primary cells were seen to 
be more sensitive to LPC. Unpublished data from the lab (S.Foale and D. Fulton unpublished) 
demonstrated concentrations which could be used to injure OL cells, which were used to 
   
164 
 
determine the concentrations used within this work. These processes where then reimaged 
using the time-lapse imaging parameters described above.  
Table 5.2: Icy Tracking parameters. The parameters shown here were optimised utilising the Oli-neu cells, and were 
utilised for all the cells used within the analysis in this chapter. 
Parameter Setting 
Expected number of False positives 30 
Probability of detection 0.9 
Expected number of new tracks per frame 20 
Expected number of objects within the first frame 50 
Expected track length 20 
Average predicted displacement 5 
Minimum probability of existance 0.5 
Threshold of thermination 0.0001 
Gate Factor 4 
Depth of track trees 4 
Number of new tracks per frame 15 
5.2.6  Extraction of data 
Images were imported into ICY bioanalysis for particle detection and tracking516. The images 
were opened and the contrast within the images adjusted to aid the detection of the processes 
by eye. Regions of interest were then constructed around the processes of the cell within the 
first image of the stack. The region of interest was verified with the other images within the 
stack to ensure it encompasses the process throughout the stack, and adjusted to ensure the 
region of interest was tightly confined to the process of the cell (Figure 5.4). In cases where 
the process moved within imaging, the longer segment was taken forward for imaging, or the 
images were excluded from analysis. This region of interest was then inputted into the Spot 
detector function, which utilises a wavelet particle detection protocol, and was set to expect 
detected particles to be approximately 3 pixels in diameter on a dark background, as previous 
imaging showed this to be an appropriate assumption381. Once particle detection was 
complete the detected particles were input into the particle tracker, utilising the parameters 
shown in Table 5.2, where the detected particles were compared to each other and the most 
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likely particle track was calculated for each detection384. This particle tracker utilises a multiple 
linkage hypothesis tracking algorithm to link the particles between each frame. These 
detected particle tracks were then filtered to remove any particle tracks which are 
exceptionally small, as these were deemed as tracks which would not provide useful data, and 
verified by eye to remove any tracks which were not bound within the confines of the cell517.  
Once the tracks were filtered, data was extracted using the motion profiler plugin, mean 
squared displacement plugin, and the export to XLS function within ICY bioanalysis. These 
operations provided outputs for the mean squared displacements for each track, the net 
displacement, gross displacement, the track lengths, and the raw track data516,518. These data 
were then utilised to produce comparative data for the different conditions. 
 
Figure 5.4: Selection of the region of interest within the image and spot tracking. Regions of interest (Green) were 
carefully drawn to cover the whole process (A). These regions were run through the spot detector function to find the 
particles within the image (B). These detections (Red) were then run through the particle tracker in order to produce 
particle tracks.  
5.2.7  Data analysis 
The outputted data was imported into Matlab, where the confinement ratio and diffusion 
coefficients were calculated from the displacement, and mean square displacement (MSD), 
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using both Equation 5.1 and Equation 5.3 respectively. The confinement ratio provides details 
on particle interactions, as particles which interact more with their environment show lower 
mobility, which suggests that there is either a structural interaction impeding its movement, 
or a functional relationship where the particle interacts with another molecule. This works 
well with the diffusion coefficient which provides the rate of diffusion of the particles within 
the region of interest. Thus, while the confinement ratio provides details on interactions, the 
diffusion coefficient provides data on movement. Histograms for the diffusion coefficient and 
the confinement ratio were produced to visualise the variation of behaviours within the 
system. 
5.2.7.1  Confinements 
The confinement ratio is defined as the amount of particle movement detected between the 
first frame of the track and the last frame, calculated by Equation 5.1. Confinement can be 
long lasting, or transient, such as the case with lipid rafts and brief molecular interactions519. 
It is also referred to in the literature as the Meandering index, or the chemotaxic index. As it 
is determined by the amount of net movement divided by the gross movement, the values 
produced are bound between 0 and 1, with lower values signifying constrained movement 
and high values signifying free movement520. If a particle being tracked constantly changes 
direction the confinement ratio will tend towards zero, as little net movement will be 
achieved, where as if the particle moves in a directed manner the ratio will tend to 1 as a large 
proportion of net movement will be achieved521. One key problem with the confinement ratio 
is that it tends towards zero with longer track lengths, as there are more possible regions of 
transient confinement, or movement back on itself. This is corrected for by the using the 
square root of the track duration as a correction factor, Equation 5.2519,522 . 







Equation 5.1: Equation to calculate the confinement of a particle (rcon). The net diffusion of the particle dnet is divided by 




 𝑡( ) 
Equation 5.2: Equation to calculate the confinement ratio corrected utilising track length (ttrack). This prevents short 
tracks from having larger ratios than longer tracks as the confinement of longer tracks tend to zero, however, this 
correction stops the ratios from lying between 0 and 1. 
 
5.2.7.2  Diffusion coefficient 
The diffusion coefficient is the amount of molecular movement through a surface over a unit 
of time, given by Fick’s first law. This relies on the mass of the substance, the level of 
interaction of the solute with the solvent, the concentration, temperature and pressure. It can 
be calculated through Equation 5.3 or through the gradient of the root mean squared 
displacement graph. Freely diffusive molecules have a higher diffusion coefficient, freely 
diffusive rhodamine 6G and GFP have the coefficients of 2.8 × 10−10 m2/s  and 1.63x10-10 at 
20oC respectively, where as highly restricted molecules tend to have a lower coefficients523–
525. These numbers are dependent on factors such as the temperature, the size of the particles, 
and the concentration of particles existant526. This metric was chosen within this work as it 
provides a rate of movement for the particle tracks, allowing greater understanding of not 
only interactions, but also directionality of movement. 
  







Equation 5.3: Equation to calculate the diffusion Coefficient from the MSD. The mean squared displacement in cm2 (<x2>) 
is divided by the dimensionality constant for the image (qi) and the time interval in seconds being used. The qi for the 
images used in this work was 4 as all recordings were made in only 2 dimensions. 
5.3  Results 
5.3.1  Qualitative view on Particle Movement  
To provide a qualitative overview of particle movement prior to the quantitative description 
of particle diffusion and confinement representative motion profiles are presented from 
single regions of interest. Motion profiles illustrate the two-dimensional movement (X Y) of all 
particles from a region of interest with the origin of each particle set as 0, 0. 
Oli-neu cells: From plotting the MBP particle displacements within each track it can be seen 
that particle tracks within Oli-neu cells do not show directionality. This can be seen as the 
distribution of displacements on the motion profile graph (Figure 5.5) is more elliptical, rather 
than linear, which is representative of random particle movements, and non-directed 
movement. It can also be seen from the displacement graph that movement within the sample 
is approximately equivalent in all directions with the graph being centred at 0, 0.  




Figure 5.5: Oli-neu motion profile graph. Each coloured line within the graph represents the displacement of a particle in 
pixels, with 0, 0 being the position of the particle in frame 1. The graph is non-directional as the tracks extend in all 
directions in near equal proportions. 
Primary OPC. From plotting the particle displacements of OPC cells a similar distribution can 
be seen within the graph as that seen with Oli-neu cells (Figure 5.6). The plot possesses an 
elliptical shape with particle tracks extending between both the positive and negative regions 
of the graph, showing movement in all directions. Compared to the displacement of the Oli-
neu cells it can be seen that the graph has a less linear morphology, but movement extends 
to the same distances on average, and both morphologies are still quite elliptical. The particle 
tracks forming the displacement graph are more spread out, with particle tracks within the 
Oli-neu cells being seemingly clustered in direction and distance. However the OPC tracks 
seem to be more spread out, an example of which is the dark blue tracks within each, the 
tracks move in many directions both towards and away from its starting point in the OPC 
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graph, whereas a dark blue tracks in the Oli-neu graph originally moves away from its start 
point, but then is seen moving generally associated to its new point. 
 
Figure 5.6: OPC motion profile. The graph is exceptionally elliptical in shape, demonstrating random movement in all 
directions. 
Differentiated OPC: For differentiated OPC it can be seen that depending on the morphology 
of the cell the particle displacement varies, as seen in Figure 5.7 to Figure 5.9. When looking 
at the POLs it can be seen that like the Oli-neu and immature OPC cells particle displacement 
when graphed is elliptical (Figure 5.7) suggesting Brownian motion. For PMOLs the morphology 
of the displacement graphs tended to be more elliptical (Figure 5.8) and dependant on the 
length of the processes. For EMOL processes (Figure 5.9), it can be seen that the shape of the 
graph has a more linear presentation than that seen for the OPC cells and the Oli-neu cells. 
This varied depending on the size and the number of myelinating bubbles, with processes with 
numerous smaller bubbles producing graphs with a much more linear morphology.  





Figure 5.7: Motion Profile of pOLs. The motion plot displays an elliptical phenotype suggesting that little to no 
directionality exists within the movement of particles. 
 
Figure 5.8: Motion profile of PMOLs. The PMOLs display an elliptical pattern in the plot of track motions, suggesting little to 
no directionality and random movement. 




Figure 5.9: Motion Profile of EMOLs. The graph is quite linear with many tracks displaying similar motion within the cells. 
5.3.2  Diffusion Coefficients 
It can be seen from the diffusion histograms that MBP particles in all of the cell types 
investigated have a range of diffusion profiles underlying their behaviours. The diffusive 
bodies can be divided into 3 groups, the slow moving populations, intermediate speed 
populations, and fast moving populations. Each cell type within this work is defined by 
different proportions of molecules classified within each group. For OPCs it can be seen that 
there is a broad range of particle movements (Figure 5.10) from the slow moving particles 
with coefficients less than 2.4e-3 mm2/s which make up the majority of tracks, to the 
intermediary particles with diffusions between 2.4e-3 mm2/s and 4.7e-3 mm2/s, and faster 
moving particles with diffusion coefficients above 4.7e-3 mm2/s which make up the smallest 
population within the tracks. Showing that particles within the OPCs still have the potential to 
be diffusive. When OPCs are differentiated this  profile transforms into one which is more 
sedentary with slower moving particles still dominating the motion profile, and some 
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intermediately diffusive molecule tracks existing, but the faster moving particles being lost 
(Figure 5.11). These data suggest a reduced capacity for MBP diffusion within the OL 
phenotype. This phenotype is further enhanced when these cells are injured using LPC, with a 
loss of the intermediately diffusive particles, (Figure 5.12). 
  




Figure 5.10: Histogram of OPC diffusion. It can be seen that although many of the particles would be classified as slow 
moving with diffusions less than 2.4e-3 mm2/s (Red), there is a range of diffusion profiles with fast moving particles with 
diffusions greater than 4.7e-3 mm2/s (Green), and particles of an intermediate profile between these boundaries (Yellow). 
 
Figure 5.11: Histogram of particle diffusions for the differentiate OPCs. It can be seen that majority of the particles would 
be classified as slow moving with coefficients below 2.4e-3 mm2/s (Red), however, a number of particles do exist which 
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Figure 5.12: Histogram of particle diffusions within the injured differentiated OPCs. It can be seen many particles exist 
whose diffusion would be classified within the slow moving particle category (Red), with little to nothing within the other 
movement categories. 
                            
Oli-neu cells, being a cell line derived from OPCs, were expected to show a similar profile to 
that of the OPC cells. However, they show a similar profile to that seen with the differentiated 
cells (Figure 5.13). The Oli-neu MBP molecule tracks possess a small number of intermediately 
moving particles, with the majority of profiles falling within the slow moving group. The Oli-
neu cells also show an absence of fast moving profiles seen in the OPC cells, which altogether 
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Figure 5.13: Histogram of Oli-neu diffusion coefficients. It can be seen that within Oli-neu cells particles are mainly slow 
moving (Red), but contains some potential for fast movement, with a number of particles being classified within the 
intermediate group (Yellow). 
Overall it can be seen that the OPCs exhibit the most diffusive environment of the cell types 
tested, and that differentiation of OPCs leads to a hindrance in MBP particle movement 
suggesting a less diffusive environment arises following maturation. 
5.3.3  Confinements 
It can be seen that all the samples observed contain a mixture of molecule behaviours in terms 
of confinement, with some particles being exceptionally confined with values close to 0, and 
with some particles being freely mobile with values close to one. The distribution of these 
values is key when discussing the behaviour of MBP within the samples. The confinement data 
for OPC show that these cells show a distribution of confinement profiles centred 
approximately around 0.4, with some particles being highly mobile with ratios closer to 1, and 
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while there may be some interactions within the samples, these influences do not affect all 
the particles equivalently. 
 
Figure 5.14: Histogram of OPC confinement ratios. It can be seen that there is a range of confinements within OPC cells 
with the peak of the histogram at 0.4. 
Following differentiation of the OPC cells the distribution of the particle confinements as a 
whole shifts, with the distribution of particle confinements being shifted closer to 0, 
suggesting that as the cells differentiate MBP becomes more confined (Figure 5.15 A). When 
looking at the 3 different morphologies which are present within the differentiated cells, it 
can be seen all the cell morphologies show this shift, with the more confined particles 
contributing a greater proportion of the population. Within the POL cells the peak of the 
particle confinements exists at approximately 0.1 (Figure 5.15 B), with a distribution of all 
other confinements at a positive skew. This is the same as what is seen within the EMOL (Figure 
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a more free phenotype, with the peak existing at approximately 0.4 and no strong skew seen, 
similar to what is seen with the injured OL cells (Figure 5.16). 
Following the treatment of differentiated cells with LPC, the distribution of particle 
confinements shifts again, closer to 1, with the distribution resembling that of the 
undifferentiated OPC cells. This suggests that injuring the cells interferes with the molecular 
interactions that act to increase confinement in differentiated OL.  





Figure 5.15: Histogram of differentiated OPC confinement ratios. It can be seen that a range of behaviours exist within all cell morphologies. When all three morphologies are together the 
histogram for the population is centred at 0.3, suggesting that the cells are weakly confined (A). However, when separated into the different morphologies it can be seen that the POLs (B) 
and the EMOLs (D) possess stronger confinement, with the centres at approximately 0.2 and a positive skew, than the PMOLs, which have their confinements centred at approximately 0.4 
with near even distribution around it.




Figure 5.16: MBP confinement for differentiated OPCs following injury. The distribution of the confinements of particles 
from the injured OPCs showed an even distribution with a peaks at 0.4. 
When exploring the distribution of the Oli-neu cells it can be seen that population contains 
more freely mobile particles than the OPC cells (Figure 5.17). Overall the distribution of the 
particle confinements itself is still approximately centred around 0.5, however, injured Oli-neu 
cells seem to show a slightly more even distribution, with a similar number of particles 
showing confinements greater than 0.5 and particles with confinements less than 0.5. 
Following injury to the Oli-neu cells the distribution of particle confinements show little 
change, with the profile of confinements still being approximately centred at 0.5, with a similar 
number of particles on each side, unlike with the differentiated OPC cells which showed a shift 
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Figure 5.17: Oli-neu cell confinement. A) Oli-neu cells have an even distribution of confinements in baseline conditions. B) Following injury, the profile of Oli-neu cells does not change. It 
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5.4  Discussion 
The results of this chapter demonstrate that (1), the maturity of OLs alter the protein dynamics 
of MBP, with cells which are more mature possessing proteins showing more confinement, 
and less free movement; (2) Injury to OLs cause a more immature phenotype in terms of MBP 
protein dynamics, with proteins being more mobile and less confined; (3) The Oli-neu cell line, 
although an immature cell line, in terms of MBP protein dynamics is more complex in 
phenotype, with a mature phenotype for diffusion rates, but an immature phenotype for 
confinement (Figure 5.18). 
5.4.1  The effect of OL maturity on MBP protein dynamics 
Observation of MBP protein dynamics in OPC and differentiated OLs have shown that MBP 
becomes less mobile as cells progress down the OL lineage. This can be seen with both the 
confinement data, which shows that MBP increases in its confinement following maturation, 
and the diffusion rates which show that particles do not move as quickly following maturation. 
This change in mobility of MBP molecules, following maturation, may come about due to the 
expression of other mature myelin proteins, such as PLP and CNP, which have been shown to 
interact with MBP137. These interactions may also induce homotypic interactions between 
MBP molecules, leading to reduced MBP mobility within the samples161. However, this 
transition is not as marked as expected, as OPCs at the earliest stages of maturation still 
contain molecules which MBP interacts with such as lipids within the bilayer, actin, and the 
gangliosides137,527,528. 
In addition to its effect on the motility of the particles, maturity of the cells also effects the 
directionality of the molecules movements, as seen when looking at the plots of particle 
displacement. As the cells became more mature the particle displacement plots were found 
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to become more linear. This is quite evident at the point of EMOL cells where the plot is more 
linear than elliptical, but difficult to see within the other conditions. The EMOL cells show a 
level of directionality within their particle movements, this could be due to the presence of 
the bubbles which are assumed to contain nascent myelin structures which may provide an 
environment favouring greater directionality. The presence of presumed myelin with the 
bubble structures would also explain the observation that cells with multiple myelinating 
bubbles presented with more linear plots. This could suggest that myelin shuffles to the edges 
of the bubble to either facilitate bubble expansion, or to forms a meshwork for process 
flattening. However, MBP is known to perform an extrusion role on other proteins within 
myelin, such as CNP, MOG and MAG, which could also lead to a directional movement of MBP 
to the sides of the bubble, this could be confirmed by dual staining of MBP, and either MAG 
or MOG to explore whether extrusion of either of the proteins has occurred when this process 
occurs within the cells161. It may be difficult to detect directionality at earlier developmental 
stages, as for example the PMOL cells possess highly branched processes in multiple directions, 
so if there is directionality within the molecular movements away/towards the cell body, or 
even from one membrane to another to form myelinating bubbles, this would be masked by 
the large amount of moving particles existent within the sample which will be moving in 
various directions. From the confinement histograms it can be seen that PMOL cells present 
with less confinement than the other differentiated OPC types. The greater MBP particle 
mobility could be related to the expression of proteins which MBP interacts with, such as PLP, 
which could help induce MBP reorganisation, and therefore the formation of myelinating 
bubbles137,156. Alternatively it could simply reflect the absence of such interactions due to 
lower levels of these mature myelin components. 
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5.4.2  The effect of injury on protein dynamics 
Injury with LPC effects the MBP protein molecular dynamics within differentiated OL precursor 
cells, causing them to be more mobile than uninjured cells. However, from the diffusion 
coefficients it can be seen that no fast moving molecules appear. The absence of faster moving 
elements within the injured cells suggests that MBP still has many particle interactions which 
are working on it despite the effects of the injury treatment, which hinder its movement.  
These interactions must be either transient to allow particles to move, explaining the increase 
motility, or the particles MBP is interacting with must be mobile and interact with other 
molecules within the sample. One explanation to the increased motility would be MBP 
particles leaking out of the cell following injury. However, particle movement is non-
directional, and very few to no particles are seen extracellularly following injury, either in the 
environment or leaving the cells. Another explanation could be particle shuttling to the cell 
body for recycling, as part of process retraction. This is supported by the loss of processes 
following injury, with very little cell debris observed. However, if particles were being 
retracted to the cell body particle movement will yet again be directional which has not been 
observed. One final explanation is the formation of MBP aggregates following injury, which 
has been observed within demyelining conditions529,530. This explanation supports the data 
well, as individual MBP particles will be able to diffuse faster than the clusters, and following 
aggregation the aggregate may also be mobile, but with the larger size would be slower 
moving. However, the absence of this phenomenon within the Oli-neu cells suggests that the 
trigger for this MBP aggregation may not exist within the Oli-neu cells. This suggests the trigger 
for this response may lie within the profile of proteins existent within the differentiated cells, 
as this is the key difference between Oli-neu and the differentiated cells. 
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5.4.3  The Oli-neu cell type 
The Oli-neu cell type is a well-established cell line model for OPC behaviour. From the work 
presented within this chapter, it can be seen that the Oli-neu cell line is peculiar in terms of 
its molecular dynamics. It presents with highly mobile particles, similar to that of the OPC cells, 
but, also lacks the fast moving populations present within the OPC cells, as was also apparent 
with the differentiated OPCs. This suggests that the OPCs used as a source for the Oli-neu cells 
may have been immortalised at a maturity level beyond that of the OPC cells but, one which 
is less developed than the pOLs which display more confined molecular dynamics. This 
suggests that on a molecular level, Oli-neu cells do not provide a particularly faithful model 
for OPCs, whether mature or immature, but rather represent their own unique morphology. 
It should be noted however that the MBP characteristics observed here may be specific to the 
source of Oli-neu lines used in this work since additional sources of Oli-neu (e.g. cells not 
maintained in the Fulton laboratory) were not examined. The Oli-neu cells stocked in the lab 
have retained an OPC profile with the typical morphology and expression of NG2 expected of 
the line. However, stocks of the original donated line were not maintained thus experiments 
were performed on lines that had undergone multiple passages. There may then have been 
other molecular shifts in the phenotype that could account for the particular profile of MBP 
dynamics observed here. Further experiments with a fresh batch of cells with a known history 
could be useful for checking this possibility.  
Unlike the differentiated OPC cells the Oli-neu cells do not change in molecular dynamics 
following injury, with cells treated with LPC showing similar dynamics to that seen in uninjured 
Oli-neu cells. This suggests that Oli-neu cells do not possess the mechanisms present in 
differentiated OPCs that cause slower moving particles with greater mobility. Oli-neu cells 
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show a MBP dynamics with a similar mobility, whether injured or uninjured, probably because 
Oli-neu cells do not possess the mature myelin proteins that would enable mobility reducing 
molecular interactions449. It has been suggested that MBP needs to interact with a number of 
molecules to induce aggregations161.  Unpublished data from the lab confirms the expression 
of PLP, MOG, CNP and CD9 in the differentiated OPCs used in the present work (M. Otsu and 
D. Fulton, unpublished), which are known to be absent in Oli-neu cells. Therefore the number 
of interacting molecules such as CNP and PLP are limited leading to molecules being close to 
freely mobile with both the injured and uninjured systems161. 
5.5  Conclusions 
The work within this chapter has explored the molecular dynamics of MBP within different 
levels of maturity. The results of this chapter support the hypothesis that mature 
oligodendrocyte cells will display a more confined molecular phenotype than immature cells. 
This was demonstrated by the observation of both the diffusion coefficient of the particles 
being tracked, as well as the confinement. Contrary to previous beliefs, Oli-neu cells did not 
display the same phenotype as immature OPC cells, but an intermediate phenotype on the 
molecular scale. This provides evidence against its use as a model for OL behaviour, at least 
on the molecular scale. Following injury to the cells a change of phenotype was observed in 
the mature cells, with MBP being less confined within the mature OLs, reverting to a 
confinement phenotype similar to that of the immature cells. With the immature cell types, 
such as the OPC and Oli-neu cells, a change of phenotype was not observed, suggesting that 
the change of phenotype seen in mature cells may be linked to the expression of mature 
markers. 
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General Discussions  
 
 
"We Live in a society exquisitely dependant on science and technology, in 
which hardly anyone knows anything about science and technology"  
- Carl Sagan 
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6.1  Main Findings 
This thesis aimed to develop tools and protocols to enable SMI analysis of MBP molecules 
during oligodendrocyte development and injury, and to apply these models of myelin injuries 
that are relevant to demyelinating conditions such as multiple sclerosis and neuromyelitis 
optica. It is hoped that these tools and protocols will provide new information on myelin injury 
that will support future pharmacological intervention for these conditions.  
The work shown within this study has accomplished the following 
1) The production of multiple viral constructs for the delivery of fluorescently tagged 
MBP, with a number of fluorescent proteins, for SMI observation of MBP behaviour. 
These proteins have been characterised according to their expression kinetics (onset 
and duration), and toxicity. 
2) An immune based injury model was tested and optimised for the observation of myelin 
injury within brain slices. The models mechanism of action has been confirmed, and 
optimal treatment composition duration determined. This model was shown to 
produce a chronic injury which has minimal recovery. 
3) The mobility of single MBP molecules has been characterised within immortalised and 
primary oligodendroglial cells of different maturities. This work shows that MBP 
becomes more immobilised (reduced diffusion / increased confinement) following 
maturation of the cells. 
4) The mobility of single MBP molecules following chemical injury was characterised 
within both mature oligodendrocytes, and the Oli-neu cell line. This has shown that 
the mobility of MBP is altered following injury only in mature oligodendrocytes. 
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6.1.1  SFV Constructs for investigating protein function 
The various SFV constructs produced were exploited in various ways within the work 
presented. The construct containing GFP proved useful for labelling oligodendrocytes, both in 
cell cultures and brain slices, as it allowed the development of the skills to morphologically 
identify oligodendrocytes within tissues, especially within transgenic animals. These skills 
were essential to develop for the work performed within this thesis, and the GFP chimera 
allowed these skills to be developed whilst the other chimera were being developed. The 
construct which contained mCherry was utilised for live imaging of OL in brain slices, where 
they were useful for identifying the kinetics of OL injury during complement-mediated injury. 
In addition mCherry labelled OLs could be identified using post-hoc immunohistochemistry. 
The Dendra2 virus was essential for the SMI work presented within Chapter 5, as the 
photoconversion allowed the isolation of the sparse signals required for SMI experimentation. 
These viral constructs showed useful characteristics for imaging as expression of the 
fluorescent chimeric proteins occurred within 6 hours of infection and was existent for a 
number of days. From the single molecule work it could be seen that the useful imaging 
window was between 6 and 9 hours of infection, this was determined as processes within the 
imaging dishes displayed characteristics suggestive of process retraction following 10 hours, 
such as intermittent process thickening and blebbing. This was followed by a slight level of 
process retraction. This imaging window (6 to 9 hours) allowed imaging of many processes, 
and allowed enough time to induce an oligodendrocyte injury, which could confidently be 
distinguished from potential cytotoxic effects resulting from the SFV vector at later time-
points. 
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The expression pattern of MBP is different to that which is reported within the literature for 
MBP expression. The literature suggests that MBP is expressed locally from polysomes within 
the oligodendrocyte processes452–454. However, the results from the expression of MBP by the 
SFV virus suggest that MBP is actually expressed centrally within the cell body and transported 
to the process. This expression behaviour can be seen with all the SFV chimeric constructs. 
This may be related to the use of the SFV virus, as SFV contains a viral genome which is 
translated when the virus hijacks the host ribosomes. This may have led to MBP expression 
somatically, rather than locally like the literature suggests. This may also be the case as the 
MBP chimera lacks the regulatory elements that are contained within the normal golli-MBP 
gene, and which may contain targeting elements. One interesting finding from the MBP 
expression results is the bulk movement of MBP. Within the experiments performed it can be 
seen that MBP movement to the processes is accompanied by a change in oligodendrocyte 
morphology, this change in morphology usually progressed with a slight loss of processes 
following MBP expression, followed by the production of new processes arising from the 
perikaryal membrane containing MBP. These processes were of different thickness to that 
seen before MBP expression. These observations provide evidence for MBP producing strong 
interactions with the membrane, as no MBP expression is seen progressing within the pre-
existing processes. Also, the production of thinner processes following the appearance of MBP 
supports the idea that MBP plays a compaction role even before the production of myelin 
sheets. 
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6.1.2  Immune model 
The anti-MOG / complement myelin injury provides a useful model as it may replicate features 
of the early phases of injury within MS. Complement has been shown to be aberrantly 
activated in the early phases of MS, suggesting that the initiation of the myelin injury within 
MS occurs in a similar manner to the anti-MOG / complement model. Following this the injury 
progresses with or without complement activity, as can be seen within the 30 minute 
complement incubation experiments, and with the complement inhibition within patients 
suffering with MS280,420. The use of complement itself is well established for induction of injury 
within the CNS467,468. However, the conditions within the treatment needed to be optimised, 
to ensure injury is induced without over activation of the complement system, and with little 
to no axonal injury.  
Within the work presented the m IgG control/complement treatment was treated as an 
experimental control condition. However, as seen from the work with the C9 time course, the 
m IgG control/complement condition produced extensive C9 activation, albeit on a slower 
time-course than that seen with in the anti-MOG/complement condition. This suggests that 
the m IgG control/ complement condition has the potential to induce an injury, which would 
be seen later than that resulting from anti-MOG/complement treatment. This was confirmed 
with the live imaging experiments, and the injury time course experiments, which showed that 
myelin injury is apparent in the IgG control/complement condition following 24 hours, and 
that, much like the anti-MOG/complement treatment, the myelin is completely devastated 10 
days following treatment. These findings differ from those previously published by Harrer et 
al. 2009, where IgG control/complement treatment was used as a control for anti-MOG 
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induced injury468. Based on our observations the complement alone, or antibody alone 
conditions used in this thesis provide a more suitable control condition, as these conditions 
show little to no injury within the injury progression experiments. 
6.1.3  Mobility of MBP following maturation 
MBP is a myelin protein known to be heavily involved in myelin compaction88. This myelin 
compaction requires the existence of other mature myelin proteins, such as PLP and Gal C531. 
Interaction with these proteins initiates self-adhesion of MBP to other MBP molecules in order 
to form a framework for myelin compaction161. Although MBP is expressed within all 
experimental groups in these experiments, seeing as maturity of the cells varies within 
conditions, not all cells show the confined behaviour normally seen within mature 
oligodendrocytes. This is due to both the reduced number of proteins which develop as the 
cell matures, such as PLP which MBP interacts with, and also the reduced levels of MBP in the 
cells at the earlier stages of differentiation, compared to mature myelin, reducing the number 
of potential interacting molecules that any particular MBP molecule may form interactions 
with during self-propagation of the interactions. 
6.1.4  Response of MBP following myelin injury 
Within the work presented two key forms of myelin injury were performed. The first was a 
physical injury produced by complement proteins puncturing the membrane of cells. The 
second was a chemical injury to the myelin membrane induced by the myelin toxin LPC. Both 
injury modalities produced a dramatic response within oligodendrocytes involving the loss of 
processes. However, only cells injured with LPC revealed an increased mobility following 
injury. This may be related to the means of imaging, as different microscopy techniques were 
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utilised, however, within the live imaging experiments following complement induced injury, 
protein reorganisation should be noticeable on the ensemble level.  
6.2  Future experiments 
6.2.1  Determination of cell death mechanism in complement myelin injury 
Although the work presented thus far has shown that the anti-MOG / complement injury 
utilises the classical pathway of complement injury, and that the observed injury involves 
production of the membrane attack complex, shown by the delay between the peak of C9 
staining and the presentation of the injury, the mechanism of injury is still not fully 
characterised. Whether the membrane attack complex induces injury through membrane 
attack, or if the injury is seen through the triggering of an apoptotic pathway by high C9 levels 
has not been determined. In order to determine this a cell death assay must be performed, 
where cells are stained for apoptosis, and necrosis and the quantity of each type of cell death 
compared between injured and control slices. This approach would be helpful in confirming 
whether the observed myelin injury arises due to membrane attack complex induced necrosis, 
or whether the C9 complex induces a slower, intracellularly driven means for injury. One 
means to observe these pathways is through the dual use of the nucview apoptosis assay 
system and propidium iodide. Nucview provides a marker for caspase 3 activation which is 
highly prominent during apoptotic cell death, whereas propidium iodide labelling requires 
only an increase in cell membrane permeability which occurs during necrosis and the later 
stages of apoptosis.  
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6.2.2  Investigating excitotoxic injury 
Within this work all the myelin injuries observed have actions which are believed to occur 
extracellularly, with complement making a membrane attack complex to permeabliise the 
membrane, and LPC disrupting the membrane268,532. In order to further understand the effect 
of myelin injury on MBP, injuries which originate intracellularly must also be investigated, as 
these can have pronounced effects on the function of MBP. One key form of injury which was 
not addressed within the work presented was excitotoxicity. Excitotoxicity has been 
associated with the injuries seen within MS, which means its molecular dynamics must be 
understood in order to understand injury within MS485,533–536. Excitotoxicity is a pathological 
process where over activation of receptors leads to cellular damage. This is most commonly 
associated with glutamate receptors. Blockage of the NMDA, and AMPA glutamate receptors 
has been shown to reduce damage to oligodendrocytes in the EAE model system from 
MS535,537,538. Although glutamate exicitotoxicity effects both axons and myelin, 
oligodendrocytes have been shown to be more susceptible than axons539,540. This 
susceptibility may be underpinned by the role of oligodendrocytes in glutamate homeostasis, 
the upregulation of glutamate receptors within MS, and the role of glutamate in 
oligodendrocyte precursor cell differentiation448,541–543. 
6.2.3  Investigating the interaction between MBP and other proteins 
In this study it has been demonstrated using SMI methods that MBP interacts with other 
elements within oligodendroglia, which changes its protein dynamics. In order to elucidate on 
these findings further some of these interactions should be probed. In order to achieve this 
co-labelling of MBP and proteins such as PLP, Gal C, and calmodulin should be used for further 
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SMI studies. This would allow interaction times between MBP and these molecules to be 
observed, and could help to determine whether disturbances within these molecules during 
injury leads to the change in MBP dynamics observed. Of key interest is PLP, which is known 
to both be a membrane protein and to interact with MBP. PLP is a positively charged molecule, 
which is bound to the cytosolic surface of myelin421. It has been found to interact with MBP 
reversibly, in a non-electrostatic manner422,544.  Within the work presented both injury 
modalities used (complement and LPC) involved damage to the myelin membrane, so to 
understand the increased mobility of MBP, following these myelin injuries, a membrane 
bound protein might provide a useful target for study. This approach may be especially 
relevant in understanding the lack of change in MBP dynamics following injury in early OPC 
cells since PLP reaches its maximal levels when oligodendrocytes are myelinating545. 
6.3  Conclusion 
Thus far demyelinating conditions such as MS and neuromyelitis optica do not have any 
functional cures, although many pharmacological interventions have been attempted. 
The work presented here addressed the response of MBP to myelin injury. This was achieved 
by the production of SFV vectors containing fluorescently tagged MBP chimera proteins. This 
was utilised to establish a model system for myelin injury, similar to the injury seen in 
demyelinating conditions such as MS. The response to this injury was compared to that of a 
known model for demyelination, LPC. The LPC injury was investigated using SMI 
methodologies, where MBP was found to change its behaviour in response to myelin injury, 
only when in mature cells. This suggested that the response of MBP to demyelinating stimuli 
relies on the interactions it makes with other molecules with myelin such as lipids and other 
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myelin proteins. These interactions are therefore important targets for future work aiming to 
understand how the early stages of demyelination progress, and identify new targets for 
myelin protection. The work presented provides several interesting avenues for progression 
of this work, most notably the exploration of MBP interactions with other myelin proteins, 
which may explain the behaviour discrepancies seen within different stages of differentiation 
of the cells investigated. The investigation of whether MBP behaviour varies with different 
types of injuries is also a key question for future work, the resolution of which may provide 
new directions for pharmacological interventions aiming to protect myelin from injury.  
  







“Science is not everything, but science is very beautiful.” 
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“People keep saying ‘science doesn't know everything!’ Well, science ‘knows’ it 
doesn't know everything; otherwise it would stop.” 
- Dara Ó Briain   
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7.1  Image randomising code 
 
 
str = input('What is the file type?','s');   % User input of file type 
path=uigetdir('C:\','Where are your files?')   % User defines the location of the files 
fls=dir(fullfile(path,strcat('*.',str)));   % produces a list of files with defined type in the directory 
flnm={fls.name}';   % extracts the filenames of all files 
imgcbe=[];   % Make empty matrix for data 
filename = 'Rankings.xlsx';   % defines the name of the excel file 
ltrs=’acegik’   % Every second letter of the alphabet for matrix allocation later 
for j=1:numel(flnm)   % Loop to open all defined files in directory 
    imgcbe{j}=imread(strcat(path,'\',char(flnm(j))));   % Saves images as an element in cell 
array 
end 
for g=1:4   % Loop for the number of repeats for the ranking to be performed 
rp = randperm(size(flnm,1),size(flnm,1));   % Makes random numbers 
finalfilertng=[];   % New matrix for storing rankings and file information 
for i=1:numel(rp)   % Loop of all files 
    imshow(imadjust(imgcbe{rp(i)}))   % Opens random file determined by random number matrix 
    rtng=input('Rating of Injury from 1 to 4 is ');   % User defines the Ranking for image 
    close all   % Closes image 
    finalfilertng=[finalfilertng;flnm(i),strcat('File N',num2str(rp(i))),rtng];  % adds file information 
to matrix with ranking 
end 
srtflrnt=sortrows(finalfilertng,3);   % Sorts the files in filename order 
writetable(,filename,'Sheet',1,'Range',strcat(ltrs(g),'1'))  % Outputs the matrix to excel 
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7.2  Image J Image Processing Macro 
 
dir1 = getDirectory("Choose Source Directory ");   % User defines the location of the files 
dir2 = getDirectory("Choose Destination Channel Directory ");   % User defines the 
destination of the split channels 
dir3 = getDirectory("Choose Destination Directory ");   % User defines the destination 
of the z projected files 
list = getFileList(dir1);   % Makes list of files in directory 
setBatchMode(true);   % Runs the loop in batch mode 
for (i=0; i<list.length; i++) {                      % Loop of all the files in the directory 
showProgress(i+1, list.length);                 % Has an output for user to see in console 
run("Bio-Formats Importer", "open=["+dir1+list[i]+"] autoscale color_mode=Default 
split_channels view=Hyperstack stack_order=XYCZT"); 
% Opens files in Bioformat plugin 
for (h=0;h<nImages;h++) {                 % Loop of all the images open 
selectImage(h+1);             % Selects image 
title = getTitle;               % extracts the filename from the image 
saveAs("tiff", dir2+title);                  % saves file as tiff 
  print(title);                  % outputs filename 
  selectImage(h+1);             % selects image which has been saved 
   close();                      % closes image 
}  
} 
list2 = getFileList(dir2);                   % makes list of all files in split channel directory 
setBatchMode(true);               % runs in batch mode 
for (i=0; i<list2.length; i++) {            % Loops all files in directory 
showProgress(i+1, list2.length);               % Has an output for user to see in console 
open(dir2+list2[i]);                % Opens file 
run("Z Project...", "projection=[Max Intensity]");          % Z projects the file using maximum intensity 
run("Enhance Contrast", "saturated=0.35");           % contrasts file 
run("Apply LUT");                    % applies contrast 
saveAs("TIFF", dir2+list[i]);              % Saves file as tiff 
close();   % Closes file 
} 
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Supplementary Figure S4.1: IgG stain on brain slices, and MOG stain on brain slices. A) IgG Staining shows no structural 
localisation with majority being confined to cell bodies. B) MOG staining shows localisation to cell processes and 
confinement to mainly the white matter. 
